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“by convention sweet and by convention bitter, 
by convention hot, by convention cold, by convention color; 
but in reality atoms and void.” 




“How long will this last, this delicious feeling of being alive, of 
having penetrated the veil which hides beauty and the wonders of 
celestial vistas? It doesn't matter, as there can be nothing but 
gratitude for even a glimpse of what exists for those who can 
become open to it.”   









Recent approaches to constraining peptide sequences into more structurally-defined α-
helical secondary structures, so-called peptide stapling, are discussed. Stapled peptides 
are a class of therapeutics that have been shown to more effectively target protein-
protein interactions, which are harder to target using a classical small-molecule 
therapeutic approach. Stapling a peptide constrains it into a well-defined secondary 
structure. This more accurately mimics the protein-protein interaction making the 
peptide a more viable therapeutic.  
 
Starting from the p53-MDM2 interaction, a protein-protein interaction with important 
implications in cell health, a known peptidyl inhibitor of this interaction was stapled 
and analysed for increased α-helicity. This was achieved by using monomers that 
utilise the copper (I) alkyne azide cycloaddition as a cross-linking methodology, which 
has been less well researched in the context of peptide stapling. The viability of a novel 
stapled peptomer inhibitor approach, accomplished using a new, optimised monomer 
synthesis, is investigated. 
 
Additionally, the synthesis of a ligand series designed for use in the copper(I) alkyne 
azide cycloaddition is also discussed.  




Proteins are large molecules which have a number of important functions within the 
body, such as keeping cells healthy. Proteins can regulate these functions in many 
ways, including interacting with other proteins. The p53 protein is very important in 
maintaining cell health, and is regulated by the MDM2 protein. In cancerous cells the 
levels of p53 and MDM2 are often different to those found in healthy cells, and so 
finding a way of restoring the balance could be an effective cancer treatment. 
 
Molecules called peptides, which are built from the same building blocks that the body 
uses to make proteins, can be created to mimic the p53 protein. These man-made 
molecules can interact with the MDM2 protein, disrupting the interaction with p53, 
and potentially increasing the amount of p53 in cells. 
 
The peptide molecules made in the laboratory however do not have the same 3D shape 
as the natural p53 protein, which is vital for effective interaction with the MDM2 
protein. Also, because the peptide molecules are made from amino acid building 
blocks, the body can recognise the peptides and break them down. This thesis discusses 
ways of making peptide molecules that more effectively mimic the shape of the p53 
protein, and are more stable to breakdown by the body; making these non-natural 
peptides more effective as possible cancer treatments. 
 
  





4-(BM)MB 4-(bromomethyl)methyl benzoate 
5-CP 5-chloropent-1-yne 
6Cl-W 6-chloro tryptophan 
Ac acetyl 
Ac3c 1-aminocyclopropane carboxylic acid 
Aib α-aminoisobutyric acid 
Alg allylglycine 
Alloc allyloxycarbonyl 
AP Active Peptide 
Bak BCL-2 homologous antagonist killer 
BCL B-cell lymphoma 
BCL-xL B-cell lymphoma extra large 
BH BCL-2 homology 
BID BH3 interacting domain agonist 
Boc tert-butyloxycarbonyl 
Cba cyclobutylalanine 
CD circular dichroism 
CETSA Cellular Thermal Shift Assay 




DMF N,N-dimethyl formamide 
DMPU N,N'-dimethylpropylene urea 
DMSO dimethyl sulfoxide 
DNA deoxyribose nucleic acid 
EDA ethylene diamine 
ELISA enzyme linked immunosorbent assay 
eq equivalents 
ESI electrospray ionisation 
Fm 9-fluorenylmethyl 
Fmoc 9-fluorenylmethyloxycarbonyl 
HBS hydrogen bond surrogate 
hDM2 human double minute 2 
hDMX human double minute X 
HFA hexafluoroacetone 
HMBC heteronuclear multiple-bond correlation 
HMPA hexamethylphosphoramide 
HSQC heteronuclear single quantum coherence 
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IC50 inhibitory concentration 50% 
IR infra-red 
ITC isothermal titration calorimetry 
Kd dissociation constant 
Ki inhibition constant 
MDM2 Murine Double Minute 2 
MDMX Murine Double Minute X 
MeCN acetonitrile 
MS mass spectrometry 
ND not determined 
NMR nuclear magnetic resonance 
nOe nuclear Overhauser effect 
OSu O-Succinimide 
PDB Protein Data Bank 
pDI Peptide Dual Inhibitor 
PMI p53 MDM2/MDMX Inhibitor 
PMP 4-phosphonomethylphenylalanine 
PPI protein-protein interaction 
Pra propargyl 
PTHrP parathyroid hormone related protein 
RCM ring-closing metathesis 
RP-HPLC reverse phase-high pressure liquid chromatography 
rt room temperature 
SAHB stabilised α-helix of Bcl-2 domains 
Sar sarcosine 
SPPS solid phase peptide synthesis 
SPR surface plasmon resonance 
TBAI tetrabutyl ammonium iodide 
TBTA tris(benzyltriazolylmethyl)amine 
TEA triethylamine 
TFA trifluoroacetic acid 




TLC thin layer chromatography 
TMBA tris(2-benzimidazolylmethyl)amine 
TMS trimethylsilyl 
UV ultra violet 
 
  




The nomenclature X(i,i+Y)X(#) defines the stereochemistry (X = S or R) of the cross-
linking monomers within a stapled peptide. The relative positions of the first and 
second cross-lining monomers within the peptide are denoted i and i+Y respectively, 
with Y-1 residues between the cross-linking monomers. When present, (#) defines the 
least number of atoms that form the linker. The notation reads from the N-terminus to 




The nomenclature “u” or “c” after a peptide denotes whether the peptide is 
“uncyclised” or “cyclised” respectively. 
 
The nomenclature “1,4-” or “4,1-” before a peptide denotes the orientation of the 
uncyclised azide and alkyne or cyclised triazole as read from the N-terminus of the 
peptide. 
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Chapter 1 - Designing Stapled Peptides 
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1 Targeting α-Helical Protein-Protein 
Interactions 
 
Protein-protein interactions (PPIs) are responsible for almost all critical control points 
in intracellular processes. The α-helix protein secondary structural conformation is 
seen in approximately 40% of proteins,1 but 62% of protein-protein interactions have 
an α-helical motif at the interface.2 Given that it is estimated that on average proteins 
interact with up to 5 others, being able to target these PPIs individually and in isolation 
successfully would be of great therapeutic benefit. However, using a classical “small 
molecule” (MW < 500 Da)
3 pharmaceutical approach to inhibit PPIs is usually not 
feasible. The approximate contact surface area of small molecule-protein interactions 
is 300-1000 Å, whereas the contact area of most protein-protein interactions is 1500-
3000 Å, up to a factor of ten larger.4,5 This diminished reach of small molecules also 
does not take into account that a large number of PPIs often lack the pockets and 
grooves that small molecules can bind to,6 unlike enzymes, which have a well-defined 
binding site for a natural substrate (Figure 1). 
 
Figure 1- Representation of A Small Molecule Inhibition of an Enzyme B The 
Inneffective Inhibition of a Protein-Protein Interaction with a Small Molecule7 
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Ideally, the α-helical peptide sequence from an interacting protein could be used as a 
PPI inhibitor, however short sequence synthetic peptides do not have equivalently 
stable secondary structure when in solution and separated from the context of the 
protein.8,9 They are also easily degraded by the peptidases, and thus not viable as 
therapeutics. However by replacing amino acids not critical to binding, spaced ~3.6 
residues apart on the same face of the α-helix and linking them, the cyclised peptide 
can fold into a thermodynamically favourable α-helical conformation. As the link is 
constrains the sequence, it is said to be “stapled” (Figure 2). 
 
 
Figure 2- Representation of a Stapled Peptide 
 
A stapled peptide is theoretically a better a protein-protein interaction inhibitor 
compared to a small molecule inhibitor or a non-cyclised peptide as it more closely 
mimics the surface area and shape of the native interaction. In addition to being 
thermodynamically stabilised, stapled peptides have increased resistance to proteolytic 
enzymes, as α-helical folded peptides are not recognised by proteases.10 There is also 
evidence that stapled peptides have increased cell permeability, though there has been 
some debate as to how effective this is.11–14 The mechanism of cellular penetration is 
not definitively known, but is thought to proceed through an energy dependent 
endocytotic mechanism.15 Cyclised peptides are eventually broken down by peptidases 
into non-toxic amino acid metabolites, which is a favourable characteristic for a 
therapeutic. 
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The most commonly used method of determining whether a peptide, stapled or 
otherwise, has α-helical character is circular dichroism.16,17 This uses circularly 
polarised light in the ultraviolet and visible region (180-250 nm) as this range spans 
most of the electronic transitions of the amide chromophore. However, the minima and 
maxima that are observed are significantly different depending on the secondary 
structure of the peptide. An α-helical peptide has characteristic minima at 220 nm and 
208 nm, with a maximum peak at 193 nm (Figure 3). 
 
 
Figure 3- Circular Dichroism Spectra of Peptide Secondary Structure Characteristics 
Solid line, α-helix; long dashed line, anti-parallel β-sheet; dotted line, type I β-turn; 
cross dashed line, extended 310-helix or poly (Pro) II helix; short dashed line, irregular 
structure17  
   
1.1 Methods of Stapling 
 
There are many documented methods of constraining peptides into various secondary 
conformations, from using non-covalent interactions including salt bridging,18–23 ion 
complexing,24–29 π,π-interactions30 and cation,π-interactions,31,32 to using thiol 
chemistry to form disulphide bonds,33,34 and thioether linked spacers.35–37 There are 
examples of reversible oxime linkers38 and photoactived azo-benzene39 and 
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pyrazoline40 linkers. Recently it has been shown that it is possible to form macrocyclic 
peptides using tryptophan residues.41,42 With all these methods available, it is essential 
to consider certain key properties when looking to design a peptide stapling system. 
Analysis of some of the most thoroughly investigated stapling systems should 
emphasise these trends. 
 
1.1.1 Side Chain Lactamisation  
 
One of the simplest ways of forming a peptide staple is to use the inherent reactivity 
of the functional groups found on the side chains of amino acids. By using common 
proteinogenic residues such as lysine, aspartic acid and glutamic acid, a stable amide 
bond can be formed (Figure 4).43 The cyclisation can be easily monitored by MS and 
IR. 
 
Figure 4- A Proteinogenic Residues used in (i,i+4) Lactamisation B Representation 
of Lactam Stapled Peptide 
 
 Lactam Linker Length/Regioisomerism 
 
One restriction of using proteinogenic residues, however, is the linker can only 
encompass one helical turn effectively. Shepherd et al.44 previously demonstrated that 
polymers of the lactamised pentapeptide motif Ac-[KARAD]n-NH2 had increased 
helicity as shown by circular dichroism spectra16,17 (Figure 5), and resistance to 
proteolytic cleavage by trypsin when compared to the uncyclised counterparts. 
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Figure 5- CD Spectra of Lactamised Pentapeptide Polymers Ac-[KARAD]n-NH2 in 
10 mM phosphate buffer44 
 
Taking this concept further, Shepherd et al.45 attempted to stabilise a single 
pentapeptide, the minimum number of residues to represent one helical turn (Figure 
6), using a lactam bridge.  
 
Figure 6- Pentapeptide Single Helical Turn 
 
To investigate the optimal linker, ornithine was used in addition to the proteinogenic 
amino acids, allowing the linker length and lactam position to be probed. The 
macrocyclisation was achieved on resin using the Alloc/Allyl protecting groups 
(Figure 7), which are orthogonal to Fmoc solid-phase peptide synthesis (SPPS).46–48 
Using relatively high loading resins and prolonged reaction times resulted in 
oligomerisation. Switching to a lower loading resin improved the purity and yield of 
the monomeric cyclic products (Figure 8). 
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Figure 7- Allyl/Alloc Protected Residues 
 
 
Figure 8- Regioisomeric Lactam Peptides Investigated by Shepherd et al.45 
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Table 1- % Helicity of Lactamised Pentapeptides 
 
 
The results in Figure 9 and Table 1 show that there is a clear preference for linker 
length (compare 5, 6, and 3; compare 9, 10 and 7) and position of the lactam within 
the macrocycle. Increasing the linker by one atom knocks out most of the induced 
helicity (5 vs 6). Arguably this could be due to competitive hydrogen bonding to the 
lactam, which becomes possible because of the increased flexibility in the linker. This 
flexibility may explain the increase in helicity from 6 to 10, as the position of the 
lactam has moved to an unfavourable position for this competitive bonding. Shifting 
the lactam closer to the N-terminus (5 vs 9) reduced the relative helicity. There is also 
complete elimination of helicity when the lactam linker length is kept the same, but 
the position of the lactam is more centralised (5 vs 4, 9 vs 8). 
 
 
Figure 10- CD Spectra of Ac-KARAD-NH2 5 and Hydrogen Bond Knock Out 
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Table 2- % Helicity of Hydrogen Bond Knock Out Lactamised Pentapeptides 
 
 
In Table 2 and Figure 10 the effect of removing 1 (12, 13) or 2 (14) of the peptidyl 
backbone hydrogen bonds from the optimally cyclised peptide 5 is shown. Even at 
controlled pH to remove respective terminal charges it is evident that at least 3 
hydrogen bonds are required for α-helical induction and that cyclisation in and of itself 
is not enough to induce helicity (Figure 11).45 
 
 
Figure 11- Pentapeptides with A 3 B and C 2 and D 1 Backbone Hydrogen Bond(s) 
 
It has been shown that the side chains of amino acids can be inherently α-helix 
stabilising or destabilising. To investigate this, a series of hexapeptides of the form 
Ac-RKAXAD-NH2 were synthesised, with the R residue retained to improve the 
aqueous solubility of the peptides (Table 3). It was demonstrated that helicity is highly 
dependent on sequence, and although these peptides are extremely short, possibly 
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Table 3- % Helicity of Hexapeptides 
 
 
1.2 Bio-Orthogonal Methods of Stapling 
 
A potential problem in using unmodified amino acid side-chain residues to stabilise a 
peptide’s secondary structure, via a staple, is the inevitable loss of efficacy that will 
occur when the staple is eventually cleaved by some physiological process. One way 
to circumvent this is to use a bio-orthogonal macrocyclisation technique to close the 
staple. This strategy has the advantage that the staple can be formed without the need 
for protecting groups, simplifying synthesis, and the product will typically be 
biologically inert.    
 
1.2.1 Ring Closing Metathesis 
 
Ring-Closing Metathesis (RCM) is a catalytic carbon-carbon bond forming technique 
which involves the scission and consequent combination of two olefin groups via some 
late transition metal alkylidene (Figure 12).49–51 The direct formation of carbon-carbon 
bonds in this way is not observed in nature, and the hydrocarbon link formed is 
biologically stable. The reaction can also easily be monitored by mass spectrometry 
due to the loss of ethylene. RCM has been shown to be synthetically useful in that the 
ruthenium catalyst centre has a high functional group tolerance, and so does not 
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Figure 12- Schematic Representation of RCM 
 
 Constriction of Peptides into Recognisable Secondary Structure 
 
One of the first investigations into the macrocyclisation of peptides via RCM was 
performed by Miller et al.52,53 They were able to demonstrate that the Grubbs catalysts 
gave complete macrocyclisation of olefin groups in the presence of free and allylated 
amide NH groups. Originally looking at RCM as a way of forming conformationally 
restricted amino acids similar to proline,52 Miller et al. turned their attention to the 
formation of a disulphide β-turn mimetic, as a RCM surrogate of a β-turn would not 
be susceptible to conditions that would cleave a disulphide bond. Following the 
replacement of cysteine residues in the tetrapeptide Boc-Cys-Pro-Aib-Cys-NHMe 22, 
a known β-turn mimetic54, with racemic allylglycine (Alg) residues to form a statistical 
distribution of 4 diastereomeric tetrapeptides (23u), the resultant peptides were then 
subjected to standard RCM conditions (Figure 13). 
 
 
Figure 13- RCM Analogue of β-Turn Tetrapeptide Boc-Cys-Pro-Aib-Cys-NHMe 
 
Interestingly, only the (S,S,S) diastereomer of 23c, was seen to form the macrocycle 
within the mixture of diastereomeric peptides. The experiment was repeated with the 
isolated (S,S,S) and (R,S,R) diastereomers of 23u only and again only the (S,S,S) 
diastereomer cyclised, with the (R,S,R) recovered unreacted. It is thought that an 
internal hydrogen bond affords some pre-organisation of the macrocycle, facilitating 
closure of the “natural” diastereomeric analogue, whilst destabilising the other 
analogues via some trans-annular effect. 
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Continuing from this preliminary work, Miller et al.53 investigated how important the 
conformationally restricting non-natural amino acid aminoisobutyric acid (Aib)55,56 
was to the mimicking of a β-turn. The Glutaredoxin active site contains an (i,i+3) 
disulphide β-turn motif57 similar to the model tetrapeptide. This new pentapeptide 
(Boc-S-Alg-Pro-Tyr(OCbz(Br))-S-Alg-Gly-OMe 24, Figure 14) was synthesised in an 
similar manner to the model. The presence of β-turn hydrogen bonding was confirmed 
by IR and NMR spectroscopy. It was noted that the unprotected tyrosine pentapeptide 
macrocycle 25c was also synthesised with similar success, showing the free phenol 
does not interfere with the efficiency of the catalyst.53 
 
 
Figure 14- RCM of Boc-S-Alg-Pro-Tyr(OX)-S-Alg-Gly-OMe 
 
Going further, the Pro-Aib motif was also removed in the original tetrapeptide, as 
proline residues are themselves conformationally constraining. The monomers were 
replaced with two leucine residues, leaving the tetrapeptide Boc-S-Alg-Leu-Leu-S-
Alg-NHBn (26, Figure 15) without any inherent secondary structure.53 Again the 
macrocyclisation was achieved with the secondary structure confirmed by IR and 
NMR. This demonstrated that the use of RCM as a peptide macrocyclisation technique 
does not require any pre-organisation. 
 
 
New Approaches to Stapled Peptides Targeting the p53-MDM2 Interaction 
 
Designing Stapled Peptides  25 
 
Figure 15- RCM of Boc-S-Alg-Leu-Leu-S-Alg-NHBn 
 
A crucial experiment performed was the macrocyclisation of peptides whilst on a solid 
support. Following standard Fmoc-SPPS (solid-phase peptide synthesis) procedures 
the resin was swollen in DCM, the optimum solvent for efficient catalyst activity, and 
the reaction repeated. After deprotection and cleavage from the resin, the stapled 
peptides was detected with the acyclic starting material. This established the utility of 
RCM in the macrocyclisation of peptides on solid supports.53 
 
 RCM Inducing Helicity 
 
The first application of this methodology to the helical constriction of peptides was 
demonstrated by Blackwell et al.58,59 Using a known helical hydrophobic peptide60,61 
to exclude any intermolecular solvent effects and promote the catalytic activity of the 
ruthenium alkylidene catalyst, Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-OMe was selected 
as a peptidyl scaffold to attempt the first RCM helical peptide staple. Replacing the 
alanine residues in the (i,i+4) positions of the sequence with O-allyl serine and O-allyl 
homoserine, selected for the availability and ease of derivatisation of the starting 
materials, allowed the investigators to probe the linker length (Figure 16-A). 
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Figure 16- A Stapling of a Helical Peptides 27 and 28 B CD Spectra of peptides 27u, 
27c, 28u and 28c. 
 
After synthesis of the peptides and subsequent RCM, the olefin was subjected to 
hydrogenation to remove any effect due to E/Z isomerism of the C=C double bond. 
Comparing the CD spectra of the cyclised (27c and 28c) and uncyclised (27u and 28u) 
peptides, it was shown that there was little to no change in the degree of helicity 
exhibited by the peptides (Figure 16-B). This however could be due to the fact that the 
peptides contain an Aib residue in the centre of the sequence, and the fact that the CD 
spectra were ran in 100% trifluoroethanol (TFE), a known kosmotropic solvent.62–64 
This solvent could both contribute to the pre-organisation of the heptapeptide into its 
most helical conformation thereby disguising any additional helix-inducing effects 
from the linker. Additional NMR experiments59 provided evidence that the cyclised 
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peptides fold into a 310-helical conformation. A 310-helix has 3 residues per helical 
turn, and so has a thinner and more extended secondary structure in comparison to an 
α-helix (Figure 17).65 This suggests that although there is a high helix propensity and 
the linkers are replacing residues on the same helical face, the linker formed may be 
too lax, stabilising the extended 310-conformation. This work highlights the need for 
linker optimisation even within a known helical peptide.  
 
 
Figure 17- Comparison of Backbone Hydrogen Bonding and Side Chain Orientation 
in A α-helix B 310 Helix65  
 
 RCM Inducing α-Helicity 
 
One of the seminal investigations to take the design and optimisation of an all 
hydrocarbon staple into consideration was described by Schafmeister et al.66 It was 
posited that not only the linker length, but the diastereomeric configuration of the 
staple could either increase or decrease the overall helicity. To add to the total stability 
imparted by the staple the synthesised monomers were methylated at the α-carbon of 
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the amino acids,67 analogous to the Aib residue. These monomers (Figure 18-A) were 
incorporated into a peptide based on the C-peptide sequence of RNAse-A, Ac-
EWAETAAAKFLAAHA-NH2,
68 a 15-mer peptide shown to have partial helicity in 
water due to side-chain salt bridge interactions.18,19 Comparison to the native sequence 
allowed any increases or decreases in helicity to be determined. 
During SPPS, residues were replaced at both (i,i+4) and (i,i+7) positions (one or two 
helical turns) within the helices (Figure 18-B,C). 
 
 
Figure 18- A α,α-Disubstituted RCM Monomers Used B Representation of X(i,i+4)X 
Stapling Position C Representation of X(i,i+7)X Stapling Position in RNAse-A 
Analogues 
 
When subjected to metathesis conditions, R(i,i+4)S linkers of any length did not undergo 
reaction. Only R(i,i+4)R and S(i,i+4)S linkers longer than 7 carbon atoms in length were 
metathesized to any appreciable extent (Table 4, 38, 39 and 41, 42 respectively). A 
similar trend with regard to an optimum linker length was noted in the (i,i+7) staples, 
with monomers only forming staples with at least 9 carbon atoms in the linker, (44-
47). This was thought to be due to the pre-organisation of the helices on solid support 
in DCE. If the sequence has already folded into a restricted conformation, only side 
chains of adequate length would be able to undergo cross-metathesis and form the 
staple (Figure 19). 
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Figure 19- Representation of A Ineffective S(i,i+4)S(6) Staple (40) and B Effective 
S(i,i+4)S(8) RCM Staple (42) 
 
Table 4- Analysis of % Helicity Before and After RCM 
 
 
Peptides that underwent macrocyclisation by RCM to ~50% or greater conversion (39, 
41, 42, 44-47) were analysed in the cyclised and uncyclised forms by CD for α-helicity 
with the native peptide sequence (36) used as a control. The inclusion of α,α-
disubstituted amino acids tended to increase helicity56,69 with respect to the native 
sequence. In the (i,i+4) sequences, cross-linking appeared to have no effect on helicity 
with respect to the unmetathesised counterparts. However in the (i,i+7) series (44-47) 
there was a range of stabilising and deleterious effects observed. Again, this seemed 
Yield (%)a
X1 X2 X3 Σ
b
u c
T A A - 36 - 41 -
T R 3 29 R 5 30 6 37 0 - -
T R 3 29 R 6 31 7 38 17 ND ND
T R 5 30 R 5 30 8 39 >98 37 39
T S3 32 S5 33 6 40 0 ND ND
T S3 32 S6 34 7 41 68 49 48
T S5 33 S5 33 8 42 >98 40 39
R 5 30 A S5 33 8 43 0 ND ND
R 5 30 A S6 34 9 44 51 54 33
R 6 31 A S6 34 10 45 77 59 47
R 5 30 A S8 35 11 46 >98 59 85











a RCM Cyclisation; b Σ atoms in linker; c cis / trans; d total yield; ND: Not Determined; 
Ac-EWAEX1AAX2KFLX3AHA-NH2
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to follow the trend of linker length, with helicity increasing with increasing linker 
length, reaching a maximum at 11 carbon atoms (26% with respect to the uncyclised 
analogue, 44% compared to the native sequence, Table 4- 46) and subsequently 
decreasing. Importantly, the C9 and C10 linkers were found to destabilise helicity with 
respect to the uncyclised versions (-21% and -12% compared to the uncyclised 
sequences respectively, Table 4- 44 and 45). The C12 cross-linked peptide displayed 
cis/trans isomerism possibly due to the increased ring size, with the two isomers having 
different retention times when purified by RP-HPLC. Interestingly the cis isomer 
showing a greater increase in helicity than the trans isomer (18% and 7% respectively, 
Table 4- 47a and 47b). It was reported that hydrogenation of the olefin linkers showed 
no marked change in α-helicity when compared to the unsaturated precursors. It was 
also determined by sedimentation equilibrium that any helical induction was not due 
to aggregation of the peptides. 
 
The R(i,i+7)S stapled peptides were tested for increased stability against proteases. As 
the sequence between the monomers contained a lysine residue, trypsin was used in an 
in vitro assay. The increased helicity afforded by the monomers alone was enough to 
decrease the rate of peptidyl degradation approximately 5-fold. Cyclisation and 
hydrogenation decreased the rate of cleavage even further. Again, this was shown to 
be related to the trend of the effectiveness of the linker inducing helicity in the peptide, 
with the C11 linker peptide (46) exhibiting the slowest rate of trypsin digestion which 
showed an approximately 9-fold reduction in cleavage with respect to the uncyclised 
analogue and a 41-fold reduction when compared to the native sequence (36). These 
experiments were the first to offer evidence of the utility of RCM as an effective α-
helical peptide stabilisation technique. 
 
 RCM Inducing α-Helicity in Biologically Relevant Peptides 
 
The increased metabolic stability of stapled peptides is one of the qualities that make 
them appealing as drug candidates for protein-protein interactions. This theoretical 
pharmaceutical activity was first examined by Walensky et al.70 The BCL-2 protein 
family are crucial in cell apoptotic pathways.71–73 The family is defined as containing 
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a number of BCL-2 homology (BH) domains, with the α-helical BH3 domain critical 
to apoptosis upon protein-protein binding.74–77 The peptide sequence from BID, a 
BH3-only BCL-2 protein, was used as the template for inserting the α,α-disubstituted 
alkene monomers (Figure 18) for macrocyclisation of the stabilised α-helices of BCL-
2 domains, (SAHBs, Table 5). 
 
 
Figure 20- Olefin Monomers Incorporated into Stapled Peptides by Walensky et al.70 
 
Table 5- BID-BH3 and Stabilised α-Helix of BCL-2 Domains (SAHB) Sequences70 
 
 
Circular dichroism of the 23-mer native sequence 48 in aqueous potassium phosphate 
solution showed little to no intrinsic helicity (~16%).  Inclusion and metathesis of the 
monomers at (i,i+4) and (i,i+7) positions highlighted in Table 5 (49-53) all increased 
helicity with respect to the native sequence (Figure 21). Interestingly, all the (i,i+4) 
staples increased the helicity to a greater extent than the (i,i+7) stapled peptide 53, the 
opposite result from the antecedent work from Schafmeister et al.66 suggesting that 
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Figure 21- CD Spectra of BID-BH3 48 and SAHBs 49 - 5370 
 
The SAHB with the highest helical content, SAHBA (49), was tested for proteolytic 
stability against trypsin (Figure 22-A) and serum (in vitro). In all the experiments, 
SAHBA showed a greater stability against digestion than the native BID-BH3 peptide 
48. To confirm that SABHA was interacting in an analogous way to the native BID-
BH3 sequence, 15N-1H HSQC NMR experiments were performed on a 15N enriched 
BCL isoform. The similarity of the spectra verified that SABHA was binding in the 
same hydrophobic pocket as the native peptide. In fact, following a fluorescence 
polarisation binding assay it was determined that SABHA showed a greater than 6-fold 
increase in binding affinity to the isoform than the native sequence (Figure 22-B). The 
fluorescently labelled peptides were also used to monitor the transit of the molecules 
through the cell membrane, which is a challenge for peptides with charged residues. It 
is thought the hydrophobic nature of the staple may impart increased lipophilicity. 
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Figure 22- A Rate of BID-BH3 and SAHBA Digestion by Trypsin B Fluorescence 
Polarisation Binding Assay70 
 
Notably, SAHBA was able to activate the apoptosis pathway, both in vitro across a 
number of leukaemia cell lines (Figure 23) and in vivo in mice. Importantly, SAHBA 
displayed no toxicity in normal tissue. This investigation provided the first evidence 
that stapled peptides could be used as therapeutics for protein-protein interactions. 
 
 
Figure 23- Therapeutic Potential of SAHBA Peptide - A SAHBA Against Leukaemia 
Cell Lines B Native BID-BH3 Against Leukaemia Cell Lines70 
 
 RCM Linker Length and Thermodynamic Benefits 
 
From the results of the previously discussed studies, it appears that the effectiveness 
of an (i,i+4) over an (i,i+7) staple cannot be predicted. To explore this, Kutchukian et 
al.78 used knowledge-based potentials in Monte Carlo folding in silico calculations79–
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81 and compared the experimental data from Schafmeister et al.66 and Walensky et al.70 
(Table 6). 
 
Table 6- Peptides Analysied in silico by Kutchukian et al. 
 
 
According to polymer theory, the stability that comes from covalently linking 
polypeptides is from the reduction in entropy, making the unfolded state less 
favourable. If this were true however, a longer linker encompassing a greater number 
of residues would be more stabilising.82–85 Following the simulations and analysis, the 
models were found to be in agreement with the experimental data of the relative 
stability of the stapled peptides. The helical contribution imparted to the individual 
residues in the RNAse A peptide66 (36) was found to be increased around both the 
(i,i+4) and (i,i+7) staples (42 and 46) with this propensity decreasing the greater the 
distance from the cross-linked residues. In the BID-BH3 peptide 48,70 the (i,i+4) staple 
(49) increased the relative helicity of all the residues, especially those within three 
residues of the staple. However the (i,i+7) staple (53) was shown to impart helicity 
towards the N-terminus effectively, but it was discovered that it helped stabilise a 
















X 1  33 ; X 2  30 ; X 3  35 ;
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Figure 24- Representative Structures of the A Native (48) B (i,i+4) Stapled (49) and 
C (i,i+7) Stapled (53) BID-BH3 Peptides78 
 
In both the macrocyclised peptides there was some degree of α-helix stabilisation, with 
evidence that the wild type sequence can access conformations disallowed in the 
stapled analogues, highlighting the entropic stabilisation given. However, it was found 
that: (i)- the enthalpic gains from the internal hydrogen bonding networks formed, and 
(ii)- the disfavourable increase in backbone torsion of the denatured peptide were 
greater contributors to the overall free energy gained by the most stabilised peptides 
than any entropic factor. 
 
 RCM (i,i+4) Staple Stereochemistry 
 
As with linker length, the relative stereochemistry of the amino acids containing the 
non-natural side chains can have an effect on the overall helicity and stability imparted 
to the peptide. This was investigated by Kim et al.86 Using the α,α-disubstituted 
pentene monomers (30, 33, Figure 25) and incorporating them into the RNAse-A 
sequence 36, Ac-EWAETAAAKFLAAHA-NH2,
66 altering the position of the (i,i+4) 
staple to the 4th and 8th residues (Table 7) it was found that the S(i,i+4)S (54) and R(i,i+4)R 
(55) cross-linked peptides had vast differences. Although there was no significant 
change in the rate or yield of the macrocyclisation step the CD spectra showed that the 
S(i,i+4)S was more helical than the R(i,i+4)R stapled peptide and the native (72%, 40% 
and 29% respectively, Figure 26-A,B). The S(i,i+4)S also displayed a greater uptake into 
HeLa cells than the R(i,i+4)R diastereomer, however both showed greater uptake when 
compared to the native sequence (Figure 26-C). 
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Figure 25- Olefinic Monomers Incorporated by Kim et al.86 
 




Figure 26- Comparison of Native, S(i,i+4)S and R(i,i+4)R RNAse-A Peptides - A 
Measured α-Helicity B Difference in % Helicity C Flow cytometry profiles showing 
cellular uptake of 36, 54c and 55c into HeLa cells86 
 
To see if the relative diminished stability of the R,R conformation was a common trend 
in (i,i+4) stapled peptides, the R,R staple was also incorporated into the BID-BH3 
sequence 48, Ac-EDIIRNIARHLAXVGDXNLDRSIW-NH2.
70 Again, compared to 
the S(i,i+4)S stapled peptide (SAHBA, 49) the R(i,i+4)R analogue imparted less helicity 
and cell permeability to the sequence (Figure 27-A,B). These results emphasise that 
stapled peptides, while able to mimic protein secondary structure successfully, cannot 
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Figure 27- Comparison of S(i,i+4)S and R(i,i+4)R BID-BH3 Peptides - A Measured α-
Helicity B Flow cytometry profile of stapled peptide cellular uptake into HeLa cells86 
 
 Necessity for α,α-Disubstituted RCM Monomers 
 
With the information that D-amino acids are generally α-helix destabilising it could be 
argued that although the aminoisobutyric acid (Aib)55,56,69 type α,α-disubstituted 
monomers increase the rigidity of the peptide backbone, they could have a minor 
destabilising effect. Alanine residues themselves have been shown to substantially 
contribute to helix propensity,89–91 and so disubstitution at the Cα may not be a 
prerequisite to stabilising α-helical folding. Yeo et al.92 explored this by replacing the 
pentenyl methyl disubstituted glycine monomers with the monosubstituted 
counterparts93,94 (Figure 28- 56) in the BID-BH3 sequence70 (Table 8). 
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Table 8- Effect of Monosubstitution in BID-BH3 Stapled Sequence 
 
 
The new monomer peptide 58 was compared to the wild type sequence, Aib analogue 
57, and the disubstituted monomer analogue 49. It was found that both the 
monosubstituted and disubstituted sequences behaved similarly in terms of overall 
helicity, proteolytic stability and binding affinity when assessed against the Aib 
substituted and native sequences (Figure 29). This data infers that α-methylated 
monomers are not a requirement for an effective peptide staple. 
 
 
Figure 29- Comparison of Wild Type 48 and Substituted Analogues 49, 57 and 58 of 
BID-BH3 A α-Helicity B Peptide digestion by trypsin in PBS buffer at 25 °C92 
 
 RCM Staple Regioisomerism 
 
With the hypothesis that an S(i,i+4)S 8 atom linker is one of the most effective RCM 
cross-linkers, Pham et al.95 considered the consequence of the position of the olefin 
within the staple using the monomers shown below (Figure 30-A). Using the RNAse-












X 1  Aib; X 2  33 ; X 3  56 ;  N L  Norleucine;
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Figure 30- Investigating the Importance of Symmetry in RCM Staples - A Olefin 
Monomers Incorporated into B Symmetrical Δ-4 Stapled C Unsymmetrical Δ-2 and D 
Unsymmetrical Δ-6 Stapled RNAse-A Peptides95 
 
It was found that cross-linking of the unsymmetrical oct-2-ene staples did not proceed 
at room temperature, unlike the Δ-4 symmetrical staple (Table 9). Heating at 60 °C 
afforded the Δ-2 analogue 60 in high yield, however even with heating, the Δ-6 
macrocyclic peptide did not form and in fact decomposed. The difference in efficiency 
of the metathesis step is thought to be due to either coordination of the ruthenium 
centre to carbonyl groups in the peptide backbone96 (Figure 31) or the allylglycine 
monomer 32 being too hindered for efficient catalysis. 
 
Table 9- Peptides Investigating Staple Symmetry from Pham et al.95 
 













New Approaches to Stapled Peptides Targeting the p53-MDM2 Interaction 
 
Designing Stapled Peptides  40 
 
Figure 31- Coordination of Ru-Alkylidene to Carbonyl in Δ-2 RNAse-A Peptide95 
 
The peptides that cyclised were analysed using CD (Figure 32). The Δ-2 
unsymmetrical staple 60 showed a greater helicity that the native sequence 36, but was 
much less helical than the symmetrical Δ-4 peptide 54. This could indicate that the 
torsional strain caused by the unsymmetrical staple may be unfavourable to α-helix 
induction. These results show that the position of the olefin within the staple is a 
variable to consider. 
 
 
Figure 32- CD Spectra of RNAse-A 36 and Stapled Analogues Δ-4 54 and Δ-2 6095 
 
 RCM Linker Length Over One Helical Turn 
 
For some protein-protein interacting peptides, it may necessary to use a short staple to 
constrain the sequence to avoid replacing critical residues, or minimise unwanted 
staple-protein interactions. Kim et al.97 have explored the feasibility of an (i,i+3) cross-
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linker, as side-chains at these positions are still on the same face of the helix, and has 
approximately the same helical pitch as the established (i,i+4) linker (0.83 and 1.11 
residues respectively). Using the RNAse-A sequence and the α,α-disubstituted 
pentenyl monomers (30 and 33, Figure 33),66 the different enantiomeric pairings were 
screened for cyclisation efficiency (Table 10). It was apparent that the R(i,i+3)S (63) 
combination was preferred, with yields comparable to the more typical S(i,i+4)S linker 
(54) (Figure 34). The position of the staple in the sequence was altered (66-69) 
however similar results were seen suggesting that this tendency is not due to monomer 
placement within the peptide. Shortening the (i,i+3) linker length to 6 carbons (not 
shown) was found to be less stabilising than the 8 atom equivalent.98 
 
 
Figure 33- Monomers Used by Kim et al.97 
 




R 5 30 R 5 30 F 62
R 5 30 S5 33 F 63
S5 33 R 5 30 F 64
S5 33 S5 33 F 65
E R 5 30 R 5 30 66
E R 5 30 S5 33 67
E S5 33 R 5 30 68


















New Approaches to Stapled Peptides Targeting the p53-MDM2 Interaction 
 
Designing Stapled Peptides  42 
 
Figure 34- Comparison of RCM Macrocylisation Yield of (i,i+3) Staple - A Enantiomer 
Pairing B RCM Macrocylisation Yield of R(i,i+3)S 63 and S(i,i+4)S 5497 
 
Molecular dynamic simulations were concordant with the experimental data, 
suggesting that the R(i,i+3)S crosslink was the most stable, with the other pairs higher in 
energy (14-37 kcal/mol) due to unfavourable interactions between the α-methyl group 
and the staple (Figure 35). 
 
 
Figure 35- Representation of (i,i+3) Staples, Highlighting Unfavourable syn-Pentane 
Interactions (Arrows)97 
 
The two R(i,i+3)S peptides 63 and 67, along with the S(i,i+4)S analogues 54 and 70, were 
analysed for induced helicity and increased stability (Figure 36-A). All the macrocylic 
peptides showed increased helicity over the unmodified sequence 36, with crosslinked 
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sequences 54 and 63 exhibiting greater helical induction. Interestingly, in the trypsin 
digestion assays, the less helical stapled peptides 67 and 70 were the most stable, with 
no noticeable degradation at an substrate:enzyme ratio of 80:1 or 20:1. Only at a 2:1 
ratio was there evidence of cleavage of the peptide 70, with peptide 67 remaining 
undigested. The incredible stability of these peptides can be attributed to the location 
of the cleavage site within the sequence; the amino acid recognised by trypsin, in this 
case lysine, is contained between the alkenyl monomers. This may be explained by the 
fact that the greatest helicity imparted to the residues encompassed by the staple,78 and 
proteases cannot recognise folded structures.99 There is also evidence that α,α-
disubstituted amino acids are not recognised by trypsin, and can halt peptidolysis when 
surrounding the enzymatically recognised residue.100 The most helical peptides were 
tested for increased cellular uptake (Figure 36-B). Surprisingly, it was found that cyclic 
peptide 63 was only moderately more penetrant than the uncyclised native 36.  
 
 
Figure 36- Analysis of RNAse-A Analogues - A CD Spectra B Flow cytometry profile 
showing cellular uptake of 36, 54 and 63 into HeLa cells97 
 
 Stereoselectivity of Bis-RCM Staples 
 
The orthogonal stereochemical preferences of the (i,i+3) and (i,i+4) linkers can also 
be utilised to design multi-stapled peptides which have been shown to have increased 
proteolytic stability.101 This was demonstrated by Kim et al.97 by incorporating the 
residues 30 and 33 (Figure 37) into two new peptides 71 and 72 based on the RNAse-
A sequence 36 (Table 11). By relying on the most favourable S(i,i+4)S and unfavourable 
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S(i,i+3)S (Figure 38-A) and S(i,i+3)R (Figure 38-B) interactions, both the doubly stapled 
peptides formed selectively. This was further illustrated by synthesising the 
polyalanine 13-mer 73. Following the reaction by LC-MS it was evident that as a result 




Figure 37- Monomers used by Kim et al. in Bis-Stapled Peptides 
 
Table 11- Bis-Stapled Peptides from Kim et al. 
 
 
Figure 38- Respresentations of Disadvantageous A S(i,i+3)S and B S(i,i+3)R Interactions 
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Building upon this and previous work on the RNAse-A peptide (36),66,86 Hilinski et 
al.102 used the information that an (i,i+4) staple would favour an 8 atom linker with the 
S,S configuration of monomers and an (i,i+7) staple would favour an 11 atom linker 
with R,S configuration (Figure 39-B). Identifying that a bis-pentenyl glycine monomer 
(Figure 39-A, 74) would have the required pro-S and pro-R side chains for both staples, 
and would maintain the α,α-disubstitution that aids this stereoselection via detrimental 
steric interactions,78 this “stitched” peptide (Figure 39-B) should theoretically have the 
same stability equivalent to a bis-stapled peptide while encompassing a greater number 
of residues within the macrocycles. 
 
Figure 39- A Monomers Incorporated into Stitched Peptides B Representation of 
Favoured (S(i,i+4)S and R(i,i+7)S) and Unfavourable (i, ii iii, iv) Interactions for cyclisation 
in RCM Stitched Peptides102 
 
This new methodology was applied to a polyarginine (R12) sequence, one of the most 
potent cell penetrating peptides known,103 but which is intrinsically disordered due to 
the cationic side-chain repulsions.104,105 The stitched polyarginine sequence, 
Ac-(33)RRR(74)RRRRRR(35)-NH2, showed a vast increase in helical secondary 
structure compared to the R(i,i+7)S(11) stapled (R-Stp) and the unmetathesised stitched 
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peptide (59%, 23% and 15% respectively, Figure 40-A), suggesting that 
macrostabilisation plays a greater role than the minor rigidifying effects from α,α-
disubstituted amino acids. Performing a computational solvation analysis, it was found 
that the stitched peptide has less water molecules associated with each residue when 
compared to the native R12 and R-Stp sequences, which is in agreement with the 
theory that macrocyclisation increases hydrophobicity and prevents disruption of 
secondary structure by co-ordinating water at amide hydrogen bonding sites.106–108 
Comparing the cellular uptake of the R12, R-Stp and R-Stc, again it was found that the 
hydrocarbon crosslinked peptides had a greater penetrance than the polyarginine 12-
mer sequence (Figure 40-B). Interestingly, while the stitched peptide has fewer 
cationic residues it displayed the greatest uptake, indicating the benefits of increased 
hydrophobicity and pre-organisation. Finally, the peptides were tested for stability in 
a trypsin digestion assay. Trypsin recognises charged basic residues, so thus not 
surprisingly at 25 °C and a substrate:enzyme ratio of 800:1, the R12 sequence was 
metabolised completely in 5 minutes. Under the same conditions, the R-Stp and R-Stc 
sequences were relatively undamaged (41% and 94%, Figure 40-C). Even after 1 h the 
R-Stc sequence was still greater than 50% intact, underlining the increased proteolytic 




Figure 40- Comparison of poly-R Peptides A α-Helicity B Epifluorescent microscopy 
analysis of cellular uptake into HeLa cells C Stability of R-Stp and R-Stc toward trypsin 
at 25 °C 102 
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 Non Side-Chain Side-Chain RCM for α-Helical Induction 
 
There is evidence that helix induction requires the pre-organisation of only three amino 
acid residues, and that overcoming this energy is the main thermodynamic 
barrier.8,109,110 Building upon previous work,111–113 Chapman et al.114 used RCM to 
mimic the chain of 13 atoms that are characteristic of α-helical secondary structure 
(Figure 41-A). Using the control peptide, Ac-GEAAAAEA-OMe (75), which had no 
inherent secondary structure, A3 was replaced by an N-allylated analogue, synthesised 
by alkylating the 2-nitrosulfonamide of alanine tert-butyl ester,115,116 and the N-
acylated glycine was substituted for 4-pentenoic acid (76u).  
 
Figure 41- Representation of A 13 Atom Chain in α-Helix Hydrogen Bonding B RCM 
Hydrogen Bond Surrogate C Peptide 75 and HBS Analogue 76u 
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It was shown that, following metathesis, the all carbon hydrogen-bond surrogate (HBS, 
76c) installed could induce a helix in the peptide sequence, as shown by the 
characteristic minima at 220 nm and 202 nm (Figure 42-A(i)). Addition of 
trifluoroethanol62–64 did not result in an increase of helicity (Figure 42-A(ii)). 
Calculating the relative percent helicity,117 and correcting for small peptides,118 it was 
discovered that the HBS peptide was determined to be 100% helical. Comparatively, 
the native sequence showed no relative helicity (Figure 42-A(iii)), in any amount of 
trifluoroethanol (Figure 42-B). 
 
 
Figure 42- CD Spectra of A(i) 76c in 30 mM Phosphate Buffer A(ii) 76c in 20% TFE in 
30 mM Phosphate Buffer A(iii) 75 in 30 mM Phosphate Buffer B 75 in 0%, 10%, 15%, 
50% and 100% TFE in 30 mM Phoshate Buffer114 
 
The HBS method, after optimisation for solid phase sythesis,119 has been shown to 
induce helicity in a number of biologically relevant peptides.120,121 One of the benefits 
of this approach is that it can be used to synthesise α-helices for protein-protein 
interactions that have residues on opposite faces of the peptide required for activity.122 
 
1.2.2 Copper(I) Alkyne-Azide Cycloaddition (CuAAC) 
 
The copper(I) alkyne-azide cycloaddition, unlike its non-catalysed precedent,123–125 
regioselectively forms 1,4-disubstituted 1,2,3-triazole products (Figure 43).126,127 This 
transformation has been used ubiquitously in synthesis. The facile, robust nature of the 
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reaction facilitates the rapid creation of combinatorial libraries, and the use of copper 




Figure 43- Schematic Representations of A Alkyne Azide Cycloaddition B CuAAC 
 
The heterocycle, which is inert to the proteasome and synthesised from biologically 
silent functional groups, can be considered an amide isostere (Figure 44) and has been 
used as such. These properties make the CuAAC reaction appealing as a stapling 
technique. 
 
Figure 44- Comparison of Amide and Triazole 
 
 CuAAC (i,i+4) Staple 
 
The first example of α-helical induction using CuAAC was from Cantel et al.129 Based 
on prior studies that showed that alkyne and azide bearing peptides can be cyclised on 
resin with high tolerance of peptidyl functional groups and in high yields,130 Cantel et 
al. looked at  Parathyroid Hormone related Protein (PTHrP), a protein associated with 
tumour malignancy which has a bioactive α-helical section.131 The Ac-PTHrP-(11-
19)NH2 sequence, Ac-KGKSIQDLR-NH2 (Figure 45-A 77u), a truncated peptide 
which had been derived from a longer sequence that already shown increased 
secondary structure stabilisation following the (i,i+4) lactamisation of K13 and D17 
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(Figure 45-A, 77c),132–134 was used as a model substrate. The lactamising residues were 
replaced with alkyne and azide equivalents (Figure 45-B) to allow direct comparison. 
 
 
Figure 45- A Ac-PTHrP-(11-19)-NH2 77u/c B CuAAC Analogue 78u/c 
 
The azide was installed in the peptide by diazo transfer on a lysine residue by triflic 
azide.135–138 Attempted cyclisation on resin however gave poor yields, or a mixture of 
product and cyclodimer.139–141 The peptide 78u was instead cleaved from the resin and, 
following purification by RP-HPLC, cyclised in solution using supra-stoichiometric 
amounts of copper to yield the cyclised monomer. The cyclised peptides were analysed 
by CD for α-helicity. The lactamyl (77c, Figure 46-A) and triazolyl (78c, Figure 46-
B) peptides showed no secondary structure in 100% water (Figure 46-A,B-Solid) but 
showed greater than 50% relative helicity (Figure 46-A,B-Dashed) in 50:50 
hexafluoroacetone (HFA):water.142 NMR nOe experiments also saw an increase in 
cross-peaks following solvent substitution, confirming organisation of the peptide. 
 
 
New Approaches to Stapled Peptides Targeting the p53-MDM2 Interaction 
 
Designing Stapled Peptides  51 
 
Figure 46- CD Spectra of A 77c and B 78c in 100% Water (Solid) and 50:50 
Water:HFA (Dashed)129 
 
 Linker Length and Regioisomerism in (i,i+4) CuAAC Staple 
 
Continuing the investigation into the utility of the CuAAC as a stapling method Scrima 
et al.,143 using the same Ac-PTHrP-(11-19)NH2 model 77u, replaced the lysine and 
aspartic acid residues for alkynyl and azido non-natural amino acids with various side 
chain lengths (Figure 47).144 The order of each of the monomers was varied to account 
for the regioisomers that exist due to the asymmetry of the triazole.145 
 
 
Figure 47- A 1,4- and B 4,1- Regioisomeric Triazolyl Peptides of 
Ac-PTHrP-(11-19)NH2 77u 
 
The circular dichroism spectra of these peptides were run in both water and water:HFA 
(50:50) for direct comparison to the previous study.129  Analysis of the spectra showed 
that the triazolyl cyclic peptides showed little secondary structure in water. In 
water:HFA all the peptides showed a high helical propensity. Molecular dynamic 
simulations from NMR experiments showed that peptides with staples where n+m = 4 
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(79c and 82c) constricted the peptides into non-canonical secondary structures. Staples 
where n+m = 7 (81c and 85c) did not constrict the peptides effectively enough, 
allowing a flexibility within the backbone that allowed irregular conformations. 
Peptides that had staples containing either n+m = 4 or 5 seemed to be the most 
effective, however it was shown that in the peptides where n+m = 5 (78c and 83c) the 
position of the triazole can affect the structure, whereas this effect was not observed 
when n+m = 6 (80c and 84c). This suggests that a linker where n+m = 6 may be more 
broadly applicable.143 
 
Expanding on their previous investigation, Scrima et al.146 continued analysis of a 
number of the triazolyl peptides previously synthesised143,144 (Figure 48). To verify 
that the α-helicity of the triazolyl peptides was not due to the water:HFA solvent, NMR 
experiments were performed in DMSO:water (80:20), a biomimetic solvent mixture 
which exhibits high viscosity and so restricts the flexibility of the peptide, allowing 
observation of the most common conformers.147–149 
 
 
Figure 48- Triazolyl Regioisomeric Peptides Analysed in DMSO:H2O by Scrimia et al. 
 
Interestingly, although in good agreement with the previous results, cyclopeptides that 
contained a 4,1-orientated triazole (82c, 88c and 89c), regardless of linker length, 
displayed non-helical or non-regular conformations. In contrast, 1,4-orientated 
triazolyl peptides where n+m = 6 or 7 (86c and 87c) allowed helical secondary 
structure. Study of the calculated structures showed that the nitrogen lone pairs of the 
triazole interacted with the serine or glutamine side chain residues either 
advantageously or deleteriously to α-helical induction, stressing the need to consider 
the chemistry of the heterocycle when using CuAAC in stapling.146 
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 Stereochemistry of Alkynyl and Azido Monomers/Bis Stapling 
 
In a comprehensive study, Kawamoto et al.150 selected the BCL9/β-catenin protein-
protein interaction as a model system for triazole stapling. Controlling a number of 
cell cycle and apoptosis regulating genes, the upregulation of β-catenin is associated 
with tumorigenesis in a number of human cancer types.151,152 It is known to form a 
complex with a number of proteins, including B-cell lymphoma 9 (BCL9). The unique 
binding site for the α-helical section of BCL9,153 a necessary interaction for β-catenin 
mediated transcriptional activation, makes the interaction attractive as a therapeutic 
stapled peptide target. Using an optimised minimum binding 24-mer sequence 
Ac-LSQEQLEHRERSLQTLRDIQRMLF-NH2 90,
154 avoiding the replacement of 
positively charged residues to enhance cell permeability,155 solvent exposed residues 
E360 and Q364 located on the same helical face in the middle of the peptide (Figure 
49) were swapped for alkynyl93,94 and azido135–138 monomers of different lengths and 
chirality (Figure 50). The % helicity and binding of the uncyclised and cyclised 
peptides were measured by circular dichroism and competitive fluorescence 
polarisation assay respectively (Table 12). 
 
 
Figure 49- BCL9 based peptide 90 (green) bound to β-Catenin with solvent exposed 
residues E360 and Q364 (magenta). PDB code 2GL7, reproduced using PyMol. 
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Figure 50- Monomers Incorporated in BCL9 Triazolyl Stapled Peptides 
 
Table 12- % Helicity and Ki of BCL9 Peptides 90 and 95 and Analogues 96-103 
 
 
The native sequences and uncyclised peptides (90, 95, 96u-103u) showed moderate 
relative helicity and binding affinity to β-catenin, however following cyclisation clear 
distinctions became obvious. As previously found,143,146 in cyclised peptides with a 
linker length n+m = 4 (98c) there was a significant drop in % helicity and a total loss 
of affinity. Interestingly, when the linker length is n+m = 6 (99), cyclisation did not 
result in increased relative helicity or binding with respect to the uncyclised sequence 
which is in contradiction to previous studies. Moving the triazole one atom to a more 
central position within the staple (100c) reduced the solubility, binding affinity and 
removed the helicity of the sequence noticeably. This once more suggests that the 
dipole of the triazole can affect the stability of stapled peptides.146 
 
The effect of monomer chirality can be seen in peptides 96, 97, and 101-103. Linear 
peptides with D-amino acids (97u, 102u and 103u) tended to have lower relative 
X1 X2 X3
a n+m u c u c
E Q M - 90 44 - 0.60 ± 0.14 -
E Q L - 95 47 - 0.94 ± 0.17 -
S92 S93 M 5 96 44 66 1.4 ± 0.2 0.33 ± 0.6
S92 R 93 M 5 97 45 90 4.9 ± 0.9 0.13 ± 0.05
S91 S93 M 4 98 42 26 2.4 ± 0.2 NB
S92 S94 M 6 99 49 48 1.4 ± 0.1 3.0 ± 0.3
S91 S94 L 5 100 50 30 1.9 ± 0.4 30 ± 5
b
S93 S92 L 5 101 49 ND
c
3.6 ± 1.0 0.77 ± 0.18
S93 R 92 L 5 102 32 57 11.0 ± 1.0 1.17 ± 0.51
R 93 S92 L 5 103 34 67 2.2 ± 0.2 4.3 ± 0.4
a L replaced M due to oxidation; b extrapolated; c peptide insoluble; ND: Not Determined; NB: No Binding; 
Ki  ± SD (μM)% HelicityAc-LSQEQLEHRX1RSLX2TLRDIQRX3LF-NH2
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helicities than the native sequences (90 and 95). A vast increase in helicity is observed 
in peptide 97c from the inversion of stereochemistry in the propargyl monomer 93 
(Figure 51), thought to be due less distortion of the peptide backbone. Again, the 
regioisomerism of the triazole affects the properties of the peptides, with the 4,1-
triazolyl peptides 101-103 showing less favourable characteristics than the 1,4-triazole 
counterparts. It could be argued that the most effective combination of 1,4-regioisomer 
with the S(i,i+4)R enantiomeric pairing (97c) is mirrored in the 4,1-regiosomer with 
R(i,i+4)S pairing (103c), which is more helical than the diastereomeric peptide 102c, 
though the pairing is less favourable overall.150 
 
 
Figure 51- % Helicity of Diastereomeric CuAAC Peptides 
 
As the native peptides 90 and 95 encompass 6 helical turns, the effect of different 
stapling positions was considered. Using the optimal linker pairing of S92(i,i+4)R93 
exhibited in peptide 97c (Table 12) and maintaining the greatest number of positively 
charged residues, new (i,i+4) staples were installed and the possibility of a bis triazolyl 
stapled peptide was also investigated (Table 13). By reversing the functionality of the 
side chain, it was postulated that the double staple would preferentially form over the 
disfavoured mixed staple (Figure 52). 
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Figure 52- Representation of Regioselectivity Expected in Bis-Triazolyl Stapled 
Analogues of BCL9  
 
Table 13- % Helicity and Ki of Mono- and Bis-Stapled BCL9 Analogues 
 
 
Moving the staple closer to the C terminus (105) was shown to increase relative 
helicity more than moving the staple toward the N terminus (104), though both 
exhibited similar binding affinity to β-catenin. This is thought to be due to the 
encompassing of threonine, a known α-helix destabilising residue.156 As the 
regioisomer 106 was also tolerated, the bis triazolyl peptides 107c and 108c were 
synthesised. Both displayed increased relative helicity and binding affinity, but a 
peptide containing two staples with the most stabilising monomer pairing S92(i,i+4)R93, 
X1 X2 X3 X4 u c u c
S92 R 93 Q L 104 21 60 1.97 ± 0.2 0.41 ± 0.05
L E S92 R 93 105 31 81 2.01 ± 0.1 0.26 ± 0.04
L E S93 R 92 106 16 42 6.66 ± 0.4 0.56 ± 0.05
S92 R 93 S93 R 92 107 12 95 13.2 ± 0.9 0.41 ± 0.07
S93 R 92 S92 R 93 108 20 96 14.5 ± 1.1 0.61 ± 0.01
X1 X2 X3 X4
S92 R 93 S92 R 93 109 ND
a
99 3.6 ± 0.1 0.19 ± 0.03
Ac-LSQEQX1EHRX2RSLX3TLRX4IQRLLF-NH2 % Helicity Ki  ± SD (μM)
Ac-LSX1EQLX2HRERSLX3TLRX4IQRLLF-NH2
a peptide insoluble; ND: Not Determined 
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removing the unfavourable 4,1-regioisomer, separated by a helical turn (109c) showed 
even greater helical induction. Notably, while the double stapled peptides showed 
greater helical induction, the binding affinity for β-catenin did not vary vastly in 
comparison to some of the mono stapled sequences. This highlights the point that 
although there is a correlation between affinity and α-helicity, the maximum affinity 
is dependent on the sequence and when reached, additional stapling will only increase 
the efficacy of the peptide.150 
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1.3 Considerations of Design 
 
After looking at the previous examples, it becomes apparent that although ultimately 
the efficiency of each staple is highly dependent on the sequence, certain properties 
need to be considered: 
 
1. Length of the linker – too short and the linker may not form or constrict the 
peptide into undesired conformations. Too long and the peptide becomes too 
flexible and the staple is redundant. An optimum linker length would constain 
the peptide, but allow for some flexibility to allow for the dynamic nature of 
PPIs.  
2. Linker position – The linker should be positioned such that it will be located 
near the greatest number of residues critical for binding. Ideally it should be 
close to helix destabilising residues also, ensuring maximum helical induction 
of these residues. 
3. Number of Staples – For short peptides (< 13 residues) a single optimised 
staple should be sufficient. For longer sequences a multiple stapling strategy 
should be considered. 
4. Regioisomerism – There will be a preferred regioisomer or directionality to the 
staple. 
5. Stereoisomerism – The optimal chiral pairing of the linking monomers will 
vary with the linker being used. 
6. Chemistry – The physicochemical properties of the stapling system may 
interfere with the induced helicity. 
 




Chapter 2- The p53 MDM2 Interaction as a 
Therapeutic Target 
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2 The p53 MDM2 Interaction 
 
The p53 protein is key in regulating cell health and viability by a number of processes 
including senescence, DNA repair, cell cycle arrest, cell metabolism, apoptosis, or 
autophagy.157 This myriad of essential effects has resulted in p53 being described as 
“guardian of the genome”.158  Unsurprisingly, loss of p53 activity is responsible for 
50% of human cancers. This is usually due to its tumour suppression being hindered 
by regulating proteins such as MDM2 and MDMX. MDM2 is an E3 ubiquitin ligase 
and has p53 as a transcription factor, and so forms a negative feedback loop.159 While 
MDMX does not have any E3 ligase activity, in forming a heterodimer with MDM2, 
ubiquitinylation of p53 is triggered and the complex is removed from the cell 
nucleus.160,161 A number of tumour cells either under-express p53 or over-express 
MDM2 and/or MDMX and it has been shown that re-activation of p53 can halt tumour 
growth. Therefore, inhibiting MDM2 and MDMX provides a non-genotoxic pathway 
for cancer therapy (Figure 53).  
 
 
Figure 53- Summary of the Autoregulatory Loop of p53, MDM2 and MDMX162 
 
Both MDM2 and MDMX bind to p53 at the N-terminal transcription activation domain 
(residues 1-44, Figure 54). While p53 has a number of intrinsically disordered 
domains,163 the transactivational domain of p53 adopts an α-helical structure when 
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binding to the MDM-homologues. To reactivate p53 activity, an inhibitor must be able 
to block both the hydrophobic pockets of MDM2 and MDMX. A number of peptide 
sequences of different length, derived from the p53 transactivation domain, have been 
used as a control to measure inhibition of MDM2 and MDMX. These peptides 
typically use sequences from within the L14 to C31 residues. However, all the 
sequences contain the three residues that are critical for binding to the hydrophobic 
pockets of both MDM2 and MDMX: F19, W23 and L26 (Figure 55).164,165 
 
 
Figure 54- Functional Domains of p53- 1-44: Transactivation domain, activates 
downstream target genes; 58-101: Proline rich domain, mediates p53 response to 
DNA damage through apoptosis; 102-292: DNA-binding domain; 325-356: 
Oligomerization domain, responsible for p53 dimer and tetramer formation; Nuclear 




Figure 55- Crystal Structure of p53 α-Helical Transactivation Domain (green) bound 
to MDM2, with Critical Residues F19, W23 and L26 shown. PDB code 1YCR, 
reproduced using PyMol.  
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2.1 Small Molecule Inhibitors of the p53 Binding Site 
 
A number of small molecule drugs have been discovered that inhibit the p53-MDM2 
interaction. The first were the Nutlin family of cis-imidizoline inhibitors (Figure 56), 
discovered from a small molecule library.167 The compounds were able to displace p53 
from MDM2 within an IC50 range of 100-300 nM. As with most pharmaceuticals, the 
chirality of the cis-imidazoline has important consequences for binding, with one 
enantiomer (Nutlin-3a, 112a) exhibiting 151-fold greater binding to MDM2 (Figure 
57). 
 
Figure 56- Structure of Nutlin Inhibitors 
 
 
Figure 57- MDM2 IC50 values for A Nutlin-1 B Nutlin-2 C Nutlin-3a and Nutlin-3b167  
 
The halophenyl groups on the Nutlin inhibitors are projected into the hydrophobic 
binding pocket of MDM2 in a similar way to the native p53 peptide (Figure 58).167 
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Figure 58- Nutlin-2 bound to MDM2.168 PDB code 1RV1, reproduced using PyMol. 
 
2.2 Peptidomimetic Inhibitors of the p53 Binding Site 
 
Although small molecules can interact with the hydrophobic pocket of MDM2, they 
cannot accurately mimic the larger surface area of a true protein-protein interaction. 
Peptidomimetics are larger molecules that more accurately simulate the larger surface 
area of a PPI. 
 
2.2.1 Oligoaryl Peptidomimetics 
 
The first report of oligoaryl peptidomimetics came from Orner et al.169 The premise 
was that ortho-side chains on a terphenyl scaffold would accurately mimic the residue 
side chains of an α-helix (Figure 59). This approach allows a great variety of function 
to be installed into the side-chains, in part due to the facile nature of the synthesis by 
sequential cross-coupling reactions. 
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Figure 59- Comparison of α-helix and Terphenyl Peptidomimetics170 
 
Employing this strategy to target the p53-hDM2 interaction was first attempted by Yin 
et al.171 Using a selection of hydrophobic ortho-substituted phenyl groups a library of 
terphenyl inhibitors was synthesised. The most effective inhibitor was found to be 113 
(Figure 60), thought to be partly due to the 2-methylnaphthalene side-chain which 
more accurately mimics the conformation of the critical residue W23 in the p53 N-
terminal binding domain. 
 
 
Figure 60- Terphenyl Inhibitors of p53-hDM2 
 
It was shown that these scaffolds can be engineered to selectively bind to protein 
targets. By changing the orientation of the methylnaphthalene side chain slightly (114), 
the binding to hDM2 is diminished 100-fold. The inhibitors were tested against two 
other apoptosis regulating proteins with hydrophobic binding pockets, Bcl-2 and Bcl-
xL which both bind the α-helical BH3 domain of the Bak protein.
76,77,172 Again, this 
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small alteration to the orientation of the naphthalene group increased the selectivity of 
114 for Bcl-xL and Bcl-2 by 22- and 124-fold respectively (Table 14).
171 
 
Table 14- Inhibitory Concentrations of Terphenyl Scaffolds 113 and 114  
 
 
Problems with the terphenyl scaffold are the inherent hydrophobicity and the lack of 
flexibility within the “backbone”. To address this, Plante et al.173 synthesised 
peptidomimetics based upon on an oligobenzamide backbone (Figure 61). This 
modification adds an amount of conformational flexibility, increases solubility of the 
scaffold and still makes synthesis from commercially available starting materials 
simple. 
 
Figure 61- Comparison of Terphenyl and Oligoamide Peptidomimetics 
 
A small library of these new oligobenzamide inhibitors were synthesised and tested 
for activity against hDM2.174 Not surprisingly the oligobenzamide inhibitor 115 
(Figure 62), which is analogous to the best terphenyl inhibitor 113, proved the most 
effective. This was also the case with the N-alkylated175 oligobenzamide 116, however 
all of these inhibitors had a similar IC50 value to the 
15-31p53 peptide sequence (Table 
15). This suggest that the oligobenzamides would be ineffective therapeutic hDM2 
inhibitors.  
K i (μM) hDM2 Bcl-xL Bcl-2
113 0.182 2.50 15.0
114 25.7 0.114 0.121
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Figure 62- Oligobenzamide Inhibitors of hDM2 
 





Peptoids are oligoamides that consist of N-substituted glycine monomers (Figure 63). 
Using amino acids means the peptoid closely mimics a peptide. Additionally, by 
moving the side-chain from the α-carbon to the nitrogen, the peptoid has increased cell 
permeability176 and resistance to proteolysis177 when compared to the equivalent 
amino acid sequence. 
 
 
Figure 63- Monomers Present in A Peptides B Peptoids 
 
Using this strategy, Hara et al.178 attempted to synthesise a peptoid inhibitor of hDM2. 
It has previously been observed that although the backbone is devoid of chirality, 
15-31p53 115 116
IC50 (μM) 1.2 ± 0.04 1.0 ± 0.11 2.8 ± 0.8
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peptoid oligomers can fold into well-defined secondary structures. In addition it has 
been shown that incorporation of chiral side chains can induce helicity.179,180 The 
peptoidyl helices are more tightly wound compared to an α-helical peptide, having 
only 3 residues per helical turn as opposed to 3.6. When comparing this to the wild 
type p53 peptide sequence, the critical 19F and 23W residues are in the (i,i+4) positions 
with respect to each other, which would not be on the same face of the peptoid helix. 
This sequence incongruity was remedied by reducing the number of residues by one 
between these positions within the peptoids. The angle at which the side chains of the 
N-substituted glycine monomers protrude from the peptoidyl helix is slightly different 
also. To accommodate for this, an extra methylene group was added to the side chains 
of the residues corresponding to the binding residues 19F and 23W, which when 
compared to the native p53 sequence in silico, appeared to reproduce the necessary 
binding conformation (Figure 64). 
 
 
Figure 64- Energy Minimised Conformation of a Peptoid with WTp53 Sequence 
Overlaid (Green). Only Critical Binding Residues are Highlighted.178 
 
During the optimisation of the peptoid 117 (Figure 65) the equivalent critical residues 
were replaced in a “sarcosine (N-methyl glycine) scan”, analogous to an alanine scan 
in peptides, to confirm that the peptoid was binding to hDM2 in a similar way to the 
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wild type p53 sequence. Systematic removal of the residues with critical side chains 
saw an increase in the IC50 value of the peptoid (118-120 vs 117, Table 16). 
 
 
Figure 65- Structure of Lead (117) and Sarcosine Scan Peptoids from Hara et al.178 
 
Table 16- IC50 Values of Peptoids 117-120 to hDM2 
 
 
Interestingly, although removing chirality in the side chains (Figure 66) induced a loss 
of helicity (determined by circular dichroism), the IC50 value of the sequence was 
Sequence 117 118 119 120
IC50 (μM) 17.8 59.8 28.3 25.3
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similar to the chiral sequence (121 vs 117, Table 17). This suggests that the peptoids 
can fold into non-helical conformations that are still efficacious, or possibly that the 
peptoids folds into a helical conformer upon binding to hDM2.178 The addition of a 6-
chloro group on the tryptophan residue has been shown to increase binding to MDM2 
and MDMX (discussed in 2.3.1.1).181,182 Incorporation of this modification into the 
peptoids 122 and 123 saw a further decrease in IC50. 
 
 
Figure 66- Chiral and Achiral Peptoid Inhibitors of MDM2 from Hara et al.178 
 
Table 17- IC50 Values of Peptoids 117 and 121-123 to hDM2 
 
Sequence 117 121 122 123
IC50 (μM) 17.8 18.2 9.9 6.6
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2.3 Peptide Inhibitors of the p53 Binding Site 
 
One way to inhibit a protein-protein interaction would be to synthesise the peptide 
sequence responsible for binding. The advantages of using peptides as inhibitors of 
PPIs include the more accurate mimicry of the protein inhibitor, as well as the greater 
surface contact and the conformational flexibility afforded from a larger molecule. 
Additionally, from a therapeutic standpoint, the peptides would be digested into non-
toxic metabolites. 
 
2.3.1 Phage Display Peptides 
 
A number of peptide inhibitors of the p53 MDM2 interaction have been discovered by 
phage display. Phage display is a technique that encodes a peptide or protein of interest 
to the surface of a bacteriophage, a virus that infects bacteria. The genetic information 
that encodes this protein is contained within the phage.  A library of these phages are 
used to target a specific protein that has been immobilised (Figure 67). A phage that 
displays a peptide that interacts with the immobilised target will also become 
immobilised upon binding, those phages that do not bind are washed away. The bound 
phages are then eluted from the immobilised protein, and are used to infect bacteria to 
amplify binding peptides or proteins. After repeating these steps a number of times 
(panning) phages will be enriched with high affinity binding partners, which can be 
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Figure 67- Phage Display: Bacteriophages are exposed to a bound target (purple). 
The active phages bind to the target and the rest are washed away (i); The active 
phages are eluted from the bound target (ii); The phages are amplified (iii); The steps 
are repeated (iv) or the phages are analysed (v). 
 
 Active Peptide - AP 
 
Following a screening of a phage display library and discovery of a high affinity 12-
mer peptide Ac-MPRFMDYWEGLN-NH2 124,
183 Garcia-Echeverria et al.181 
synthesised truncated versions, between 6-11 residues, to discover the minimum 
sequence length for hDM2 inhibition. It was found that all of the 6- and 7-mer peptides 
were poor inhibitors of hDM2, however an 8-mer peptide 125 (Figure 68) was found 




Figure 68- 8-mer Lead Peptide 125 
 
Replacing residues D3 and G7, which are on the opposite helical face to the critical 
binding residues, with helix-favouring α,α-disubstituted residues α-aminoisobutyric 
acid (Aib) and 1-amino-cyclopropane carboxylic acid (Ac3c)
69 (Figure 69) increased 
the affinity of the 8-mer 125 for hDM2 4-fold, and constricted the peptide into a more 
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helical binding conformer (126, Table 18) as observed by NMR. After exploring a 
model of peptide 126 bound to hDM2, it was found that, although replacement of the 
tyrosine and tryptophan residues would be deleterious to binding,184 they could be 
modified to improve the affinity of the peptide. It was observed that the phenolic OH 
of the tyrosine residue was close to the side chain of K94 in hDM2. Swapping the 
tyrosine residue for a similar 4-phosphonomethylphenylalanine (Pmp) would allow a 
salt bridge interaction to be established. This substitution produced a 7-fold increase 
in binding affinity of the peptide (126 vs 127).181 
 
Figure 69- Monomers used in the AP Peptide 
 





X1 X2 X3 X4
E Y W G 125
Aib Y W Ac3c 126
Aib Pmp W Ac3c 127
Aib Pmp 6Me-W Ac3c 128
Aib Pmp 5Me-W Ac3c 129
Aib Pmp 6F-W Ac3c 130
Aib Pmp 6Cl-W Ac3c 131
Aib Pmp D-6Cl-W Ac3c 132
Aib F 6Cl-W Ac3c 133 1.5
b
138 000 ± 27000
a Data From Separate Assay; b  Data from Sakurai et al.;
2210 ± 346
314 ± 88 (313a )











5 ± 1 (0.74b )
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It was also observed from the binding model and parallel computational studies185 that 
there was a small gap in the tryptophan hydrophobic pocket (Figure 70). Altering the 
tryptophan residue, by substitution at the 6-position of the indole resulted in peptides 
with significantly increased binding to hDM2 (Figure 71), with the 6-Cl substitution 
giving rise to the lowest IC50 value (131). Substitution at the 5-position did not result 
in as great a change in the binding affinity (127 vs 129).181 Continuing the study, Chene 
et al.186 demonstrated that AP was active in vitro, though only in cells expressing p53. 
Administration of the peptide to cells overexpressing hDM2 resulted in apoptosis, and 
so AP 131 was shown to be the first inhibitor of the p53 hDM2 interaction in cells. 
Interestingly, following resolution of the crystal structure of peptide 131 by Sakurai et 
al.,187 it was discovered that the Pmp residue does not form a salt bridge with K94 in 
hDM2, but in fact projects into the solvent, forming hydrogen bonds with surface-
bound water molecules. Replacing the Pmp residue with a Phe resulted in only a 2-
fold decrease in binding affinity (131 vs 133), confirming the hydrogen bonding has 
little effect on the affinity of the peptide, and that hydrophobic contact is the most 
important stabilising factor.187 
 
 
Figure 70- p53 Peptide bound to MDM2, showing the hydrophobic space available 
below W23. PDB code 1YCR, reproduced using PyMol. 
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Figure 71- AP Peptide 131 bound to hDM2. PDB code 2GV2, reproduced using 
PyMol. 
 
 Peptide Dual Inhibitor - pDI 
 
One of the first peptidyl inhibitors to target the homologous MDMX protein in addition 
to MDM2 using phage display was from Hu et al.188 As MDMX only shares 50% 
homology in the p53 N-terminal binding domain with MDM2, a number of small 
molecule inhibitors, including the Nutlins, and terphenyl type peptidomimetics are 
ineffective at inhibiting MDMX.189–191 There is evidence that suggests that MDMX 
inactivates p53 by sequestering the protein, as opposed to acting as a E3 ligase, 
although the heterodimerisation of MDM2 and MDMX has been shown to accelerate 
ubiquitination of p53.192,193 After phage panning, it became evident that the 
immobilised MDM-homologues had a preference for the sequence 
LTFEHYWAQLTS, termed pDI (134, Table 19). In an ELSIA assay, pDI showed IC50 
values of 10 and 100 nM for MDM2 and MDMX respectively (Table 19).  These 
inhibitory concentrations are 60- and 300- fold lower than values given for 16-27p53 
and Nutlin-3a (112a) inhibition of MDM2 and 275-fold lower for 16-27p53 to MDMX. 
Replacing the key hydrophobic residues F, W and L for alanine (p3A, 135) resulted in 
a complete loss of inhibition of both proteins. The ~10-fold difference in IC50 values 
between MDM2 and MDMX for 16-27p53 and 134 further validates the proposed 
mechanism of MDMX inhibition of p53 by sequestration. 
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Table 19- Comparison of pDI Peptide to Known Inhibitors of MDM2 and MDMX 
 
 
Using pDI as a starting point, Phan et al.194 attempted to design a peptide with 
improved binding properties. Replacing the tyrosine residue for tryptophan, another 
hydrophobic aromatic amino acid, improved the binding to MDMX approximately 2-
fold (pDI6W, XX, Table 20). From the crystal structures of pDI and pDI6W bound to 
both MDM2 and MDMX, it was observed that a large number of co-ordinated water 
molecules were conserved, with both the phenolic hydroxyl and indolic amine groups 
contributing to hydrogen bonding at the 6th residue position. It is argued that a greater 
contributor to the increased binding was the additional number of hydrophobic van der 
Waals interactions from the tryptophan residue (Y6 vs W6). This is in agreement with 
the attenuation or removal of activity of the peptide with more polar residues 
asparagine or serine (137, 138). The replacement of L1 for glutamic acid to increase 
solubility (L1E, 139) resulted in an additional 2-fold decrease in binding from pDI6W. 
Replacement of the alanine residue with a serine (A8S, 140), to form an intrapeptide 
hydrogen bond, lead to a decrease in IC50 value in comparison to both pDI and pDI6W. 
Inhibition of the MDM-homologues also increased upon the substitution of the C-
terminal threonine for leucine (T11L, 141), to increase hydrophobic interactions. 
Incorporation of all these advantageous mutations, (L1E, Y6W, A8S, T11L) 
culminated in peptide pDIQ (peptide dual inhibitor quadruple mutant, 142), which 
exhibits a 55- and 5-fold decrease in IC50 of MDM2 and MDMX with respect to p53
17-







pDI 134 0.01 0.10
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Table 20- Peptide Library of Mutations from Phan et al.194  
 
 
 p53-MDM2/MDMX Inhibitor – PMI 
 
Around the same time as pDI 134, the peptide sequence TSFAEYWNLLSP, termed 
p53-MDM2/MDMX Inhibitor (PMI 143) was discovered by phage display by Pagzier 
et al.195 The sequence was compared against two p53 peptides, 17-28p53 and the 
extended 15-29p53 sequence SQETFSDLWKLLPEN using isothermal titration 
calorimetry (ITC). It was found that PMI bound to MDM2 and MDMX with Kd values 
of 3.3 and 8.9 nM respectively (Table 21). This corresponds to an approximately 20-
fold increase when compared to 15-29p53 binding to MDM2 and MDMX. When 
compared to the 17-28p53 sequence, which consists of the same number of residues, 










pDI 134 44 550
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Table 21- Comparison of PMI to p53 Sequences 
 
 
The increase in binding affinity of PMI compared to the p53 peptides is thought to 
come from an increased number of α-helix stabilising hydrogen bonds. It has 
previously been demonstrated that the P27S mutation of p53 increases the helicity of 
the sequence and, consequently, the binding affinity for MDM2 50-fold.196,197 This 
substitution correlates to S11 in PMI. In addition, the SXXE sequence is typical of an 
N-terminal expanded capping box, a common helical motif in peptides and 
proteins.198–201 This arrangement is present in PMI (S2-E5, Figure 72) but absent in 
the wild type sequence. 
 
 
Figure 72- SXXE N-Terminal Capping Box Motif in PMI. PDB code 3EQS, reproduced 
using PyMol. 
 
The PMI peptide binding to MDM2 and MDMX was verified by a surface plasmon 
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PMI was compared to Nutlin-3 and pDI. Again, PMI exhibited the greatest binding 
affinity for both MDM2 and MDMX (Table 22). 
 
Table 22- Comparison of PMI to Known Inhibitors of MDM2 
 
 
To try to understand and increase the affinity further, Li et al.202 conducted alanine 
scans on the PMI peptide and the equivalent 17-28p53 sequence (Table 23). 
 




p53a 140 ± 5 270 ± 9
p53b 452 ± 11 646 ± 26
112 263 ± 60 -
pDI 134 19.6 ± 1.4 77.0 ± 8.7
PMI 143 3.36 ± 0.75 4.15 ± 1.47











MDM2 MDMX MDM2 MDMX
p53b 4.4 ± 0.4 x10-7 6.4 ± 0.5 x10-7 0.00 0.00
E17A 5.6 ± 0.2 x10
-7 6.8 ± 0.1 x10-7 0.14 0.03
T18A 1.2 ± 0.1 x10
-6 2.3 ± 0.1 x10-6 0.58 0.75
F19A - - - -
S20A 2.1 ± 0.1 x10
-7 3.1 ± 0.1 x10-7 -0.43 -0.43
D21A 8.3 ± 0.2 x10
-7 1.1 ± 0.1 x10-6 0.37 0.32
L22A 5.0 ± 0.4 x10
-6 9.0 ± 0.8 x10-6 1.41 1.54
W23A - - - -
K24A 2.3 ± 0.2 x10
-7 4.9 ± 0.4 x10-7 -0.39 -0.15
L25A 7.3 ± 0.1 x10
-7 6.9 ± 0.6 x10-7 0.30 0.04
L26A 2.7 ± 0.1 x10
-5 6.6 ± 0.1 x10-5 2.39 2.00
P27A 5.1 ± 0.3 x10
-8 2.4 ± 0.2 x10-7 -1.26 -0.58
E28A 2.4 ± 0.2 x10
-7 3.3 ± 0.1 x10-7 -0.36 -0.39
p53c 3.5 ± 0.4 x10-5 1.3 ± 0.2 x10-4 2.55 3.07NH2-FSDLWKLL-CO2H
ΔΔG (kcal/mol)a
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In agreement with previous work,196,197 the P27A mutation in the 17-28p53 sequence 
increases the binding affinity of the peptide 10- and 3-fold for MDM2 and MDMX 
respectively. The difference in binding between the 17-28p53 P27A and P27S for 
MDM2 (10- and 50-fold in comparison to the native 17-28p53 sequence) gives 
additional weight to the proposed hydrogen bonding stabilisation imparted by serine. 
The L22A substituted peptide showed an increase in Kd, which as previously 
discussed,194 is due to decreased hydrophobic contact at this position. Similarly, T18A 
and D21A mutations decrease the affinity of the 17-28p53 sequence. This is thought to 
be due to the disruption of hydrogen bonding analogous to the SXXE capping box 
motif.198–201 The octapeptide 19-26p53 was still found to have binding affinity to both 
MDM-homologues, which is in agreement with previous work.181,186,187,203  
 
Table 24- Alanine Scan of PMI Peptide 143 
 
 
After performing the alanine scan on PMI (Table 24), the only significantly deleterious 
residue detected was from the N8A substitution (150). The crystal structures of PMI 
shows that the N8 residue does not interact with MDM2 or MDMX. By replacing it 
with alanine, the binding affinity increases 6.5- and 3.5-fold for MDM2 and MDMX 
MDM2 MDMX MDM2 MDMX
PMI 143 3.2 ± 1.1 x10
-9 8.5 ± 1.7 x10-9 0.00 0.00
144 6.2 ± 0.1 x10
-9 1.6 ± 0.3 x10-8 0.39 0.35
145 2.7 ± 0.4 x10
-8 3.7 ± 0.4 x10-8 1.24 0.85
146 3.8 ± 0.2 x10
-5 1.2 ± 0.1 x10-4 5.46 5.57
PMI 143 3.2 ± 1.1 x10
-9 8.5 ± 1.7 x10-9 0.00 0.00
147 2.1 ± 0.1 x10
-8 6.7 ± 0.8 x10-8 1.10 1.20
148 6.1 ± 0.7 x10
-7 6.7 ± 0.8 x10-7 3.06 2.55
149 1.6 ± 0.3 x10
-4 2.3 ± 0.1 x10-4 6.31 5.94
150 4.9 ± 2.1 x10
-10 2.4 ± 0.6 x10-9 -1.10 -0.74
151 2.4 ± 0.5 x10
-9 9.0 ± 2.1 x10-9 -0.17 0.03
152 8.9 ± 0.1 x10
-7 4.3 ± 0.4 x10-7 3.28 2.28
153 3.9 ± 0.3 x10
-9 1.1 ± 0.2 x10-8 0.12 0.17
154 2.1 ± 0.5 x10
-9 1.4 ± 0.3 x10-8 -0.25 0.31
155 8.9 ± 0.7 x10
-6 4.4 ± 0.5 x10-5 4.62 4.98
Sequence K d (M)
NH2-TSFAEYANLLSP-CO2H
NH2-TSFAEYWALLSP-CO2H
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respectively. This is thought to be due to the properties of the asparagine residue itself, 
which is one of the least commonly found residues in α-helices in globular proteins, 
and has the poorest helical propensity of any of the proteinogenic residues.91 
Interestingly, the substitution does not create any new energetically significant 
intermolecular interactions, but stabilises hydrogen bonding in the amide backbone. 
The truncated octapeptide 155, corresponding to the 19-26p53 peptide, showed a 3-fold 
greater binding affinity by comparison. This difference appears to be solely due to the 
favourable L22-Y6 mutation. To date, the PMI N8A peptide has the strongest binding 
affinities for both MDM-homologues known.202 
 
2.3.2 Stapled Peptides 
 
Although peptides can display high binding affinity for MDM2 and its homologues in 
vitro, peptides are not cell penetrable and are easily digested by enzymes making them 
therapeutically unviable. Stapling, as discussed in Chapter 1, constrains peptides into 
conformations that replicate the natural secondary structure of the protein they are 





The first stapled peptide targeting the p53-hDM2 interaction from Bernal et al.155 was 
based on the wild type 14-29p53 sequence. To design stapled analogues of the 14-29p53 
sequence, the non-natural amino acids 33 and 156 (Figure 73) were used to replace 
non-critical residues at a number of positions (157c to 160c, Table 25). The olefinic 
monomers were spaced 7 residues apart, equivalent to 2 helical turns, ensuring the 
ring-closing metathesis macrocyclisation between the side chains occurs on the same 
face of the α-helix. 
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Figure 73- Monomers used by Bernal et al.155 
 
Table 25- Peptide Library from Bernal et al.155 
 
 
Examining the relative helicity of the peptides by circular dichroism revealed that, 
after replacing residues for the olefinic monomers and subjecting the peptides to cross-
metathesis conditions, the S20 and P27 substitutions (160c) induced the greatest 
helicity. This is in further agreement with other work highlighting the detrimental 
helix-breaking effect of P27.196,197,202 This swap also increased the affinity of the 
peptide almost 3 orders of magnitude and improved the proteolytic stability with 
respect to the native sequence. When cells were incubated with the peptides however, 
there was no evidence of cell penetration. This is thought to be due to the negative 
charge of the peptide at neutral pH, a quality uncommon in potent cell-penetrating 
peptides.104,204,205 By replacing the aspartic and glutamic acid residues with the 
equivalent amide residues asparagine and glutamine (161c, 162c), the peptide charge, 
and therefore permeability, was modulated favourably. Although the peptides could 
enter the cells, the apoptotic pathway was not activated. By mutating residues known 
% Helicity K d (nM) Charge
a C. Entryb C. Deathc
p53d 11 410± 19 -2 - -
157c 25 100 ± 8 -2 - -
158c 10 400 ± 50 -2 - -
159c 12 1200 ± 89 -2 - -
160c 59 0.92 ± 0.11 -2 - -
161c 20 0.82 ± 0.05 0 + -
162c 14 56 ± 11 1 + -
163c 36 50 ± 10 1 + -
164c 85 55 ± 11 1 + +
165c 39 > 4000 1 + -




a Charge of peptide at pH 7.4; b  Cell Permeability; c Cell Death; d 
14-29
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to contribute to the degradation of p53 (L14 and K24)206,207 the peptide 164c was 
shown to affect cell viability by restoring the pro-apoptotic p53 pathway by inhibition 
of hDM2 and hDMX.155,208 
 
The peptide 164c was crystallised with MDM2 by Baek et al.209 and two important 
binding aspects were revealed. The staple was shown to constrain the peptide such that 
the extended helical section is extended and now contains L26. This is not observed in 
any of the unconstrained peptides, which have higher affinity for MDM2, suggesting 
a degree of flexibility would be more favourable. In addition, the staple was shown to 
interact favourably with the surface of MDM2, contributing approximately 10% of the 
contact area of 164c. It is also thought to shield the tryptophan hydrogen bond to 
MDM2 from competing solvent interactions (Figure 74). 
 
 
Figure 74- SAH-p53-8 (164c, green) bound to MDM2. The hydrocarbon staple (cyan) 
protecting the W23 indole hydrogen bond (magenta) to Leu54 (orange). PDB code 
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 ATSP-7041 
 
With the SAH-p53-8 peptide 164c as a foundation, Chang et al.210 attempted to refine 
a stapled version of the pDI peptide 134. Using the same olefin stapling monomers 33 
and 156 (Figure 75) in the optimal position determined by Bernal et al.155 the stapled 
pDI 167c exhibited an almost 15- and 3-fold increase in binding affinity to MDM2 and 
MDMX respectively (Table 26). 
 
 
Figure 75- Monomers used by Chang et al.210 
 
Table 26- Peptide Library from Chang et al.210 
 
 
Further modification showed that a H5E mutation (169c) increased the binding affinity 
to MDMX 6-fold with respect to the unstapled sequence. This may be due to the 
stabilising effect of the N-terminal TXXE capping box motif.199 Substitution of L10 
for β-cyclobutyl alanine (Cba) and extending the α-helix by additional alanine 
residues at the C-terminus saw the binding affinity for MDM2 increase to the pM range 
MDM2 MDMX
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(ATSP-7041, 170c). Interestingly, the overall charge of ATSP-7041 is -1, however the 
peptide was shown to both penetrate cells and reactivate the p53 pathway,210 showing 
that it is not necessary to have a neutral/positively charged peptide for in vitro activity 




In a similar approach, Brown et al.211 used the more potent PMI peptide 143 as a 
starting scaffold for a stapled peptide inhibitor of MDM2 and MDMX. Computer 
simulations of the stapled peptide showed that because of the induced helicity of the 
staple the P12 residue would not bind optimally and so this was deleted from the 
sequence (172, MTide-01). This sequence had olefin monomers 33 and 156 (Figure 
76) substitute the 4 and 11 residues respectively to form the equivalent stapled peptide 
sMTide-01 173c. The position of the stapling residues is identical to the previous p53-
based stapled peptides SAH-p53-8 164c155 and ATSP-7041 170c.210 SAH-8 was used 
as a control, and the measured Kd’s for MDM2 and MDMX were similar to reported 
literature values.155,208 
 
Figure 76- Monomers used by Brown et al.211 
 
Incorporating the N8A mutation, which has been shown to be beneficial for binding,202 
gave rise to peptides 174 and 175c. The stapled peptides showed a 3 to 4-fold decrease 
in Kd for MDMX compared to the unstapled analogues. However when using a T22 
assay for cellular p53 activity, 175c induced the greatest transcription response seen 
in this assay. This was increased even further with the substitution of W7 with 6-
chlorotryptophan residue 6Cl-W, which has shown to increase binding,181,182 to give 
176c. 
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Table 27- p53 Response of Peptide Library from Brown et al.211 
 
 
Table 28- Binding Affinity and IC50 values of Peptide Library from Brown et al.211 
 
 
While the activity of the MTide peptides are still in the low nanomolar range, the phage 
sequence 143 has a greater affinity. It is known that N-acylation and C-amidation of 
the PMI peptides weaken the binding by approximately a factor of two,202 however 
taking this into account the stapled peptides are still at least 10-fold weaker than the 
native phage peptide. What is required is a stapling methodology that would ideally 
match or better the binding affinity of the PMI N8A peptide, while constraining the 
peptide into the required α-helical secondary structure. This would increase the 
stability of the peptide to proteolysis and therefore the therapeutic potential. 
 
T22 (25 μM)
164c 1.34 ± 0.05
172 1.40 ± 0.01
173c 2.62 ± 2.51
174 1.23 ± 0.03
175c 48.63 ± 1.85
176c 82.67 ± 2.90








Peptide MDM2 MDMX MDM2 MDMX
164c 50.21 ± 5.53 14.03 ± 1.85 1.11 ± 0.09 0.26 ± 0.03
172 46.34 ± 6.89 33.16 ± 4.62 1.10 ± 0.10 0.55 ± 0.04
173c 86.99 ± 0.02 118.3 ± 0.04 1.80 ± 0.10 1.57 ± 0.22
174 28.04 ± 1.38 16.33 ± 2.00 0.75 ± 0.02 0.29 ± 0.02
175c 34.35 ± 2.03 45.73 ± 7.65 0.94 ± 0.04 0.66 ± 0.06
176c 6.76 ± 2.11 1360 ± 600 0.32 ± 0.02 3.49 ± 0.63
K d (nM) IC50 (μM)




Chapter 3- Synthesis of Peptides Targeting 
the p53-MDM2 Interaction 
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3 Rationale of Stapled Peptide Inhibitor Design 
 
There are a number of possible ways to reactivate p53 activity. One of the most recent 
examples using peptides is described by Soragni et al.212 Previous work showed that 
mutated, misfolded p53 tends to aggregate not only other mutated p53 protein, but 
wild type, active p53 protein also.213 Analysis of the DNA-binding domain in silico, 
several segments of which are aggregation prone, identified that residues 252-258 
(LTIITLE) were the most likely to form an amyloid adhesive segment, or “steric 
zipper”. By taking this sequence and probing the structure, the group were able to 
confer specificity for the peptide to bind to unfolded p53 and minimise homobinding 
of the peptide. This new sequence, ReACp53 (LTRITLE) is able to reactivate mutant 
p53 into a wild-type like active state (Figure 77). This allows the reactivated p53 to 
enter the nucleus and induce cell death in both in vitro and in vivo models. 
 
 
Figure 77- Dispersion and reactivation of wild-type p53 (red spheres) and misfolded 
mutant p53 (purple/maroon) due to peptide ReCAp53 (green) binding 
 
It was decided that to investigate methods of peptide stapling starting from a known 
MDM2 inhibitor would be advantageous, given the wealth of information available 
about the p53-MDM2 protein-protein interaction. According to the recent literature, 
the peptide PMI N8A is the most potent inhibitor of both MDM2 and MDMX that is 
synthesised from only proteinogenic amino acids.202 This was used as the starting 
scaffold for the library of macrocyclised peptides. Despite the small increase of affinity 
afforded to the sequence to MDMX, truncation of PMI N8A by removing the helix-
breaking proline residue is thought to be beneficial,211 as it competes conformationally 
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with the helical induction of the staple. Analysis of the 11-mer sequence (174, Figure 
78) showed that there were few other residues that could be replaced for stapling 
monomers without some possible detrimental effect. 
 
 
Figure 78- Truncated and Capped PMI N8A Scaffold 174 
 
Phenylalanine F3, tryptophan W7 and leucine L10 are critical for binding to MDM2 
and MDMX, with tyrosine Y6 considered an important hydrophobic residue.194 Serine 
S2 and glutamic acid E5 are part of a SXXE N-terminal capping box motif,198,199,201 
threonine T1 is one of the most common N-terminal helix inducing residues156,200 and 
there is evidence that serine S11 also stabilises α-helical induction in the 
sequence.196,197,202 Considering these factors, over 70% of the residues may contribute 
to the potency or stability of the sequence. With this in mind, the two alanine residues 
A4 and A8 have (i,i+4) spacing, and so are on the same helical face. From the helical 
wheel projection of peptide 174 (Figure 79) and the crystal structure of PMI N8A 
bound to MDM2 (Figure 80), it can be seen that the side chains of A4 and A8 are 
orientated away from the hydrophobic binding pocket. As few other of the residues 
could be replaced without significantly affecting the conformational stability of the 
peptide these alanine were selected as the stapling position within the peptide library. 
This is the first example of an (i,i+4) stapled peptide targeting the p53 MDM2 
interaction. 
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Figure 79- Helical wheel projection of peptide 174. The alanine residues A4 and A8, 
to be substituted for cross-linking residues, are seen on the opposite face to the three 
critical hydrophobic residues F3, W7 and L10. 
 
 
Figure 80- PMI N8A (143, Green, with critical residues F3, W7 and L10 shown) bound 
to MDM2, A4 and A8 Side Chains Highlighted (Magenta). PDB code 3EQS, 
reproduced using PyMol 
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3.1 Monomer Synthesis 
 
As previously discussed, linker lengths of around 7-9 atoms are effective for an (i,i+4) 
α-helical peptide staple. It was decided to use a CuAAC triazolyl staple as the 
methodology has not been used in the context of inhibiting the p53 MDM2 interaction. 
From published investigations, it is evident that moieties within the staple can affect 
the induced helicity of the peptide. To try and minimise any helical disturbance, the 
linker was designed such that the triazole has the greatest distance between it and the 
peptide. This is so that i) the dipole of the triazole will be pointing directly away from 
the peptide minimising any disruptive electronic effects and ii) the effectiveness of the 
macrocyclisation would be at a maximum with the azido and alkynyl functional groups 
equidistant on the side chain residues. This would result in a pseudo-symmetrical 
staple, with the linker having the same number of atoms on each side of the triazole. 
This restricted the linker length to either 7 or 9 atoms, as the triazole CH is the centre 
of pseudo-symmetrical plane. A 9 atom linker length was chosen (Figure 81), as this 
was thought more to be an optimal length. If moderately too long however, it would 
allow a degree of flexibility, as opposed to a 7 atom linker potentially constraining the 
sequence too tightly.  
 
 
Figure 81- Pseudosymmetrical 9 Atom Triazole Staple 
 
Jacobsen et al. showed it was possible to staple a peptide into a 310 helical structure 
using the synthetic amino acids azido ornithine and propargyl serine.214 Although a 
310-helix requires a shorter (i,i+3) substitution to locate the side chains on the same 
helical face, the overall helical conformation is extended (Figure 82).65 
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Figure 82- Comparison of A α-helix B 310 Helix65 
 
The introduction of the ether from the serine residue may have some slight effect as 
there is an additional hydrogen bond acceptor with respect to a hydrocarbon side chain, 
but is importantly still as chemically stable under biological conditions. These 
monomers (Figure 83) provide a synthetically simple route to the 9 atom linker desired. 
To probe any differences that may occur from the regiochemistry of the triazole, the 
position of the azide and alkyne monomers within the sequence were swapped (eg 179 
vs 183). In addition, both enantiomers of the monomers were incorporated into 
peptides to investigate the effect of D-amino acids in the helical induction of the staple, 
as it is important to investigate diastereomerism within the staple, as previously 
discussed in chapter one. These 8 peptides were compared to their uncyclised 
sequences and the native alanine substituted peptide 174 for increased helicity which 
results from the staple. The stability and increased cell permeability of peptoids in 
comparison to the peptide counterparts has been thoroughly documented.176,215 With 
this in mind, incorporation of N-substituted glycine stapling monomers may further 
enhance the desired properties of a stapled peptide. However, using N-substituted 
glycine monomers removes 2 backbone hydrogen bonds, and so there will be an α-
helix destabilising effect. There is only one example of a (i,i+4) CuAAC stapled 
peptide-peptoid hybrid within the literature from Park et al.216 By combining an 
alanine scan with a sarcosine (N-methyl glycine) scan,217 residues were replaced within 
the target sequence at positions that showed the greatest tolerance for both 
substitutions. As with any macrocyclised peptide, it was shown that the position of the 
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staple in the peptomer was critical to the effectiveness of the staple. However, there 
was no direct comparison to the equivalent CuAAC stapled peptide, or consideration 
of linker length and so this work did not reveal much about the relative efficiency of 
peptoid monomers as stapling residues. Conversely, the N-substituted glycine 
monomers 187 and 188 are directly comparable in length to the azido ornithine (177) 
and propargyl serine monomers (178) used. Also, by swapping the relative positions 
of 187 and 188 in the sequence the effect of the regiochemistry of the triazole moiety 
on relative helicity can be compared to both the peptide library and the equivalent 




Figure 83- Non-natural monomers incorporated into peptide library to form 9-atom 
staple 
 
3.1.1 Amino Acid Synthesis 
 
The non-proteinogenic monomers 177 and 178 can be synthesised from commercially 
available amino acids in one- or two-pot processes. Starting from chiral reagents 
removes any need for chiral induction. The monomers were synthesised based on 
procedures from Sminia et al.218 
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 Synthesis of Fmoc Azido Ornithine  
 
The synthesis of amino acids containing azide side chains is well documented. 
Commonly, the corresponding amine or ammonium starting material is converted in 
one step to the azide via a diazo transfer reagent and metal(II) catalyst. These reagents 
are highly reactive, and sometimes require in situ generation. One of the most 
frequently used diazo transfer reagents is imidazole-1-sulfonyl azide 192 (Figure 84). 
This reagent is usually handled as an imidazolium salt, which are stable crystalline 
solids, making the use of 192 much simpler. The salts of 192 reproduce yields 
comparable to triflic azide, with the anion having little effect on the efficiency of the 
diazo transfer. Imidazole-1-sulfonyl azide salts have been shown to have a high 




Figure 84- The Diazo Transfer Reaction with Imidazole-1-Sulfonyl Azide 192 
 
Beginning from commercially available enantiomers of the orthogonally protected 
amino acid Fmoc-Orn(Boc)-OH 194, the Boc protecting group was removed using a 
20 M solution of trifluoroacetic acid in DCM at room temperature (Scheme 1). After 
2 hours stirring the reaction was complete by TLC. The excess TFA can be removed 
easily in vacuo, giving the crude ammonium trifluoroacetate salt 195 quantitatively 
with no losses from transfer. The salt was resuspended in a mixture of methanol and 
water. Water was added to help solvate the catalytic copper sulfate and K2CO3 base. 
The catalytic amount of copper(II) used was 5 mol%, but reports suggest that loading 
can be as low as 1 mol%. At least 3 equivalents of K2CO3 must be added to bring the 
solution to operational pH (9-10), since the free amine acts as the nucleophile in the 
diazo transfer. 
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Scheme 1 - Synthesis of Fmoc Azido Ornithine 177 
 
The transfer proceeds cleanly over 18 hours, with no evidence of Fmoc deprotection. 
After removing the methanol in vacuo the basic solution was washed with toluene to 
remove the sulphonamide byproduct 193 effectively with little leaching of the 
azidoornithine product. 
 
 Synthesis of Fmoc Propargyl Serine 
 
The literature is full of examples of alkylated serine derivatives starting from the 
commercially available Boc-Ser-OH 196.219–221 A number of non-nucleophilic bases 
have been used to deprotonate the hydroxyl group, with the most commonly used base 
being sodium hydride in dry DMF (Scheme 2). This base has the advantage that it is 
both a non-interfering conjugate base and the release of hydrogen acts as an observable 
indicator of completed alkoxide formation. The reaction temperature was maintained 
at 0 °C during the deprotonation step to prevent racemisation, the reaction proceeds 
cleanly with no byproducts. The DMF was removed in vacuo to simplify the 
separation. The crude carboxylate salt was dissolved in dilute aqueous HCl to prevent 
appreciable Boc deprotection of 197. The Boc group was removed with a 20 M 
solution of trifluoroacetic acid in DCM at room temperature. The crude ammonium 
trifluoroacetate salt was reacted with FmocCl in basic dioxane to give the Fmoc 
monomer 178.  
 
Scheme 2- Synthesis of Fmoc Propargyl Serine 178 
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3.1.2 N-Substituted Glycine Monomers 
 
The synthesis of N-substituted glycine monomers can be accomplished in a number of 
ways. One common method is the submonomer approach from Zuckermann et al.222 
Performed on resin, the monomers are built from the combination of 2 submonomers, 
an α-haloacetic acid and a primary amine (Figure 85). The submonomer synthesis 
approach is attractive in that there is minimal protecting group chemistry required, in 
addition there is a huge variety of primary amines commercially available which 
allows for installation of non-classic functionality within the sequence, and is 
compatible with SPPS.223,224 
 
 
Figure 85- Solid Phase Submonomer Synthesis 
 
A disadvantage of the submonomer approach is the large excess of amine required, 
typically 20-40 equivalents. While this is not unfeasible for most primary amines, the 
primary amine required for the submonomer synthesis of the azido monomer was 3-
azido propylamine. This molecule falls within the explosive risk parameters of organic 
azides,225,226 and so the submonomer synthesis was not considered a viable option.     
 
Currently, there is no synthetic precedent for the synthesis of both the desired N-
substituted glycine monomers. However, there have already been syntheses of azido 
peptoid monomers from the Hulme group (Scheme 3).227 Based upon methodology 
from Unciti-Broceta et al.228 the synthesis of the desired monomer 187 is accomplished 
in 5 steps from 1,3-diaminopropane in a 39% overall yield. The amine alkylation is 
the lowest yielding step (54%), due to disubstitution. A new synthetic methodology 
was designed, attempting to improve upon these results   
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Scheme 3- Hulme Group Synthesis of Azido Monomer 187227 
 
Evaluating the N-substituted monomers retrosynthetically, there are two obvious 
disconnections that can be made. Approach A disconnects the nitrogen side-chain 
bond, while approach B disconnects the nitrogen α-carbon bond (Figure 86). Both 
approaches can be achieved with reductive amination and alkylation reactions. A 
problem with the alkylation approaches is the decreased yield arising from over-
alkylation and formation of the tertiary amine product. This could be overcome with 
increased number of equivalents of amine, however both the alkylations would still 
require low molecular weight azides. The reductive amination reactions have the 
advantage of controlled mono-substitution of an amine to the aldehyde moiety, but 
again require low molecular weight azides. A solution to this is to install the amine 
function with a side chain containing a leaving group that would allow both the azide 
and alkyne to be synthesised from a common intermediate. Ideally, this intermediate 
would be protected with a tert-butyl ester to allow for orthogonal deprotection of the 
acid moiety after the Fmoc group is added. 
 
 
Figure 86- Retrosyntheses of N-Substituted Glycine Monomers 
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Reductive amination approach A would combine a non-commercially available low 
molecular weight aldehyde and glycine tert-butyl ester. The alternative reductive 
amination approach requires a volatile amine and tert-butyl glyoxylate, which is not 
commercially available and which syntheses of are typically long and poor 
yielding.229–231 With these considerations in mind, an alkylation procedure was 
pursued. In designing an analogous alkylation procedure (Figure 87), approach A 
requires a dihalopropane and glycine tert-butyl ester. While formation of the azetidinyl 
byproduct is unfavorable, dimerization and oligomerization are feasible side reactions, 
though this could be controlled by use of a dihalopropane with different 
nucleofugalities e.g. 3-chloro-1-iodopropane. Approach B requires an α-halo tert-
butyl acetate and a low molecular weight amine, which has already been deemed 




Figure 87- Possible Divergent Amine Alkylation Retrosyntheses 
 
A solution to the dialkylation problem is the use of an amine protecting group. The 
protecting group must be easy to install, allow the alkylation to proceed, and be 
removed under mild conditions. The most common amine protecting groups are 
amides, carbamates and sulfonamides, as all can be synthesised easily from an amine 
and an acylating agent. The use of an amide protecting group significantly decreases 
the pKa of the nitrogen proton (Figure 88), but requires a strong base for deprotonation 
so reaction times and yields can be hindering and hydrolysis of the amide requires 
harsh conditions. Carbamate protons have a similar pKa to amides, but can be removed 
under milder conditions, as the release of CO2 is a thermodynamic driving force. 
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Sulfonamides decrease the pKa of the nitrogen further and so a milder base can be 
used, but can require harsh hydrolysis conditions. Trifluoroacetamides can be 
synthesised in near quantitative yields from the amine starting material, increase the 




Figure 88- N-H pKas of Selected Amine Protecting Groups in DMSO232 
 
In considering a trifluoroacetamide alkylation methodology, both retrosynthetic 
disconnections are still feasible (Figure 89). In approach A trifluoroacetyl (Tfac) 
glycine tert-butyl ester is alkylated with a dihalopropane, however using a dihalo 
reagent there is a risk of dimerization. In approach B, a haloalkyl trifluoroacetamide is 
alkylated by an α-halo tert-butyl ester. This approach has an electron-withdrawing 
group on the carbon with the leaving group, which is advantageous given the generally 
poor nucleophilicity of amides. It is also simple to install different reactivities in the 
trifluoroacetamido alkyl halide and the α-halo tert-butyl acetate to prevent 
polymerisation of the haloalkyl trifluoroacetamide. From there, the formation of the 
azide and alkyne side chains can be achieved by substitution at the alkyl halide. With 
these advantages apparent, this approach was pursued. 
 
 
Figure 89- Possible Divergent Trifluoroacetamide Alkylation Retrosyntheses 
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 Synthesis of the Common Intermediate 
 
Starting from 3-chloropropylamine hydrochloride 198, the ammonium salt was reacted 
with trifluoroacetic acid anhydride (TFAA) and a non-nucleophilic base in DCM to 
give trifluoroacetamide 199 (Scheme 4). Addition of the TFAA last tended to require 
additional reagent (1.5 - 2.5 eq) for the reaction to go to completion, so the ammonium 
salt and TFAA was stirred before addition of non-nucleophilic amine base. Addition 
of 2.2 equivalents of either triethylamine (TEA) or di-isopropylethylamine (DIPEA) 
worked equally well.  
 
 
Scheme 4- Synthesis of 3-Chloropropyl Trifluoroacetamide 199 
 
The alkylation step used commercially available tert-butyl bromoacetate to exploit the 
different leaving group tendencies of the halides. From the literature, a number of 
bases have been used to alkylate trifluoroacetamides, including metal hydrides,233,234 
potassium tert-butoxide,235 and K2CO3.
236 Esiringu et al.232 found that using caesium 
carbonate (Cs2CO3) was very effective, needing only a moderate increase in 
stoichiometric equivalents with respect to the trifluoroacetamide, if at all, to affect the 
alkylation. This was attributed to the increased solubility of the base in organic 
solvents. Interestingly, a catalytic amount of Cs2CO3 added to reactions employing 
K2CO3 as the base dramatically accelerated the alkylation. A number of solvents can 
be used, but DMF and MeCN showed the shortest reaction times. Emulating this 
strategy, Cs2CO3 was stirred with the trifluoroacetamide 199 at 35 °C for 5 minutes 
before addition of the tert-butyl bromoacetate. The reaction proceeded cleanly by TLC 
in 3 or 4 hours when using DMF or MeCN respectively, with little difference in yield 
(Scheme 5). As the reaction provided the product 200 efficiently, the reaction mixture 
can simply be filtered through a silica pad to remove the inorganic salts. 
 
New Approaches to Stapled Peptides Targeting the p53-MDM2 Interaction 
 
Synthesis of Peptides Targeting the p53 MDM2 Interaction 100 
 
Scheme 5- Alkylation of 3-Chloropropyl Trifluoroacetamide 200 
 
The alkylation produced a tertiary amide, and so rotamers were observed in the NMR 
spectra. This was confirmed with a set of variable temperature NMR experiments 
which ran from 313 K in 10 K increments up to 373 K, which was high enough for 
signal coalescence to be observable (Figure 90). 
 
 
Figure 90- Abstracts of variable temperature 1H experiments (4.45 – 3.50 ppm, d7-
DMF) showing α-carbon CH2 rotameric signals (4.35 and 4.20 ppm) and overlapping 
CH2Cl and TfacNRCH2CH2R’ rotameric signals (3.78 – 3.66 ppm). Full series of 
spectra can be found in Section 5.1.2.1. 
 
In both the 1H NMR and 13C NMR, there is coupling to the fluorine nuclei of the 
trifluoroacetamide. Studies have shown that there is an observable trans coupling in 
tertiary trifluoroacetamides (~1-2 Hz).237–239 This allowed the complete assignment of 
each signal to a specific rotamer of 200 from HSQC and HMBC experiments, which, 
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along with 19F, showed that the rotameric ratio was 50:50. In the 1H NMR spectrum 
5JHF couplings are seen, with the complimentary 
4JCF couplings in the 
13C NMR 
spectrum (Figure 91). The coupling was confirmed with a 19F-decoupled 1H NMR 
experiment (Figure 92). 
 
 
Figure 91- Rotameric 19F Coupling Seen by 200 α-Carbon from trans Interaction to 
CF3 
 
Figure 92- Abstract of NMR spectra (4.15 – 3.98 ppm, CDCl3) comparing 1H (Red) 
and 19F Decoupled 1H (Blue) spectra, showing α-Carbon 1H Peaks of 200 
 
Although there are examples of the displacement of alkyl chlorides by azide and 
alkynyl nucleophiles,240,241 the decreased reactivity of alkyl chlorides compared to 
alkyl bromides and iodides tends to result in longer reaction times, greater amounts of 
nucleophile required, or heating being necessary to affect complete substitution. These 
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reaction conditions are generally undesirable when using highly reactive azides. The 
Finkelstein reaction converts less reactive alkyl halides to alkyl iodides using sodium 
iodide (NaI) in a polar organic solvent.242 The equilibrium is driven to the products by 
the insolubility of the sodium halide salt formed compared to the solubility of NaI in 
the polar solvent (Figure 93). 
 
 
Figure 93- The Finkelstein Reaction 
 
Classically, the reaction uses acetone as the solvent, however MeCN was used instead. 
Sodium iodide is still relatively soluble in acetonitrile (24.9 g/ 100 g MeCN vs 50.4 g 
/100 g acetone) and NaCl is highly insoluble in MeCN (3 mg / 100 g MeCN).243 
Acetonitrile however has a higher boiling point (81-82 °C vs 56-57 °C acetone) which 
allowed increased reaction temperatures and subsequently shorter reaction times. At 
95 °C the reaction of 200 was complete in 5 hours using only 1.25 equivalents of NaI 
(Scheme 6). The end point was difficult to determine by TLC due to the similar polarity 
of the alkyl chloride and iodide 201, but by monitoring the reaction by NMR the 




Scheme 6- Finkelstein Reaction of Alkyl Chloride 200 
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Figure 94- Abstract of 13C Spectra (0 - 50 ppm, CDCl3) of Chloride 200 (Red) and 
Iodide 201 (Blue), highlighted are the rotomeric RCH2X Peaks. 
 
The preparation of the common intermediate 201 was achieved in a 79% yield over 
three steps (Scheme 7). The simple purification procedures made the synthesis 
amenable to scale up with little variation in yield. With this intermediate in hand, the 
divergent synthesis of the azido and alkynyl monomers continued. 
 
 
Scheme 7- Synthesis of Iodide 201 from 3-Chloropropylamine Hydrochloride 198 
 
 Synthesis of Fmoc N-3-Azidopropyl Glycine 
 
Beginning from the common intermediate 201, the synthesis of the azido monomer 
187 required 4 steps (Scheme 8): nucleophilic substitution of the alkyl iodide 201 to 
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the alkyl azide, hydrolysis of the azido trifluoroacetamide 202, conversion of the 
secondary amine 203 to the Fmoc carbamate 204 and finally deprotection of the tert-
butyl ester to the free acid 187.   
 
 
Scheme 8- Proposed Synthesis of Fmoc N-Azidoproylglycine 187 from Common 
Iodide Intermediate 201 
 
A simple method of azidification of alkyl halides from Alvares et al. was used.244 
Dimethyl sulfoxide (DMSO) was shown to dissolve sodium azide sufficiently. The 
displacement of alkyl bromides was achieved using a 1.2 equivalents of NaN3 solution 
(0.5 M in DMSO) at room temperature overnight. Adapting this procedure, a modest 
increase in equivalents of NaN3 added in a more concentrated DMSO solution (1 M) 
gave the corresponding alkyl azide 202 in high yield in 4 hours at room temperature 
(Scheme 9). 
 
Scheme 9- Azide Displacement of Common Iodide Intermediate 201 
 
Hydrolysis of the trifluoroacetamide can be affected under extremely mild conditions. 
Common reaction conditions utilise aqueous hydroxide solutions with a miscible 
organic co-solvent, or sodium borohydride.245 However, partial cleavage of the tert-
butyl ester was seen when hydroxide bases were used, and although the borohydride 
worked well, another base mediated method was selected instead. Aqueous K2CO3 
solution in methanol246,247 gave complete transformation as cleanly as sodium 
borohydride at room temperature but in longer reaction times (1 h vs ~18 h). With a 
moderate increase in temperature (40 °C) the reaction was complete in 4 hours 
(Scheme 10). 
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Scheme 10- Hydrolysis of Azido Trifluoroacetamide 202 
 
The protection of the amine 203 with FmocCl was achieved easily using TEA in 
MeCN at room temperature in 2 hours (Scheme 11). Similarly to the 
trifluoroacetamides 200-202 the NMR spectra showed rotamers, due to the restricted 




Scheme 11- Fmoc Carbamate 204 Formation 
 
The opportunity to telescope the trifluoroacetamide hydrolysis and Fmoc protection 
steps was apparent when using the base mediated deprotection of azide 202 (Scheme 
12). An excess of K2CO3 was used in the hydrolysis step, and so by removing the 
aqueous methanol in vacuo, the crude amine and K2CO3 can be used directly in the 
acylation step. Using the same amount of FmocCl, the reaction was complete in the 
same time. Following aqueous work up and column chromatography, the carbamate 
ester 204 was isolated in a similar yield to the non-telescoped route. 
 
 
Scheme 12- Telescoped Synthesis of 204 
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Finally, the tert-butyl ester was deprotected using 20 M TFA in DCM to give the 
azidopropyl N-substituted glycine monomer 187 in high yield (Scheme 13). The 
rotameric ratio (56:44) suggested a slight preference for one conformation. This 
preference will be due to the cleavage of the bulky tert-butyl ester, allowing a greater 




Scheme 13- Acid Deprotection of tert-Butyl Ester 204 
 
Once again, an opportunity to telescope the synthesis was pursued (Scheme 14). Upon 
completion of the Fmoc protection, the MeCN was removed in vacuo and the crude 
tert-butyl ester 204 was redissolved in DCM and filtered through a silica plug to 
remove the potassium salts. The DCM solution was concentrated and TFA added. 
After the reaction was complete and the TFA/DCM removed in vacuo, the crude 
monomer was taken up in ethyl acetate and extracted into aqueous sodium bicarbonate. 
This step separates any excess FmocCl or 9-Fluorenemethanol (FmOH) from the 
reaction mixture. Acidification of the aqueous layer to pH 3 and extraction with EtOAc 
allowed the isolation of the desired monomer 187. In telescoping three steps, a greater 
overall yield was achieved than that of the separate reactions (77% vs 63%). 
 
 
Scheme 14- Telescoped Synthesis of N-Substituted Glycine 187 
 
The azido N-substituted glycine monomer 187 was synthesised from the iodide 201 in 
a 4 step, 2 pot process in 72% yield.  
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 Synthesis of Fmoc N-Pentyn-4-yl Glycine 
 
Beginning from the common iodo intermediate 201, the synthesis of the alkynyl 
monomer 188 was visualised as 4 steps (Scheme 15): nucleophilic substitution of the 
alkyl iodide to the alkyne, hydrolysis of the trifluoroacetamide 205, conversion of the 




Scheme 15- Proposed Synthesis of Fmoc N-Pentyn-4-yl Glycine 188 from Common 
Iodide Intermediate 201 
 
Alkylation of the iodide 201 was attempted with lithium acetylide ethylenediamine 
complex,248 an easily handled solid. However, even at -78 °C in THF, cleavage of the 
trifluoroacetamide group was observed (Scheme 16). 
 
Scheme 16- Unsuccessful Synthesis of Alkyne 205 
 
To explore solutions to this problem a model system was devised (Scheme 17). The 
trifluoroacetamide 199 was converted to the corresponding iodide 208, which would 
allow favourable alkylation conditions to be explored. Also, successful alkylation of 
iodide 208 would provide an alternative synthetic route to the desired alkyne 
monomer.  
 
Scheme 17- Finkelstein Reaction of Alkyl Chloride 199 
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A number of variables were tested in the model system (Scheme 18). Alternative 
nucleophiles trimethylsilylacetylene and ethynylmagnesium bromide were used in 
addition to LiC≡CH·EDA. Deprotonation of TMSC≡CH with NaH as well as BuLi to 
see if metal coordination has a significant effect. Addition of N,N′-dimethylpropylene 
urea (DMPU), a safer alternative to HMPA, to coordinate the metal cations to prevent 
activation of the trifluoroacetamide was also attempted, yet none of the conditions 
attempted were successful. Given the mild deprotection conditions that can be used to 
remove the trifluoroacetyl group, in retrospect these results were not surprising. 
Following these negative results, an alternative synthesis was planned. 
 
 
Scheme 18- Attempted Syntheses of Alkyne 209 from Iodide 208 
 
After the failed divergent synthesis from the alkyl iodide 201, the original 
retrosyntheses to the alkyne monomer 188 were reassessed. An alternative synthetic 
approach involved alkylation of the trifluoroacetylglycine tert-butyl ester 210 (Figure 
95). This retrosynthesis was not chosen as it was thought that the amide alkylation 
would proceed better with an electron withdrawing effect of the tert-butyl ester next 
to the leaving group. However, with the azido monomer 187 in hand, this second 
synthesis of the alkynyl monomer was more attractive than possible alternatives due 
to the clear parallels with the azido monomer synthesis, and the robust methodology 
established within. 
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Figure 95- Alternate Retrosynthesis of Trifluoroacetamide 205 
 
Starting from glycine tert-butyl ester hydrochloride 211, identical conditions 
previously used furnished the trifluoroacetamide 210 in good yield (Scheme 19). 
 
 
Scheme 19- Trifluoroacetylation of Glycine tert-Butyl Ester Hydrochloride 211 
 
Attempts to alkylate the trifluoroacetamide 210 with commercially available 5-
chloropent-1-yne (5-CP) using the conditions previously employed were unsuccessful. 
This is a result of the comparatively poorer leaving group ability of the chloride 
nucleofuge, the decreased electrophilicity of the methylene carbon, or more likely a 
combination of both. A number of conditions were varied, including adding a sub-
stoichiometric amount (0.2 eq) of tetrabutylammonium iodide, a phase transfer 
catalyst thought to increase the solubility of the amide anion in organic media.249–251 
This, in addition to an increase in the temperature (rt to 95 °C), number of equivalents 
of alkyl chloride (1.2 to 1.5) and Cs2CO3 (1.2 to 1.5 eq), afforded the alkyne 205 
cleanly in high yield (Scheme 20). 
 
 
Scheme 20- Alkylation of Trifluoroacetylglycine tert-Butyl Ester 210 
 
Following the antecedent methodology, the 3 step telescoped trifluoroacetamide 
hydrolysis, Fmoc acylation and tert-butyl ester deprotection proceeded cleanly in good 
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yields comparable to the azide monomer 187 (Scheme 21). Again, following cleavage 
of the tert-butyl ester, the rotameric ratio showed a preference for one conformer 
(61:39 for 188 vs 52:48 for 207).  
 
 




Four monomer building blocks were required for the investigation of a (i,i+4) triazolyl 
stapled peptide. For incorporation into stapled peptides, both enantiomers of Fmoc 




Scheme 22- Complete Synthesis of Enantiomers of Fmoc Azido Ornithine 177 
 
Beginning from Boc Serine 196, the enantiomers of Fmoc Propargyl Serine 178 were 
synthesised in a 3 step, 2 pot process on gram scale in good yields (Scheme 23). 
 
 
Scheme 23- Complete Synthesis of Enantiomers of Fmoc Propargyl Serine 
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Two N-substituted glycine monomers were synthesised for incorporation into stapled 
peptomers. The Fmoc N-Azidopropyl glycine residue 187 was synthesised 
successfully from 3-chloropropylamine hydrochloride 198 in 7 steps in a 57% overall 
yield on gram scale with no column chromatography required (Scheme 24). Although 
this methodology has an additional two steps compared to the previous synthesis from 
the Hulme group,227 the overall yield was improved by 18% (57% vs 39%) while using 
simpler purification procedures.  
 
 
Scheme 24- Complete Synthesis of Fmoc N-Azidopropyl Glycine 187 
 
In a 5 step, 3 pot process, the Fmoc N-pentyn-4-yl glycine monomer 188 was 
synthesised for the first time from commercially available glycine tert-butyl ester in a 
66% overall yield (Scheme 25). This was also achieved, as with the azido monomer 
187, on gram scale without a single chromatographic purification. 
 
 
Scheme 25- Complete Synthesis of Fmoc N-Pentyn-4-yl Glycine 188 
 
While a divergent methodology was unsuccessful in this case, the common iodo 
intermediate 201 could in theory be used to synthesise a number of side-chains from 
weaker nucleophiles. In addition, the versatility of both established synthetic routes 
could easily be utilised to produce a range of N-substituted glycine monomers from 
cheap, commercially available starting materials in high yields and purity with 
minimal purification. 
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3.2 Peptide Synthesis, Cyclisation and Purification 
 
With the monomers in hand, the peptides were synthesised using established Fmoc 
solid phase peptide synthesis protocols (Figure 96).46,48 The methodology uses a base 
to remove the Fmoc group, freeing the amine group of the polymer for coupling. The 
free acid monomers are activated by additives to make coupling to the free amine more 
efficient. To liberate the peptide from the resin and deprotect the side-chains, acid 
sensitive protecting groups and an acid labile linker are used as these utilise orthogonal 
conditions to the Fmoc deprotection. A number of reviews and practical guides are 
available and so the vast number of permutations will not be discussed.252,253 
 
 
Figure 96- Generic Fmoc Based Protocol for the Synthesis of a Peptide 
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3.2.1 Peptide Synthesis 
 
The peptides were synthesised manually, using an aminomethyl polystyrene resin with 
a Rink amide linker.254 The Rink amide linker was selected as it releases an amidated 
carboxy terminus upon acidic cleavage of the peptide (Figure 97). The amine handle 
of the linker was protected with an Fmoc group and so was must be removed before 
coupling the first amino acid. This deprotection, and the subsequent couplings and 
Fmoc deprotections of the amino acids were confirmed by the chloranil test for free 




Figure 97- Acidic cleavage of carboxyamidated peptide from Rink linker 
 
The Fmoc monomers were coupled using diisopropylcarbodiimide (DIC) which 
generates an O-acylisourea (Figure 98). After coupling with the free amine of the resin 
bound peptide, the soluble urea by-product diisopropylurea (DIU) is formed, 
facilitating solid phase work-up.256 Ethyl (hydroxyimino)cyanoacetate (Oxyma), a 
coupling additive, was also used.257 The addition of Oxyma forms an activated Oxyma-
ester which is less reactive than the O-acylisourea, but still reactive enough to allow 
peptide coupling to occur (Figure 98-A). This less reactive Oxyma-ester suppresses 
racemisation via oxazolone formation (Figure 98-B),257–260 prevents N-acylurea 
formation (Figure 98-C)261 and is a safer alternative to other coupling reagents such as 
hydroxybenzotriazole (HOBt).257,262,263 After completion of the sequence the peptides 
were capped using an excess of acetic anhydride (Ac2O) and DIPEA. This step was 
also confirmed by the chloranil free amine test.255 
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Figure 98- Activation of Fmoc-amino acids with DIC to form the corresponding O-
acylisourea A Reaction with Oxyma to form the activated Oxyma-ester and DIU B 
Reaction with Fmoc carbamate to form S-oxazolone and DIU. The S-oxazolone can 
then racemise via the achiral oxazolate C O-acylisourea undergoes an O→N shift to 
form the N-acylurea 
 
3.2.2 Peptide Cyclisation 
 
Upon completion of each sequence, the peptide-loaded resin was split in half. The 
uncyclised peptides were then cleaved from the resin using TFA and triisopropylsilane 
as a scavenger. The other half was kept to be cyclised on resin. Previous attempts by 
other groups to cyclise peptides on resin using the CuAAC reaction has proved 
problematic, and can result in oligomerisation and cyclodimerisation. This is thought 
to be caused by two main interactions. Firstly, the peptide chains folding over toward 
the resin and interacting in a β-sheet system, separating the azide and alkyne moieties 
on the same peptide and putting the reactive groups closer in space to neighbouring 
chains (Figure 99-A). Secondly, the bicationic dependent catalysis of the CuAAC 
reaction is thought to be problematic in that by using a typical sub-stoichiometric 
amount of copper, there may be chelation of the opposing peptide chains to the reactive 
metal. One way to overcome this problem would be to increase the number of 
equivalents of copper, however excess copper could cause the peptide to fold in an 
unwanted way (Figure 99-B). 
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Figure 99- Representations of Detrimental Interactions for On-Resin CuAAC  
A Hydrogen Bonding Between Polymer Chains B Copper Coordination 
 
To overcome the first problem, a dual solvent system of 4:1 DCM:TFE was used. This 
would both swell the resin, separating the peptide chains and due to the trifluoroethanol 
addition would fold the peptides/peptomers into a helical structure, thereby increasing 
the chance of cyclisation over cyclodimerisation. The second problem was tackled by 
using 2 equivalents of tetrakis(acetonitrile)copper(I) tetrafluoroborate, 
Cu(MeCN)4BF4, a copper salt with increased solubility in organic solvents and a non-
interfering counteranion. This was premixed in the solvent mixture with 2 equivalents 
of Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, TBTA, a ligand commonly 
used to protect the Cu(I) centre from redox and to solubilise the cation in organic 
solvents.264 The polydentate nature of the TBTA ligand also increases the likelihood 
of two copper centres being close in space, minimising any unwanted chelating to the 
peptide backbone (Figure 100).265 The resin bound peptides were left in this solution 
at room temperature for 48 h and a test cleavage performed. An observable shift in 
retention time suggested the reaction was complete (see Figure 103 in Section 3.2.3). 
 
 
Figure 100- A TBTA Ligand B Bis-Copper TBTA Complex.265 
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To accelerate the reaction time, microwave heating was used. Microwave heating is 
now commonly used in peptide synthesis, decreasing reaction times and increasing the 
purity of the crude peptide.266 To the on-resin peptides/peptomers Cu(MeCN)4BF4 and 
TBTA were added. This was then dissolved in degassed DMSO, a solvent that is able 
to solubilise metal ions as well as organic compounds, disrupts hydrogen bonding and 
has a high tanδ value, a ratio that describes the efficiency of microwave heating for 
solvents.267  The reaction vial was heated at 80 °C for 0.5 h and was monitored using 
infra-red spectroscopy. After the 0.5 h reaction time a small amount of resin was 
washed and then swollen in DCM. The disappearance of the characteristic azide peak 
at 2096 cm-1 (Figure 101) indicated that the reaction had gone to completion. While 
this is an improvement over the previous reaction conditions, there is still scope for 
further investigation and enhancement. 
 
 
Figure 101- Overlayed IR Spectra Showing Disappearance of Azide Peak after 
Microwave Assisted On-Bead Cyclisation of peptide 179 
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3.2.3 Peptide Purification 
 
Following cleavage from the resin, the uncyclised and cyclised peptides were purified 
using semi-preparative reverse-phase HPLC. Water and acetonitrile, standard solvent 
choices for RP-HPLC, with a 0.1% TFA additive were used to elute the peptides from 
the column. By monitoring both at 220 nm and 280 nm, wavelengths absorbed by 
amides and aromatic side chains respectively, it was relatively facile to note when the 
peptides were eluting. The only charged position (at pH 7) in the sequence was the 
carboxy acid of the glutamic acid residue. This meant that the peptides eluted at a 
relatively low H2O:MeCN ratio, approximately 3:2, as the glutamic acid side chain 
was protonated by the TFA additive making the peptide relatively hydrophobic. After 
purification, all the isolated peptides were found to be ≥ 90% pure by analytical RP-
HPLC. The uncyclised and cyclised peptides were analysed by electrospray ionisation 
(ESI) mass spectrometry (Table 29). Although there is no change in mass after 
cyclisation, and therefore no way to tell whether cyclisation has occurred using this 
method, the presence of dimeric and oligomeric products was able to be discounted. 
This was possible as there was no evidence of [2M+X]+ (where X = H, Na) peaks 
present (Figure 102). 
 
 
Figure 102- ESI-MS Spectrum of peptide 179c (1,4-(S,S)), showing no [2M+X]+ 
peaks, with 1451.7036 [M+H]+. 
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Table 29- Elution Times and Observed Ions of Peptide/Peptomer Library 
 
 
When compared to the native peptide, the uncyclised peptides all had greater elution 
times with the converse being true for the cyclised peptides (Figure 103). This is 
consistent with the premise that cyclic peptides are more easily solubilisable in organic 
media than their uncyclised counterparts. 
Peptide Notation Rt (minute)
a Mass (Da) Theor. Mass (Da) Ion
174 Native 10 1350.6289 1350.6341 [M+Na]
+




179c 1,4-S ,S -c 8 1451.7036 1451.6954 [M+H]
+
180u 1,4-S ,R -u 18 1473.6828 1473.6773 [M+Na]
+
180c 1,4-S ,R -c 7 1451.7029 1451.6954 [M+H]+
181u 1,4-R ,S -u 16 1451.6953 1451.6954 [M+H]
+
181c 1,4-R ,S -c 7 1451.6921 1451.6954 [M+H]
+
182u 1,4-R ,R -u 16 1473.6769 1473.6773 [M+Na]
+
182c 1,4-R ,R -c 7 1451.7002 1451.6954 [M+H]
+
183u 4,1-S ,S -u 16 1473.6770 1473.6773 [M+Na]
+
183c 4,1-S ,S -c 9 1451.7127 1451.6954 [M+H]
+
184u 4,1-S ,R -u 16 1451.7028 1451.6954 [M+H]
+
184c 4,1-S ,R -c 8 1451.7075 1451.6954 [M+H]
+
185u 4,1-R ,S -u 16 1451.7014 1451.6954 [M+H]
+
185c 4,1-R ,S -c 6 1451.7048 1451.6954 [M+H]
+
186u 4,1-R ,R -u 16 1473.6824 1473.6773 [M+Na]
+
186c 4,1-R ,R -c 7 1451.6974 1451.6954 [M+H]
+
189 N -Native 5 1350.6389 1350.6341 [M+Na]
+
190u 1,4-N ,N -u 14 1471.7047 1471.6981 [M+H]
+
190c 1,4-N ,N -c 5 1449.7229 1449.7161 [M+H]
+
191u 4,1-N ,N -u 11 1471.7052 1471.6981 [M+Na]
+
191c 4,1-N ,N -c 5 1449.7165 1449.7161 [M+H]
+
a Isocratic gradient 62:38 (Water + 0.1% TFA:MeCN + 0.1% TFA);
b Isocratic gradient 65:35 (Water + 0.1% TFA:MeCN + 0.1% TFA)
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Figure 103- HPLC Spectra of 179u (Blue) and 179c (Red). 
 
3.3 Circular Dichroism 
 
After purification, solutions of the peptides (Figure 104) and peptomers (Figure 105) 
were made up for analysis by circular dichroism. As helical induction from the 
kosmotropicity of trifluoroethanol levels off after 25% in aqueous solutions,64 this 
solvent system was chosen. 
 
 
Figure 104- CD Spectra of A Native Peptide 174 (Black) and Uncyclised Peptides 
179u-186u and B Native Peptide 174 (Black) and Cyclised Peptides 179c-186c in 
25% TFE in water. Enlarged copies are available in Section 5.3. 
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Figure 105- CD Spectra of Native Peptide 174 (Solid Black) and Peptomers 189 
(Dashed Black), 190u/c (red) and 191u/c (blue) in 25% TFE in water. An enlarged 
copy is available in Section 5.3. 
 
To calculate % helicity for each of the peptides/peptomers, a theoretical minimum 
value at 222 nm must be calculated. This can be calculated from the equation (−44 000 
+ 250T)(1 − k/n), where T is the temperature that the spectra were recorded at in 
degrees Celsius, k is a finite length correction (commonly 4.0 for small peptides) and 
n is the number of amide bonds in the molecules.45,121 As the peptides/peptomers are 
N-acetylated and C-amidated, this must be taken into account also, giving an n-value 
of 12. This gives the theoretical minimum at 222 nm as -25166. This was used to 
calculate the % helicity of each of the peptides and peptomers from the spectra. These 
values were compared to the % helicity of the native sequence, and each of the cyclised 
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Table 30- Calculated % Helicity of Peptide/Peptomer Library 
 
 
Interestingly, the % helicity of the peptides/peptomers follows no observable pattern. 
Each of the sequences displays a different maximum at 222 nm. The greatest observed 
increase in helicity with respect to the native sequence 174 was the uncyclised 1,4-
(S,S) peptide 179u. There is no known research into mutations of the alanine residues 
within the native sequence, and so it is entirely plausible that some proteinogenic 
residues may have a similar effect of increasing the α-helicity of the sequence without 
cyclisation. The greatest increase in helicity after cyclisation was seen in the 4,1-(R,S) 
peptide 185. The uncyclised peptide displayed little helicity (6%), even in helix 
forming trifluoroethanol. This may be due to the inclusion of a helix breaking d-amino 
acid. However, the cyclised peptide showed a % helicity comparable to the native 
sequence (36% and 37% respectively). By comparison, the 1,4-(R,S) peptide 181 
exhibited the second greatest decrease in helicity after cyclisation (32% to 18%). The 
Peptide Notation [θ]222 [θ]222/[θ]Max % Helicity % H wrt Native % H wrt u
174 Native -9243.69 0.367 37 - -
179u 1,4-SS -u -11766.9 0.468 47 10 -
179c 1,4-SS -c -6266.8 0.249 25 -12 -22
180u 1,4-SR -u -5356.71 0.213 21 -15 -
180c 1,4-SR -c -6123.75 0.243 24 -12 3
181u 1,4-RS -u -8148.33 0.324 32 -4 -
181c 1,4-RS -c -4458.26 0.177 18 -19 -15
182u 1,4-RR -u -710.88 0.028 3 -34 -
182c 1,4-RR -c -2491.73 0.099 10 -27 7
183u 4,1-SS -u -6262.08 0.249 25 -12 -
183c 4,1-SS -c -8376.37 0.333 33 -3 8
184u 4,1-SR -u -1509.63 0.060 6 -31 -
184c 4,1-SR -c -1963.13 0.078 8 -29 2
185u 4,1-RS -u -1574.34 0.063 6 -30 -
185c 4,1-RS -c -9068.38 0.360 36 -1 30
186u 4,1-RR -u -3911.54 0.155 16 -21 -
186c 4,1-RR -c -2196.19 0.087 9 -28 -7
189 N -Native -506.724 0.020 2 -35 -
190u 1,4-(NN )-u -918.208 0.036 4 -33 -
190c 1,4-(NN )-c -4728.12 0.188 19 -18 15
191u 4,1-(NN )-u -126.48 0.005 1 -36 -
191c 4,1-(NN )-c -1834.6 0.073 7 -29 7
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greatest decrease in α-helicity after cyclisation was seen in the 1,4-(S,S) peptide 179 
(47% to 25%). Contrasting this, the % helicity of the 4,1-(S,S) peptide 183 increases 
following cyclisation (25% to 33%). Analysis of the peptomers 189, 190u/c and 
191u/c clearly show the detriment of removing hydrogen bonding from the sequence, 
with the N-Native peptomer 189 and uncyclised peptomers exhibiting almost no 
helicity at all. Nonetheless, the cyclic 1,4-(N,N) peptomer 190c displayed an increase 
in % helicity compared to the uncyclised sequence (4% to 19%). However, looking at 
the CD spectrum (Figure 105) the graph looks more like the spectrum of a 310-helix, 
suggesting a shorter linker may be effective. A number of conclusions can be drawn 
from the above results: 
 
1. While all the cyclised peptides and peptomers were less helical than the native, 
the fact that 179u (1,4-S,S-u) was shown to be more helical than the native 
suggests that it may be possible to increase the helicity of the native peptide 
using a stapling methodology in the (i,i+4) position selected. 
 
2. Cyclisation did increase the % helicity of some of the peptides with respect to 
the uncyclised counterparts, but not all. It is possible that an investigation into 
linker length or asymmetric linkers would show further increases the helicity 
of the peptides. 
 
3. Although the cyclic peptomers 190c and 191c had a greater helicity than the 
uncyclised counterparts, all the peptomers, including 189 (N-Native) were 
nowhere near as helical as the native peptide sequence, highlighting the 
devastating effect of knocking out central hydrogen bonding on α-helicity. 
 
4. Importantly, all of the circular dichroism results for every peptide and 
peptomer were different. While this could be due to the ether moiety in the 
propargyl serine monomer, it shows that it is critical to screen all permutations 
available in any stapling methodology to find the most effective pairing. 
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3.4 Future Work 
 
With the library of peptidyl inhibitors synthesised and purified, a number of further 
analyses could be performed. These would mostly comprise of in vitro experiments. 
One of the first series of experiments would examine the library’s stability toward 
proteolytic enzymes compared to the native sequence. This would likely be done with 
chymotrypsin, as opposed to trypsin, as the sequence contains neither a lysine nor 
arginine residues which are required for recognition by trypsin. Chymotrypsin cleaves 
peptides at the carboxyl end of bulky, hydrophobic residues such as phenylalanine, 
tyrosine and tryptophan. As the sequence contains all three of these residues this would 
be an effective experiment to probe any increased stability toward proteolytic 
enzymes. 
 
The next experiment would examine the binding affinity of the peptide library to 
MDM2/MDMX. This could be done using isothermal titration calorimetry (ITC)268 or 
surface plasmon resonance (SPR).269 While SPR requires an immobilised protein 
target, it lends itself to high-throughput screening which, out of these two techniques, 
may be better to investigate a library of inhibitors. 
 
Continuing it would be possible to measure cell penetrance and activity using the T22 
reporter assay.270,271 This does not require the peptides to be fluorescently labelled, as 
it relies on T22 cells transfected with a p53 responsive β-galactosidase reporter, which 
are then stained. This also avoids attaching a highly hydrophobic fluorescent dye to 
the peptides, which may have some effect on the ability of the sequence to enter cells. 
Another similar method would involve probing both cell penetrance and binding with 
cellular thermal shift assays (CETSAs).272,273 This relatively new technique relies on 
the different melting temperatures of the target protein with or without a bound ligand, 
even in cells. This techniques has already been used to probe the affinity of stapled 
peptides targeting the p53-MDM2 interaction274 and avoids the use of fluorescence 
which, as mentioned, can alter the ability of a peptide to penetrate a cell. 
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3.5 Summary 
 
For the first time, a peptide targeting the p53 MDM2 interaction has been stapled using 
the copper alkyne-azide cycloaddition reaction. The staple was in a (i,i+4) position, 
which has also not previously been attempted for a p53 MDM2 target. All possible 
stapling diastereomers were synthesised using non-natural amino acids for cyclisation. 
In addition, peptomers containing novel N-substituted glycine monomers were also 
synthesised for the first time. The majority of the peptides and peptomers were cyclised 
on-resin, which was facilitated by microwave heating. Although none of the cyclic 
peptides or peptomers were more helical than the native target sequence by circular 
dichroism, increases in helicity with respect to some of the uncyclised peptides suggest 
that further investigation into this methodology could yield desired results.    




Chapter 4- Design of a Bis-Copper (I) Ligand 
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4 The Copper (I) Alkyne–Azide Cycloaddition 
(CuAAC) Reaction 
 
The copper (I) alkyne-azide cycloaddition (CuAAC) reaction was first reported in 
2002 by the Sharpless and Meldal groups independently.126,127 The non-catalysed 1,3-
dipolar cycloaddition, explored by Huisgen,124 heats an azide and an alkyne for hours 
or days to form a mixture of 1,2,3-triazole regioisomers (Figure 106-A). However, 
with the addition of catalytic amounts of Cu(I), the 1,4-regioisomer is formed 
selectively under much milder conditions and in shorter times (Figure 106-B). 
 
 
Figure 106- Alkyne-Azide Cycloaddition A Huisgen Cycloaddition B Copper(I) 
Catalysed Cycloaddition 
 
While there is still debate about the specifics of the catalytic mechanism, it has been 
established that the rate of the reaction is second order with respect to the concentration 
of Cu(I).139,275 One equivalent is thought to coordinate to the pi orbitals of the alkyne, 
reducing the pKa of the methine proton
276 (Figure 107-I). This increase in acidity 
allows the formation of the copper alkylidine from the second equivalent (Figure 107-
II). The dicopper alkylidine is able to coordinate the organoazide, bringing the two 
reactants in close proximity (Figure 107-III). Rearrangement of the bonds forms the 
copper triazolide,277 via some dicopper intermediate278–280 (Figure 107-IV). This ring 
is protonated from unreacted alkyne starting material or from solution, regenerating 
the catalyst (Figure 107-V). 
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Figure 107- Catalytic Cycle of CuAAC: I Cu(I) coordinates to alkyne pi bonds, 
reducing pKa of terminal proton II formation of copper alkylidine III azide coordinates 
to copper alkylidine IV rearrangement to form copper triazolide V protonation of 
copper triazolide and regeneration of catalyst 
 
4.1 Ligands used in CuAAC 
 
The use of Cu(I) presents some problems synthetically. The metal cation has poor 
solubility in organic media and is easily oxidised to Cu(II).281,282 The unwanted 
oxidation can be suppressed by addition of a reducing agent, commonly sodium 
ascorbate is used.283 A miscible bisolvent mixture, for example water and tert-butanol, 
helps solvate both the organic reactants and the ionic catalyst, though the reaction can 
proceed in water alone.127 Commonly, an organic ligand is added to both solvate the 
copper cation and help protect the copper centre from oxidation.  
 
4.1.1   Tris-(benzyltriazolylmethyl)amine (TBTA) 
 
One of the first designed ligands discovered that exhibited increased catalytic activity 
was tris-(benzyltriazolylmethyl)amine (TBTA) from Chan et al.264 (Figure 108-A). 
When screening a number of soft coordinating ligands, it was found that the 
oligotriazoles derived from proparylamines showed the greatest enhancement, even 
under challenging conditions (1 mol% loading of Cu(I) and ligand, no use of reducing 
agent, no attempt to purge oxygen from solvent). Cyclic voltammetric analysis of a 
water soluble derivative of TBTA, tris(hydroxypropyltriazolylmethyl)amine (THPTA, 
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Figure 108-B), exhibited an increase in the redox potential of approximately 300 mV, 
giving direct evidence that the ligand protects the sensitive Cu(I) centre. 
 
 
Figure 108- Polytriazole ligands A TBTA and B THPTA 
 
The synthesis of TBTA uses the CuAAC reaction in a one-step procedure from benzyl 
azide (BnN3) and tripropargylamine (N(Pra)3) in an autocatalytic process (Figure 109). 
 
 
Figure 109- Synthesis of TBTA 
 
Donnelly et al.265 were able to obtain a crystal structure of a bis-Cu(I) bis-TBTA 
complex (Figure 110). This isolable but oxygen sensitive complex showed that one of 
the triazolyl moieties of each ligand bridges the two copper cations, with the tertiary 
amine having no part in complexation in the solid state. The formation of the dimer 
may be a function of the non-interfering counterion of the copper tetrafluoroborate 
salt. When the complex was added as a catalyst for an azide-alkyne cycloaddition the 
reaction proceeded as normal, with no need for an additional reducing agent. 
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ylmethyl)amine tripotassium - (BimC4A)3 
 
In a similar investigation, Rodionov et al.284 looked into the utility of copper ligands 
primarily based on Tris(2-benzimidazolylmethyl)amine (BimH)3 (TMBA, Figure 111-
A). This core is a known ligand of a number of metals, with crystal structure data of 
copper(I) iodide coordinated to an N’-npropyl derivative available285 (Figure 111-B). 
 
 
Figure 111- Cu(I) trisbenzimidazole ligands A (BimH)3 B Crystal structure of Copper 
[N’-propyl tris(2-benzimidazolylmethyl)amine] iodide, CCDC reference code 
CERRUM.285 
 
After using reaction calorimetry to screen a number of alkylated benzimidazole 
derivatives the ligand Tris(N1-[4-carboxylatobutyl]benzimidazol-2-ylmethyl)amine 
tripotassium (BimC4A)3 was shown to be the most efficient (Figure 112).
284 This 
ligand was then compared in a low-loading experiment with both (BimH)3 and TBTA. 
It was shown that even at loadings of 0.01 mol% of Cu(I) and ligand the desired 
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triazole product was formed in high yield within 24 h. Additionally, the alkyl 
carboxylate groups are able to solubilise the ligand in aqueous media, simplifying 
work-up. 
 
Figure 112- Water soluble Cu(I) ligand tris(N1-[4-carboxylatobutyl]benzimidazol-2-
ylmethyl)amine tripotassium - (BimC4A)3284 
 
4.2 Ligand Design 
 
With the second order dependence of copper required in the CuAAC reaction139,275 it 
follows that a bis-copper chelating ligand, synthesised by somehow tethering together 
two molecules of TBTA (Figure 113), may affect the reaction beneficially. The close 
proximity of the two protected copper centres would likely decrease reaction times, 
given the nature of the copper alkylidine formation.276 This could result in the reaction 
requiring lower catalytic loadings, making it possible to use Cu(I) catalysis in 
bioconjugation reactions where copper toxicity can be an issue.286,287 The ligand may 
also provide an air stable bis-copper complex, simplifying reaction procedures. 
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Figure 113- Possible bis-Cu(I) complexes to improve the CuAAC 
 
One of the more obvious solutions to tether the two TBTA molecules is to use a diazide 
as one of the components in a typical TBTA synthesis.264 A small library, using both 
aliphatic and aromatic diazide tethers, would further investigate whether a flexible 
linker is most efficient, or if there is an optimum rigid arrangement (Figure 114). The 
bis-TBTA crystal structure shows that the two copper centres are coordinated 
saturated, therefore the chelating bonds must be broken for the catalysis. Having only 
one tether would maximise the possibility of the copper centres becoming unsaturated. 
 
 
Figure 114- Diazide linkers B01-B06 selected for incorporation into bis-TBTA ligands 
 
To allow for further functionalisation, the benzylic groups of TBTA were replaced 
with those including a p-methyl ester moiety (Figure 115). This may in itself increase 
the solubility of the highly hydrophobic bis-TBTA ligand. Additionally, it would allow 
for further functionalisation of the ligand. Transesterification with a PEG group or 
hydrolysis of the ester to the carboxylate salt could result in increased solubility in 
aqueous media similar to the (BimC4A)3 ligand.
284  
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Figure 115- Library of bis Cu(I) ligands B07-B12 
 
4.3 Ligand Synthesis 
 
A typical TBTA synthesis, as discussed previously, uses 3 equivalents of benzyl azide 
and one of tripropargylamine.264 However, synthesis of the ligand required a 
selectivity in the reaction procedure not required in a TBTA synthesis. Incorporating 
one equivalent of a diazide tether with four equivalents of 4-(azidomethyl)methyl 
benzoate B13 would result in a multitude of products, diminishing the yield of the 
desired ligand (Figure 116). 
 
Figure 116- Rejected synthesis of ligand library B07-B12 
 
Drawing from the literature,288,289 it was apparent that the ditriazolyl alkyne B14 could 
be synthesised from the double reductive amination of propargylamine (PraNH2) and 
the triazolyl aldehyde B15 (Figure 117). This would avoid the need to selectively 
“click” one alkyne with the diazide tether. 
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Figure 117- Retrosynthesis of ditriazolyl alkyne B14 
 
The triazolyl aldehyde can be synthesised using the CuAAC reaction. This would 
require the oraganoazide B13 and propynal (Figure 118). The azide can easily be 
obtained from the corresponding commercially available bromide 4-
(bromomethyl)methyl benzoate (4-(BM)MB). Propynal however is not commercially 
available and is volatile, so a more accessible, stable alternative was sought. The 
corresponding alkynyl carboxylic acid and esters would require reduction to the 
required triazolyl aldehyde B15, which is not compatible with the p-methyl ester 
moiety. Propargyl alcohol could be used, but was rejected as the free alcohol would 
likely be more water soluble and so could present problems during work up. Instead, 
3,3-diethoxypropyne (3,3-DEP) was selected. This alkyne is commercially available, 
and can be easily hydrolysed to the desired triazolyl aldehyde B15 without hydrolysis 
of the methyl ester. 
 
 
Figure 118- Retrosynthesis of triazolyl aldehyde B15 
 
4.3.1 Synthesis of Diazide Tethers  
 
There are a number of ways the six diazide tethers could be synthesised. A modified 
procedure from Alvares et al.244, which uses sodium azide dissolved in DMSO. The 
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methodology afforded the 6 diazides B01-B06 from the corresponding dibromides 
(confirmed by TLC) in excellent yields and in gram quantities (Scheme 26). This 
methodology did not require heating unlike a number of azide displacements in the 
literature, which was advantageous as heating could present a risk in low molecular 
weight diazides, particularly 1,6-diazidohexane B01. 
 
 
Scheme 26- Synthesis of diazides B01-B06 
 
4.3.2 Synthesis of Ditriazolyl Alkyne 
 
The desired ditriazolyl alkyne B14 can be obtained from the double reductive 
amination of propargylamine and the triazolyl aldehyde B15. This methodology avoids 
the chance of forming an ammonium salt, which could occur during an alkylation 
approach using propargylamine and bromoester 4-(BM)MB. 
 
 Synthesis of Triazolyl Aldehyde 
 
Starting from 4-(bromomethyl)methyl benzoate (4-(BM)MB), the previous conditions 
to obtain the diazides B01-B06 were used (Scheme 27).244 Fewer equivalents of 
sodium azide were added to both reduce the explosive risk and to minimise waste, 
producing the azide B13 on gram scale in good yield. A shift in retention time (TLC) 
indicated that the reaction had gone to completion. 
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Scheme 27- Azidification of bromoester 4-(BM)MB 
 
The copper(I) alkyne-azide cycloaddition with azide B13 and 3,3-diethoxypropyne 
(3,3-DEP) was performed with 5 mol% copper(II) sulfate pentahydrate and a 20 mol% 
excess of sodium ascorbate as the reducing agent (Scheme 28). The reaction was 
complete after approximately 18 hours at room temperature with quantitative 
conversion to the triazolyl acetal B16. 
 
 
Scheme 28- CuAAC of Azide B13 
 
The formation of the triazolyl acetal B16 was confirmed by 1H NMR (Figure 119). 
The appearance of the triazole proton E, acetal proton F and the ethyl protons G, H 
(CH2) and I (CH3), plus the shift of the benzylic peak C (4.42 to 5.57 ppm) due to the 
deshielding effect of the triazole π-electrons proves with high certainty that the desired 
compound was synthesised. The ethyl CH2 peaks G and H, instead of appearing as a 
single quartet, appear as two doublets of quartets (dq). This is because of the 
diastereotopic nature of these protons and is a common feature of diethyl acetals.290 
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Figure 119- 1H NMR Spectra (8.5 – 0.5 ppm, CDCl3) of azide B13 (red) and triazolyl 
acetal B16 (blue). 
 
Following the methodology described by Wei et al.291 the hydrolysis of the acetal B16 
was achieved (Scheme 29). By stirring the acetal in dry chloroform with a vast excess 
of TFA (20 eq), the aldehyde was revealed without aqueous acid, thereby preventing 
any hydrolysis of methyl ester. This “hydrolysis” has been shown to proceed via a 
hemiacetal trifluoroacetyl ester intermediate B17. The reaction was complete in 5 
hours at room temperature and afforded the triazolyl aldehyde B15 in excellent yield. 
 
 
Scheme 29- Deacetalisation of triazolyl acetal B16 
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The formation of the triazolyl aldehyde B15 was verified by 1H NMR (Figure 120). 
The disappearance of the ethyl CH2 (G, H) and CH3 (I) peaks, and the downfield shifts 
of the triazole (E) and acetal (F) upon the unmasking of the electron withdrawing 
aldehyde group all give good evidence that the triazolyl acetal B16 was hydrolysed. 
 
 
Figure 120- 1H NMR Spectra (10.5 – 0.5 ppm, CDCl3) of triazolyl acetal B16 (red) 
and triazolyl aldehyde B15 (blue). 
 
The triazolyl aldehyde B15 was synthesised in three steps from commercially available 
starting material in 96 % overall yield and gram quantities (Scheme 30). 
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Scheme 30- Complete synthesis of triazolyl aldehyde B15  
 
 Double Reductive Amination  
 
With the triazolyl aldehyde B15 in hand, the double reductive amination with 
propargylamine could take place. A number of reductants were considered for the 
transformation. It was decided that sodium triacetoxyborohydride (NaBH(OAc)3, 
STAB-H) would be the most suitable reductant to use.292 More common reductants, 
including the mild sodium borohydride (NaBH4), would reduce the aldehyde before 
the formation of the imine or iminium intermediates could take place.293 Alternatively, 
STAB-H is mild enough to allow the more electrophilic imine and iminium 
intermediates to form without significant reduction of the aldehyde (Scheme 31).294 
The other milder alternative, sodium cyanoborohydride (NaBH3CN) was rejected due 
to toxicity issues associated with the reagent.295  
 
 
Scheme 31- Double reductive amination of triazolyl aldehyde B15 and 
propargylamine  
 
The reaction was complete in 6 hours at room temperature. The ditriazolyl alkyne B14 
was obtained in 59% yield in gram quantity. Assessment of the 1H NMR spectra 
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(Figure 121), the appearance of the propargylic CH2 (J) and CH (K) peaks, with typical 
doublet and triplet peak splitting of a propargyl 4JHH coupling, suggests that the 
propargylamine has been incorporated into the product. The shift of the aldehyde peak 
(F) and the triazole peak (E) upfield (10.14 to 3.84 ppm and 8.03 to 7.53 ppm 
respectively) shows that the aldehyde has been reduced. As the desired double 
reductive amination product has a plane of symmetry, no additional new peaks appear, 
but the peak integrals doubled in comparison to the triazolyl aldehyde B15. This 




Figure 121- 1H NMR Spectra (10.5 – 1.5 ppm, CDCl3) of triazolyl aldehyde B15 (red) 
and ditriazolyl alkyne B14 (blue). 
 
4.3.3 CuAAC of Bis-TBTA Ligands 
 
After synthesis of the diazides B01-B06 and the ditriazolyl alkyne B14, formation of 
the bis-TBTA ligand library was attempted. As a test substrate, 1,8-diazidooctane B03 
was selected first, as this is the longest and most flexible linker (Scheme 32). After 6 
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Scheme 32- CuAAC of ditriazolyl alkyne B14 and diazide B03 
 
The 1H NMR spectrum of the isolated product B09 was compared to the ditriazolyl 
alkyne starting material B14 (Figure 122). The transformation of the propargylic CH2 
doublet and CH triplet peaks into downfield singlets (J and K respectively) indicate 
the formation of the triazole groups. The additional octanyl methylene peaks from the 
from the diazide linker B03 (L, M and N) also indicate that the ligand has formed. The 
N3CH2 methylene protons (L) have also moved to a more deshielded position (3.29 to 
4.30 ppm, see experimental) also giving evidence of triazole formation. Similar to the 
ditriazolyl alkyne B14, the ligand B06 has a plane of symmetry. This means that the 
signals observed are degenerate. Conversely however the mono-CuAAC product 
would have non-degenerate signals from the octanyl linker, and would therefore be 
easy to identify. As there are two triazole proton peaks (E and K) in a 2:1 ratio and two 
triazolylic (analogous to benzylic) proton peaks (F and J) also in a 2:1 ratio, in addition 
to the degeneracy of the octanyl methylene peaks, it is assured that the desired bis-
TBTA ligand B09 was synthesised. 
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Figure 122- 1H NMR Spectra (8.5 – 1.0 ppm, CDCl3) of ditriazolyl alkyne B14 (red) 
and bis-TBTA ligand B09 (blue). 
 
The next bis-TBTA ligand attempted used 1,4-diazidomethylbenzene B06 as the 
tether, employing the same reaction conditions as the 1,8-diazidooctane tether 
(Scheme 33). After 4 hours the ditriazolyl alkyne B14 appeared to be consumed (TLC). 
However, after work up, it became apparent that the bis-TBTA ligand B12 had not 
formed in any appreciable amount. A range of reaction conditions were attempted, 
including altering the copper source and solvent but none were successful (Table 31). 
 
 
Scheme 33- Failed synthesis of Ligand B12 
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Table 31- Conditions attempted in Synthesis of Ligand B12 
 
 
To determine whether this poor yield was due to the lack of flexibility in the linker or 
a function of the tether length, the synthesis of the bis-TBTA ligand B07 which uses 
1,6-diazidohexane B01 was attempted (Scheme 34). The aliphatic tethers offer a 
greater degree of flexibility, which would allow the bulky ditriazolyl alkynes to “click” 
with the shorter tether. However, if the problem was a function of steric bulk and linker 
length, the shorter tether would not form the bis-TBTA ligand. A number of conditions 
were attempted (Table 32) however again none gave the desired bis-TBTA ligand B07. 
 
 
Scheme 34- Failed synthesis of Ligand B07 
 
Table 32- Attempted Conditions in synthesis of Ligand B07 
 
Cu(I) Source Amount (mol%) Solvent Solvent Ratio Temp (°C) Additive Amount (mol%)
CuI 10 MeCN - 25 Et3N 120
CuI 10 MeCN - 45 Et3N 120
CuI 10 MeCN - 25 DIPEA 120
CuI 10 MeCN - 45 DIPEA 120
CuI 20 MeCN - 25 Et3N 120
CuSO4/NaAsc 5/20
t BuOH:H2O 2:1 25 - -
CuSO4/NaAsc 5/20
t BuOH:H2O 2:1 45 - -
CuSO4/NaAsc 10/20
t BuOH:H2O 2:1 45 - -
CuSO4/NaAsc 5/20
t BuOH:H2O 1:1 45 - -
CuSO4/NaAsc 10/20
t BuOH:H2O 2:1 45 NaHCO3 15
Cu(I) Source Amount (mol%) Solvent Solvent Ratio Additive Amount (mol%)
CuI 10 MeCN - Et3N 120
CuI 10 MeCN - DIPEA 120
CuI 20 MeCN - Et3N 120
CuSO4/NaAsc 5/20
t BuOH:H2O 2:1 - -
CuSO4/NaAsc 10/20
t BuOH:H2O 2:1 - -
CuSO4/NaAsc 10/20
t BuOH:H2O 2:1 NaHCO3 15
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The failure of these reactions highlighted some restriction from either the steric bulk 
of the ditriazolyl alkyne B14 or the length of the diazide linkers in yielding the desired 
products. As such, to obtain the ligands the synthesis route had to be redesigned. 
However due to time pressures this project was halted in favour of the stapled peptide 
research. 
 
4.4 Future Work 
 
4.4.1 Alternate Synthesis of Bis-TBTA Ligands 
 
With additional time, the ligand synthesis could have been completed by altering the 
synthesis sequence to a more stepwise approach. Rather than build the periphery of the 
ligands and tether them together, the library would be built from the tether out (Figure 
123). This would be using similar methodology to that previously attempted. The 
diazide tethers B01-B06 would form the ditriazolyl diacetals B18-B23 from the 
cycloaddition of 3,3-diethoxypropyne (3,3-DEP). The acetals could then be 
hydrolysed to reveal the ditriazolyl dialdehydes B24-B29. 
 
 
Figure 123- Proposed synthesis of ditriazolyl dialdehydes B24-B29 
 
From here, there are a couple of possible routes. In one pathway, the ditriazolyl 
dialdehydes B24-B29 would undergo reductive amination with dipropargylamine 
(NH(Pra)2), which is commercially available. This pathway would yield the library of 
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tetra-alkynes B30-B35. From here, the CuAAC with azide B13 would give the 
complete library of bis-TBTA ligands B07-B12 (Figure 124). 
 
 
Figure 124- Proposed linear synthesis of ligands B07-B12 from ditriazolyl 
dialdehydes B24-B29 
 
In the second route the reductive amination step would be the final step, resulting from 
the condensation of the ditriazolyl amine B36, which is formed from the CuAAC of 
dipropargylamine (NH(Pra)2) and the azido ester B13 (Figure 125). This route could 
present a similar problem to the failed syntheses in that the ditriazolyl amine B36 is 
relatively bulky, and so the reaction may not go to completion. 
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4.4.2 Analysis of Ligands 
 
The utility of the bis-TBTA ligands B07-B12 would be explored by addition to a 
stereotypical CuAAC reaction, for example benzyl azide and phenylacetylene. 
Experiments to determine the minimum catalytic loading would be carried out to 
compare the effectiveness of these new ligands. A direct comparison of the ligands 
and TBTA would also provide excellent evidence of the increased activity. 
Crystallisation of the bis-Cu(I) complexes would offer insight into preferred 
conformations, as it may be possible that rather than forming a bis-Cu(I) monomer, 
certain tethers would favour dimeric or oligomeric/polymeric structures (Figure 126). 
 
Figure 126- Representations of ligand conformations. Solid curved lines - chelating 
TBTA moiety; dashed curved lines – linker; A monomeric conformation B dimeric 
conformation C polymeric conformation 
 
Along with previously discussed ligands, the cyclic voltammetry profile of each of the 
bis-TBTA library would be valuable to see how well protected both the copper centres 
are from redox. This, along with experiments probing the “bench stability” of the bis-
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4.5 Summary 
 
The synthesis of a small library of novel bis-copper(I) ligands was attempted. While 
the library was not finished, a new sequence has been proposed for obtaining the 
complete series. From there, experiments designed to probe the properties and utility 
of these ligands have been suggested.    




Chapter 5- Experimental 
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5 General Experimental 
 
All non-aqueous reactions were performed in air using oven-dried glassware. All 
reagents and materials were obtained from commercial suppliers and used without 
further purification unless otherwise stated. Acetonitrile and dichloromethane were 
dried and purified by activated alumina column (PPT Glass Contour). 
Dimethylformamide was purchased over 4 Å molecular sieves (Acros Organics). 
Triethylamine was distilled over calcium hydride and stored over 4 Å molecular sieves 
in an inert atmosphere. NMR spectra were obtained on Bruker instruments at the stated 
frequencies at 300 K unless otherwise stated. Electrospray ionisation mass spectra 
were obtained on a Bruker MicroToF Focus 2. Electron ionisation mass spectra were 
obtained on a MAT 900 XP mass spectrometer. Infra-red spectra were obtained neat 
on a Shimadzu IRAffinity-1S. Optical rotation were measured on an AA Series 
PolAAr 20 polarimeter with a 1 dm pathlength at 589 nm (sodium D line). Semi-
preparative reverse phase HPLC was performed using a Waters 600 (225 µL) system 
using a Waters 486 tuneable absorbance detector recording at 254 nm equipped with 
a Phenomonex Luna C18(2), 5 µm, 250 x 21.2 mm column at a flow rate of 21.2 mL 
minute-1. Analytical reverse phase HPLC analysis using a Waters 600E (100 μL) 
gradient pump using a Waters 996 PDA equipped with a PhenomenexLuna C18(2), 5 
μm, 250 x 4.6 mm column at a flow rate of 1 mL min-1. Microwave heating was 
accomplished using a Biotage Initiator and SP wave. Circular dichroism spectra were 
obtained on a JASCO J-810 spectropolarimeter with Peltier variable temperature 
controller. Melting points were determined on a Gallenkamp Electrothermal melting 
point apparatus and are uncorrected. Thin Layer Chromatography was performed on 
Merck 60F245 (0.25 mm) aluminium plates and were visualised by ultraviolet light, 
then either potassium permanganate stain or ninhydrin stain. Flash column 
chromatography was carried out using Kieselgel 60 silica (Sigma Aldrich). 
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5.1 Monomer Synthesis 
 
5.1.1 Amino Acid Monomer Synthesis 
 
(2S)-5-Azido-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}pentanoic acid L177 
 
L-Fmoc-Lys(Boc)-OH (2.318 g, 5.10 mmol), was dissolved in DCM (5.1 mL). TFA 
(7.81 mL, 102 mmol) was added dropwise and the solution was stirred at ambient 
temperature for 2 h. The solvent was removed in vacuo to give the crude TFA salt as 
a yellow oil. The oil was dissolved in MeOH/H2O (15 mL, 2:1). K2CO3 (1.90 g, 13.8 
mmol), copper (II) sulfate pentahydrate (64 mg, 255 μmol) and 1H-Imidazole-1-
sulfonyl azide·HCl (1.18 g, 5.61 mmol) were added and the pH was adjusted and 
maintained at pH 9 by addition of K2CO3 (sat. aq.). The blue reaction mixture was 
stirred for 18 h at rt. The solvent was removed in vacuo. The residue was re-dissolved 
in deionised H2O (100 mL) and washed with toluene (3 x 50 mL). The aqueous layer 
was acidified to pH 2-3 and extracted with EtOAc (3 x 50 mL). The combined organic 
layers were washed with brine (3 x 50 mL), dried (Na2SO4), filtered and concentrated 
in vacuo to give L-Fmoc-Orn(Azi)-OH as a yellow oil (1.77 g, 91%). 
 
Rf (80:15:5 tol:EtOAc:AcOH) 0.28; [α]D -2.4 (c = 1.0 MeOH), lit144,296 [α]D -2.3 (c = 
1.0 MeOH); IR (neat, cm-1) 3337 (N-H), 2091 (N3), 1728 (C=O ester), 1711 (C=O 
acid), 1680 (C=O amide), 1531 (N-H amide); 1H NMR (500 MHz, CDCl3, 323 K) δ 
8.96 (1H, br s, COOH), 7.78 (2H, d, J = 7.5 Hz, FmocArH), 7.60 (2H, s, FmocArH), 
7.42 (2H, t, J = 7.3 Hz, FmocArH), 7.33 (2H, t, J = 7.3 Hz, FmocArH), 5.42 (1H, s, 
NH), 4.75-4.45 (3H, m, FmocCH2O & CHCH2CH2), 4.24 (1H, t, J = 6.3 Hz, FmocH), 
3.32 (2H, br s, CH2N3), 2.15 – 1.50 (m, 4H, CHCH2CH2CH2N3); 13C NMR (126 MHz, 
CDCl3, 323 K) δ 176.12 (C), 156.25 (C), 143.79 (C), 143.64 (C), 141.40 (2C), 127.78 
(2CH), 127.10 (2CH), 124.94 (2CH), 120.01 (CH), 120.00 (CH), 67.26 (CH2), 53.42 
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(CH), 50.81 (CH2), 47.26 (CH), 29.64 (CH2), 24.83 (CH2); m/z (ESI+) 799 ([2M+K]
+, 
7%), 783 ([2M+Na]+, 18), 419 ([M+K]+, 38), 403 ([M+Na]+, 100), 381 ([M+H]+, 9), 
242 (19), 179 (14), 153 (7); HRMS (ESI+) C20H20N4O4Na ([M+Na]
+) requires 
403.1377, found 403.1377 (δ 0.0 ppm). 
 
The NMR data is in agreement with the literature144 
 
The enantiomer, (2R)-5-Azido-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino} 
pentanoic acid D177, was synthesised from D-Fmoc-Lys(Boc)-OH (2.287 g, 5.03 
mmol) according to the preceding procedure (1.64 g, 86%). 
 
[α]D +2.3 (c = 1.0 MeOH); IR (neat, cm-1) 3337 (N-H), 2091 (N3), 1726 (C=O ester), 
1709 (C=O acid), 1680 (C=O amide), 1531 (N-H amide); m/z (ESI+) 799 ([2M+K]+, 
19%), 783 ([2M+Na]+, 24), 419 ([M+K]+, 74), 403 ([M+Na]+, 100), 381 ([M+H]+, 16), 
242 (26), 179 (35), 153 (34); HRMS (ESI+) C20H20N4O4Na ([M+Na]
+) requires 
403.1377, found 403.1386 (δ 0.9 ppm). 
 
(2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(prop-2-yn-1-yloxy)  propanoic acid 
L197 
 
Boc-L-serine (2.10 g, 10.3 mmol) was dissolved in DMF (20 mL), cooled to 0 °C and 
NaH (902 mg, 22.6 mmol; 60% dispersion in mineral oil) was added. After stirring for 
30 min at 0°C propargyl bromide (1.22 ml, 11.3 mmol; 80% solution in toluene) was 
added dropwise. After stirring at 0 °C for 30 minutes the ice bath was removed and the 
reaction was stirred for ~18 h at rt. The solvent was removed in vacuo and the residue 
re-dissolved in deionised H2O (100 mL). The solution was acidified to pH 2-3 and the 
aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organics were 
washed with LiBr (2 x 10 mL; 2 M aq) and brine (2 x 25 mL), dried (MgSO4) and 
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concentrated in vacuo. The residue was purified by column chromatography (80:15:5, 
tol:EtOAc:AcOH) to give Boc-L-Ser(Pra)-OH as a colourless gum (1.98 g, 79%). 
Rf (80:15:5 tol:EtOAc:AcOH) 0.24; [α]D +0.1 (c = 1.0 MeOH), lit218 [α]D +0.10 (c = 
1.0 MeOH); IR (neat, cm-1) 3290 (N-H), 1705 (C=O), 1506 (N-H amide);  1H NMR 
(500 MHz, CDCl3) δ 5.69 and 5.42 (1H, d, J = 8.2 Hz, NH), 4.51 (1H, dt, J = 8.2, 4.7 
Hz, NHCHRCO2H), 4.23 (1H, dd, J = 16.0, 2.4 Hz, CHAHBC≡CH), 4.19 (1H, dd, J = 
16.0, 2.4 Hz, CHAHBC≡CH), 4.02 (1H, dd, J = 9.7, 3.1 Hz, CHCHCHDO), 3.84 (1H, 
dd, J = 9.4, 3.6 Hz, CHCHCHDO), 2.50 (1H, t, J = 2.4 Hz, C≡CH), 1.49 (9H, s, 
C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 174.65 (C), 155.78 (C), 80.47 (C), 78.68 
(C), 75.37 (CH), 69.37 (CH2), 58.71 (CH2), 53.66 (CH), 28.31 (3CH3); m/z (ESI+) 601 
(23%), 585 (45), 569 (27), 320 ([M+2K-H]+, 100), 304 ([M+Na+K-H]+, 84), 288 (13), 
282 ([M+K]+, 21), 266 ([M+Na]+, 83), 219 (17), 210 (73), 204 (18), 166 (11); HRMS 
(ESI+) C21H19NO5Na ([M+Na]
+) requires 266.0999, found 266.1015 (δ 1.6 ppm). 
 
The data is in agreement with the literature297 
 
The enantiomer, (2R)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-(prop-2-yn-
1-yloxy) propanoic acid D197, was synthesised from D-Boc-Ser-OH (2.10 g, 10.2 
mmol) according to the preceding procedure (1.70 g, 82%). 
 
[α]D -0.1 (c = 1.0 MeOH); IR (neat, cm-1) 3292 (N-H), 1705 (C=O), 1506 (N-H 
amide); m/z (ESI+) 601 (28%), 585 (41), 569 (18), 320 ([M+2K-H]+, 100), 304 
([M+Na+K-H]+, 71), 288 (13), 288 (11), 282 ([M+K]+, 14), 266 ([M+Na]+, 57), 219 
(17), 210 (50), 204 (15); HRMS (ESI+) C11H17NO5Na ([M+Na]
+) requires 266.0999, 
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(2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-(prop-2-yn-1-
yloxy)propanoic acid L178 
 
Boc-L-Ser(Pra)-OH (2.59 g, 10.6 mmol) was dissolved in DCM (11 mL). TFA (16.3 
mL, 213 mmol) was added dropwise and the solution was stirred at rt for 2 h. The 
solution was concentrated in vacuo to give the crude amine TFA salt as yellow oil. The 
crude product was dissolved in dioxane (11.5 mL) and Na2CO3 (23 mL, 15% w/v) for 
15 min at rt. Fmoc-Cl (2.78 g, 10.8 mmol) dissolved in dioxane (11.5 ml) was added 
over 5 min and the reaction mixture stirred for 18 h. The solvent was removed in vacuo 
and the residue re-dissolved with H2O (100 ml) and washed with toluene (3 x 50 mL). 
The aqueous layer was acidified to pH 2-3 and extracted with EtOAc (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 50 mL), brine (3 × 50 mL), dried 
(Na2SO4) and concentrated in vacuo to give L-Fmoc-Ser(Pra)-OH L178 as a colourless 
gum (3.11 g, 80%). 
 
Rf (80:15:5 tol:EtOAc:AcOH) 0.22; [α]D +6.0 (c = 1.0 MeOH), lit218 [α]D +6.2 (c = 
1.0 MeOH); IR (neat, cm-1) 3404, 3263 (N-H), 1761 (C=O ester), 1714 (C=O acid), 
1524 (N-H amide); 1H NMR (500 MHz, CDCl3) δ 7.80 (2H, d, J = 7.5 Hz, FmocArH), 
7.64 (2H, t, J = 6.0 Hz, FmocArH), 7.43 (2H, t, J = 7.4 Hz, FmocArH), 7.35 (2H, t, J 
= 7.4 Hz, FmocArH), 5.67 (1H, d, J = 8.3 Hz, NH), 4.63 (1H, dt, J = 6.9, 2.9 Hz, 
NHCHRCO2H), 4.49 (1H, dd, J = 10.3, 7.3 Hz, FmocCHAHBO), 4.42 (1H, dd, J = 
10.3, 7.3 Hz, FmocCHAHBO), 4.28 (1H, t, J = 7.0 Hz, FmocH), 4.23 (2H, m, 
OCH2C≡CH), 4.09 (1H, dd, J = 9.6, 3.1 Hz, CHCHAHBO), 3.87 (1H, dd, J = 9.7, 2.7 
Hz, CHCHAHBO), 2.49 (1H, t, J = 2.3 Hz, C≡CH); 13C NMR (126 MHz, CDCl3) δ 
173.81 (C), 156.18 (C), 143.81 (C), 143.70 (C), 141.34 (2C), 127.77 (2CH), 127.12 
(CH), 125.16 (CH), 125.12 (CH), 120.02 (2CH), 78.54 (C), 75.54 (CH), 69.25 (CH2), 
67.37 (CH2), 58.79 (CH2), 53.92 (CH), 47.13 (CH); m/z (ESI+) 878 (9%), 753 
New Approaches to Stapled Peptides Targeting the p53-MDM2 Interaction 
 
Experimental   153 
([2M+Na]+, 24), 513 (29), 404 ([M+K]+, 14), 388 ([M+Na]+, 100), 366 ([M+H]+, 10), 
326 (7), 242 (15), 179 (9); HRMS (ESI+) C21H19NO5Na ([M+Na]
+) requires 
388.1155, found 388.1172 (δ 1.7 ppm). 
 
The data is in agreement with the literature218 
 
The enantiomer, (2R)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-(prop-2-yn-
1-yloxy) propanoic acid D178, was synthesised from D-Boc-Ser(Pra)-OH (1.38 g, 
5.68 mmol) according to the preceding procedure (1.70 g, 82%). 
 
[α]D -5.9 (c = 1.0 MeOH); IR (neat, cm-1) 3404, 3263 (N-H), 1761 (C=O ester), 1714 
(C=O acid), 1526 (N-H amide); m/z (ESI+) 975 (6%), 878 (9), 753 ([2M+Na]+, 28), 
610 (7), 513 (15), 404 ([M+K]+, 16), 388 ([M+Na]+, 100), 366 ([M+H]+, 11), 326 (18), 
270 (17), 248 (15), 179 (11); HRMS (ESI+) C21H19NO5Na ([M+Na]
+) requires 
388.1155, found 388.1170 (δ 1.5 ppm). 
 




To a solution of 3-chloropropylamine hydrochloride (7.81 g, 60.1 mmol) in DCM (120 
mL) was added TFAA (9.32 mL, 66.1 mmol). The solution was allowed to stir at rt for 
5-10 minutes until it became homogeneous. The solution was cooled to 0 °C and TEA 
(18.4 mL, 132 mmol) was added dropwise slowly (gas released). After addition the 
solution was warmed to rt and allowed to stir for 2 h. The organic layer was washed 
with hydrochloric acid (3 x 50 mL, 1 M aq). The combined acidic aqueous washes 
were extracted with additional DCM (2 x 40 mL) and the organic extracts combined. 
The organic layer was washed with deionised water (3 x 40 mL) and brine (2 x 40 
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mL). The organic extracts were dried (MgSO4), filtered, and the solvent removed in 
vacuo to give a light yellow oil 199 that solidified on standing (9.95 g, 87%). 
 
Rf (4:1 Hex:EtOAc) 0.26; Mp: 30-32 °C; lit298 Mp = 30 °C; IR (neat, cm-1) 3306 (N-
H), 1701 (C=O amide), 1152 (C-F); 1H NMR (500 MHz, CDCl3): δ 6.62 (1H, br s, 
NH), 3.64 (2H, t, J = 6.2 Hz, CH2Cl), 3.59 (2H, q, J = 6.5 Hz, CH2NHR), 2.12 (qn, J 
= 6.7 Hz, 2H, CH2CH2CH2); 13C NMR (126 MHz, CDCl3): δ 157.52 (q, 
2JCF = 37.0 
Hz, C), 115.75 (q, 1JCF = 287.7 Hz, C), 41.99 (CH2), 37.67 (CH2), 31.17 (CH2); 19F 
NMR (471 MHz, CDCl3): δ -75.99 (s, CF3); m/z (ESI+, MeCN): 347 (50%), 242 (35), 
212 ([M+Na]+ 100); HRMS (ESI+, MeCN) C5H7NOClF3Na ([M+Na]
+) requires 
212.0061, found 212.0063 (δ 0.2 ppm 
 
1H NMR data is in agreement with the literature299 
 
tert-butyl 2-[N-(3-chloropropyl)-2,2,2-trifluoroacetamido]acetate 200 
 
To a solution of N-(3-chloropropyl)-2,2,2-trifluoroacetamide 199 (5.57 g, 29.4 mmol) 
in DMF (29.4 mL) was added Cs2CO3 (11.5 g, 35.3 mmol) and the solution warmed 
to 35 °C. After 5 minutes stirring tert-butyl bromoacetate (4.77 mL, 32.3 mmol) was 
added and the solution left to stir at 35 °C for 3 h. The solvent was removed in vacuo 
and the residue re-dissolved in DCM (10 mL). The solution was passed through a silica 
plug, which was rinsed with additional DCM (5 x 50 mL). The solvent removed in 
vacuo to yield a light yellow viscous oil 200 (8.21 g, 92%). 
 
Rf (4:1 Hex:EtOAc) 0.39; IR (neat, cm-1) 1743 (C=O ester), 1693 (C=O amide), 1138 
(C-F); 1H NMR (500 MHz, CDCl3) δ 4.11 (1H, q, J = 1.4 Hz, CH2CO2
tBu), 4.03* 
(1H, s, CH2CO2
tBu), 3.65 (2H, m, CH2CH2NR2), 3.61 (2H, t, J = 6.2 Hz, 
ClCH2CH2CH2NR2), 2.18 – 2.08 (2H, m, CH2CH2CH2), 1.51 (4.5H, s, C(CH3)3), 1.50* 
(4.5H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 166.90 (C), 166.41* (C), 157.49 
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(q, 2JCF = 36.6 Hz, C), 116.31 (q, 
1JCF = 287.3 Hz, C), 116.13* (q, 
1JCF = 288.0 Hz, C), 
83.33 (C), 82.87* (C), 50.57 (q, 4JCF = 3.5 Hz, CH2), 49.80* (CH2), 47.65 (CH2), 
46.78* (q, 4JCF = 3.0 Hz, CH2), 42.05 (CH2), 41.42* (CH2), 31.26 (CH2), 29.65* (CH2), 
27.98 (3CH3), 27.91* (3CH3); 19F NMR (471 MHz, CDCl3) δ -69.17 (s, CF3), -69.66* 
(s, CF3); (*: trans rotamer);  m/z (ESI+, MeCN): 629 ([2M+Na]
+, 35%), 515 (59), 326 
([M+Na]+ 69), 269 [M-Cl]+ (100), 248 (36), 210 (30); HRMS (ESI+, MeCN): 
C11H17NO3ClF3Na ([M+Na]
+) requires 326.0741, found 326.0744 (δ 0.3 ppm). 
 
tert-butyl 2-[N-(3-iodopropyl)-2,2,2-trifluoroacetamido]acetate 201 
 
To a solution of tert-butyl 2-[N-(3-chloropropyl)-2,2,2-trifluoroacetamido]acetate 200 
(2.55 g, 8.39 mmol) in MeCN (8.39 mL) was added NaI (1.57 g, 10.5 mmol; dried 
under high vacuum and heating with a heat gun for 5 mins) and the solution heated to 
95 °C under reflux for 8 h. After consumption of the starting material (NMR) the 
reaction mixture was cooled and the solvent removed in vacuo. The residue was re-
dissolved in DCM (10 mL) and filtered through a silica pad which was rinsed with 
additional DCM (5 x 50 mL). The solvent removed in vacuo to give a viscous dark 
yellow orange oil 201 (3.23 g, 97%). 
 
Rf (4:1 Hex:EtOAc) 0.41; IR (neat, cm-1) 1743 (C=O ester), 1691 (C=O amide), 1132 
(C-F); 1H NMR (500 MHz, CDCl3) δ 4.11 (1H, q, J = 1.3 Hz, R2NCH2CO2
tBu), 4.02 
(1H, s, CH2CO2
tBu), 3.58 (2H, m, CH2CH2NR2), 3.20 (1H, t, J = 6.9 Hz, ICH2), 3.18 
(1H, t, J = 6.8 Hz, ICH2), 2.18 (1H, qn, J = 6.8 Hz, CH2CH2CH2), 2.17 (1H, qn, J = 
6.8 Hz, CH2CH2CH2), 1.51 (4.5H, s, C(CH3)3), 1.50 (4.5H, s, C(CH3)3); 13C NMR 
(126 MHz, CDCl3) δ 166.85 (C), 166.36* (C), 157.50 (q, 
2JCF = 36.0 Hz, C), 157.43* 
(q, 2JCF = 36.5 Hz, C), 116.29* (q, 
1JCF = 287.2 Hz, C), 116.11 (q, 
1JCF = 288.3 Hz, C), 
83.37 (C), 82.90* (C), 50.50* (CH2), 50.49 (q, 
4JCF = 3.5 Hz, CH2), 49.84* (q, 
4JCF = 
3.0 Hz, CH2), 49.68 (CH2), 31.84* (CH2), 30.60 (CH2), 28.00* (3CH3), 27.93 (3CH3), 
1.91 (CH2), 0.38* (CH2); 19F NMR (471 MHz, CDCl3) δ -69.07 (CF3), -69.60* (CF3); 
(*: trans rotamer); m/z (ESI+, MeCN): 829 ([2M+K]+, 12%), 813 ([2M+Na]+, 45), 434 
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([M+K]+, 100), 418 ([M+Na]+, 84), 362 (32), 340 (28), 242 (26), 153 (26); HRMS 
(ESI+, MeCN): C11H17NO3F3INa ([M+Na]
+) requires 418.0098, found 418.0110 (δ 
1.2 ppm). 
 
tert-butyl 2-[N-(3-azidopropyl)-2,2,2-trifluoroacetamido]acetate 202 
 
To tert-butyl 2-[N-(3-iodopropyl)-2,2,2-trifluoroacetamido]acetate 201 (2.66 g, 6.73 
mmol) was added NaN3 solution (13.5 mL; 1 M in DMSO) at rt for 4 h. The solution 
was then diluted with brine (50 mL) and extracted with EtOAc (3 x 30 mL). The 
combined organic layers were washed with deionised water (3 x 20 mL) and brine (2 
x 20 mL). The organic solution was dried (MgSO4), filtered and the solvent removed 
in vacuo to give a yellow oil 202 (1.96 g, 94%).  
 
Rf (4:1 Hex:EtOAc) 0.34; IR (neat, cm
-1) 2099 (N3), 1743 (C=O ester), 1693 (C=O 
amide), 1140 (C-F); 1H NMR (500 MHz, CDCl3) δ 4.05 (1H, q, J = 1.4 Hz, 
CH2CO2
tBu), 3.96 (1H, s, CH2CO2
tBu), 3.56 – 3.48 (2H, m, CH2CH2NR2), 3.36 (2H, 
2t, J = 6.5 Hz, N3CH2), 1.86 (2H, m, CH2CH2CH2), 1.45 (4.5H, s, C(CH3)3), 1.45 
(4.5H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 166.92 (C), 166.39* (C), 157.35 
(q, 2JCF = 36.2 Hz, C), 157.31* (q, 
2JCF = 36.5 Hz, C), 116.30* (q, 
1JCF = 287.2 Hz, C), 
116.13 (q, 1JCF = 288.1 Hz, C), 83.21 (C), 82.71* (C), 50.19 (q, 
4JCF = 3.4 Hz, CH2), 
49.58* (CH2), 48.76 (CH2), 48.35* (CH2), 47.28 (CH2), 46.53* (q, 
4JCF = 3.1 Hz, CH2), 
27.86* (3CH3), 27.79 (CH2), 27.78 (3CH3), 26.21* (CH2). 19F NMR (471 MHz, 
CDCl3) δ -69.27 (CF3), -69.74* (CF3); (*: trans rotamer); m/z (ESI+, MeCN): 643 
([2M+Na]+, 46%), 638 ([2M+NH4]
+, 51), 328 ([M+NH4]
+, 100) 255 (35); HRMS 
(ESI+, MeCN): C11H17N4O3F3Na ([M+Na]
+) requires 333.1145, found 333.1146 (δ 
0.1 ppm). 
 
tert-butyl 2-[(3-azidopropyl)amino]acetate 203 
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To tert-butyl 2-[N-(3-azidopropyl)-2,2,2-trifluoroacetamido]acetate 202 (311 mg, 
1.00 mmol) in MeOH (1 mL) was added aqueous K2CO3 (1 mL; 2.5 M) and the 
solution was stirred at 40 °C for 4 h. The solvent was removed in vacuo and the residue 
re-dissolved in deionised H2O (10 mL). The aqueous layer was extracted with EtOAc 
(3 x 10 mL). The combined organic layers were washed with deionised water (2 x 10 
mL) and brine (2 x 10 mL). The solution was dried (Na2SO4), filtered and the solvent 
removed in vacuo to give a yellow oil 203 (195 mg, 91%). 
 
Rf (4:1 Hex:EtOAc) 0.08; IR (neat, cm-1) 3331 (N-H), 2093 (N3), 1730 (C=O ester); 
1H NMR (500 MHz, CDCl3) δ 3.41 (2H, t, J = 6.7 Hz, N3CH2), 3.32 (2H, s, 
CH2CO2
tBu), 2.73 (2H, t, J = 6.8 Hz, CH2CH2NHR), 1.91 (1H, s, NH), 1.80 (2H, qn, 
J = 6.8 Hz, CH2CH2CH2), 1.50 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 
171.56 (C), 81.38 (C), 51.62 (CH2), 49.42 (CH2), 46.54 (CH2), 29.27 (CH2), 28.13 
(3CH3); m/z (ESI+, MeCN): 441 (17%), 415 (100), 386 (16), 359 (27), 329 (8), 303 
(15), 273 (13), 247 (12), 215 ([M+H]+, 26), 159 (70); HRMS (ESI+, MeCN): 
C9H19N4O2 ([M+H]





To tert-butyl 2-[N-(3-azidopropyl)-2,2,2-trifluoroacetamido]acetate 202 (156 mg, 502 
μmol) in MeOH (502 μL) was added K2CO3 (502 μL; 2.5 M aq) and the solution was 
stirred at 40 °C for 4 h. The solvent was removed in vacuo and the residue re-dissolved 
in MeCN (1.5 mL). To this FmocCl (156 mg, 602 μmol) was added and the solution 
stirred at rt for 2 h. The solvent was removed in vacuo and the residue dissolved in 
deionised H2O (5 mL). The aqueous solution was acidified (0.5 M HCl) and extracted 
with EtOAc (3 x 5 mL). The combined organic layers were washed with HCl (2 x 5 
mL; 0.5 M aq), deionised water (2 x 5 mL) and brine (2 x 5 mL). The combined 
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organics were dried (Na2SO4), filtered and the solvent removed in vacuo to give a light 
yellow oil. This was purified by flash column chromatography (9:1 Hex:EtOAc) to 
give 204 as a colourless oil (188 mg, 86%). 
Rf (4:1 Hex:EtOAc) 0.24; IR (neat, cm-1) 2095 (N3), 1742 (C=O ester), 1701 (C=O 
carbamate); 1H NMR (500 MHz, CDCl3) δ 7.79 (2H, d, J = 7.5 Hz, FmocArH), 7.61 
(2H, d, J = 7.4 Hz, FmocArH), 7.43 (2H, t, J = 7.3 Hz, FmocArH), 7.35 (1H, t, J = 7.3 
Hz, FmocArH), 7.33* (1H, t, J = 7.6 Hz, FmocArH), 4.62 (1H, d, J = 5.5 Hz, 
FmocCH2O), 4.43* (1H, d, J = 6.9 Hz, FmocCH2O), 4.27 (0.5H, t, J = 5.4 Hz, FmocH), 
4.24* (0.5H, t, J = 6.9 Hz, FmocH), 3.89* (1H, s, CH2CO2
tBu), 3.85 (1H, s, 
CH2CO2
tBu), 3.45* (1H, t, J = 6.9 Hz, CH2CH2NR2), 3.39* (1H, t, J = 6.7 Hz, N3CH2), 
3.14 (1H, t, J = 7.1 Hz, CH2CH2NR2), 3.05 (1H, t, J = 6.7 Hz, N3CH2), 1.88* (1H, qn, 
J = 6.8 Hz, CH2CH2CH2), 1.52 (1H, qn, J = 6.8 Hz, CH2CH2CH2), 1.48* (4.5H, s, 
C(CH3)3), 1.47 (4.5H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 168.72* (C), 
168.65 (C), 156.26 (C), 156.07* (C), 143.97 (C), 143.93* (C), 141.43 (C), 141.31* 
(C), 127.73 (CH), 127.71* (CH), 127.17 (CH), 127.10* (CH), 125.08* (CH), 124.70 
(CH), 119.99* (CH), 119.92 (CH), 82.10* (C), 81.90 (C), 67.84* (CH2), 67.04 (CH2), 
50.30 (CH2), 50.23* (CH2), 48.96* (CH2), 48.69 (CH2), 47.38* (CH), 47.32 (CH), 
46.69* (CH2), 45.92 (CH2), 28.08 (3CH3), 27.60 (CH2), 27.52* (CH2); (*: minor 
rotamer, 49%); m/z (ESI+, MeCN): 459 (70%, [M+Na]+), 403 (19), 341 (13), 179 
(100); HRMS (ESI+, MeCN) C24H28N4O4Na ([M+Na]
+) requires 459.2003, found 
459.2000 (δ 0.3 ppm). 
 
2-[(3-azidopropyl)[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetic acid 187 
  
To tert-butyl 2-[N-(3-azidopropyl)-2,2,2-trifluoroacetamido]acetate 202 (1.72 g, 5.55 
mmol) in MeOH (5.5 mL) was added aqueous K2CO3 (5.5 mL; 2.5 M aq) and the 
solution was stirred at 40 °C for 4 h. The solvent was removed in vacuo and the residue 
re-dissolved in MeCN (16.5 mL). To this FmocCl (1.72 g, 6.66 mmol) was added and 
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the solution stirred at rt for 2 h. The solvent was removed in vacuo and the residue 
dissolved in deionised H2O (20 mL). The aqueous solution was acidified with HCl (0.5 
M aq) and extracted with EtOAc (3 x 20 mL). The combined organic layers were 
washed with HCl (2 x 20 mL; 0.5 M aq), deionised water (2 x 20 mL) and brine (2 x 
20 mL). The combined organics were dried (Na2SO4), filtered and the solvent removed 
in vacuo to give a light yellow oil, which was re-dissolved in DCM (5 mL). TFA (8.50 
mL, 111 mmol) was added dropwise and the solution left to stir for 2 h at rt. The 
solvent was removed in vacuo and the residue re-dissolved in Et2O (20 mL). The 
organic layer was extracted with NaHCO3 (5 x 15 mL sat. aq) and the combined 
aqueous extracts washed with Et2O (2 x 10 mL). The aqueous solution was acidified 
and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed 
with deionised H2O (2 x 15 mL) and brine (2 x 20 mL). The solution was dried 
(Na2SO4), filtered and concentrated in vacuo to give 187 as a colourless wax (1.63 g, 
77%).  
 
Rf (4:1 Hex:EtOAc) 0.04; IR (neat, cm-1) 2093 (N3), 1714 (C=O acid), 1653 (C=O 
carbamate); 1H NMR (601 MHz, CDCl3) δ 7.79 (1.12H, d, J = 7.5 Hz, FmocArH), 
7.76* (0.88H, d, J = 7.6 Hz, FmocArH), 7.60 (1.12H, d, J = 7.5 Hz, FmocArH), 7.56* 
(0.88H, d, J = 7.5 Hz, FmocArH), 7.43 (1.12H, t, J = 7.5 Hz, FmocArH), 7.40* (0.88H, 
t, J = 7.6 Hz, FmocArH), 7.35 (1.12H, t, J = 7.5 Hz, FmocArH), 7.31* (0.88H, t, J = 
7.5 Hz, FmocArH), 4.65 (1.12H, d, J = 5.4 Hz, FmocCH2O), 4.51* (0.88H, d, J = 6.2 
Hz, FmocCH2O), 4.27 (0.56H, t, J = 5.5 Hz, FmocH), 4.22* (0.44H, t, J = 6.2 Hz, 
FmocH), 3.99 (1.12H, s, CH2CO2H), 3.89* (0.88H, s, CH2CO2H), 3.41* (0.88H, t, J 
= 6.9 Hz, CH2CH2NR2), 3.34* (0.88H, t, J = 6.7 Hz, N3CH2), 3.14 (1.12H, t, J = 7.1 
Hz, CH2CH2NR2), 3.03 (1.12H, t, J = 6.7 Hz, N3CH2), 1.82* (0.88H, qn, J = 6.9 Hz, 
CH2CH2CH2), 1.51 (1.12H, qn, J = 6.9 Hz, CH2CH2CH2); 13C NMR (151 MHz, 
CDCl3) δ 173.89* (C), 173.79 (C), 156.47 (C), 155.87* (C), 143.80 (2C), 141.44 (C), 
141.37* (C), 127.77 (CH), 127.70* (CH), 127.21 (CH), 127.07* (CH), 124.81* (CH), 
124.67 (CH), 119.97* (CH), 119.95 (CH), 67.60* (CH2), 67.23 (CH2), 49.41 (CH2), 
48.92* (CH2), 48.85* (CH2), 48.61 (CH2), 47.29 (CH), 46.59* (CH2), 46.06 (CH2), 
27.51 (CH2), 27.44* (CH2); (*: minor rotamer, 44%); m/z (ESI+, MeCN): 403 (100%, 
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[M+Na]+), 353 (14), 279 (14), 179 (68); HRMS (ESI+, MeCN) C20H20N4O4Na 




To a solution of N-(3-chloropropyl)-2,2,2-trifluoroacetamide 199 (1.01 g, 5.33 mmol) 
in MeCN (5.3 mL) was added NaI (998 mg, 6.66 mmol, dried under high vacuum and 
heating with a heat gun for 5 mins) and the solution heated to 95 °C under reflux for 8 
h. After consumption of the starting material (TLC) the reaction mixture was cooled 
and the solvent removed in vacuo. The residue was re-dissolved in DCM (10 mL) and 
filtered through a silica pad which was rinsed with additional DCM (5 x 10 mL). The 
solvent was removed in vacuo to give a light yellow solid (1.48 g, 99%). 
 
Rf (4:1 Hex:EtOAc) 0.30; Mp: 57-59 °C; lit298 Mp = 58 °C; IR (neat, cm-1) 3302 (N-
H), 1699 (C=O amide), 1169 (C-F); 1H NMR (500 MHz, CDCl3): δ 6.46 (1H, br s, 
NH), 3.53 (2H, q, J = 6.6 Hz, CH2NHR), 3.22 (2H, t, J = 6.7 Hz, CH2I), 2.16 (2H, qn, 
J = 6.7 Hz, CH2CH2CH2); 13C NMR (126 MHz, CDCl3): δ 157.47 (q, 
2JCF = 37.7 Hz, 
C), 115.72 (q, 1JCF = 287.8 Hz, C), 40.62 (CH2), 31.95 (CH2), 1.52 (CH2); 19F NMR 
(471 MHz, CDCl3): δ -75.89 (s, CF3); HRMS (EI+) C5H7NOF3I ([M]
+) requires 
280.9519, found 280.9522 (δ 0.3 ppm). 
 
tert-butyl 2-(trifluoroacetamido)acetate 210 
 
To a solution of glycine tert-butyl ester hydrochloride 211 (1.68 g, 10.0 mmol) in 
DCM (20 mL) was added TFAA (1.55 mL). The solution was allowed to stir at rt for 
5-10 minutes until it became homogeneous. The solution was cooled to 0 °C and TEA 
(3.07 mL) was added dropwise slowly (gas released). After addition the solution was 
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warmed to rt and allowed to stir for 2 h. The organic layer washed with hydrochloric 
acid (3 x 10 mL, 1 M aq). The combined acidic aqueous washes were extracted with 
DCM (2 x 10 mL) and the organic extracts combined. The organic layer was washed 
with deionised water (3 x 10 mL) and brine (2 x 10 mL). The organic extracts were 
dried (MgSO4), filtered, and the solvent removed in vacuo to give a light yellow oil 
(2.071 g, 91%). 
 
Rf (4:1 Hex:EtOAc) 0.42; IR (neat, cm-1) 3331 (N-H), 1744 (C=O ester), 1710 (C=O 
amide), 1148 (C-F); 1H NMR (500 MHz, CDCl3) δ 6.87 (1H, br s, NH), 4.05 (dq, J = 
5.0, 0.7 Hz, 2H, CH2), 1.53 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 167.32 
(C), 157.05 (q, 2JCF = 37.7 Hz, C), 115.64 (q, 
1JCF = 287.4 Hz, C), 83.68 (C), 42.04 
(CH2), 27.99 (3CH3); 19F NMR (471 MHz, CDCl3) δ -75.92 (s, CF3); m/z (ESI+): 477 
([2M+Na]+, 100%), 250 [M+Na]+ (91); HRMS (ESI+): C8H12NO3F3Na ([M+Na]
+) 
requires 250.0662, found 250.0670 (δ 0.8 ppm). 
 
1H and 13C NMR data are in good agreement with the literature300 
 
tert-butyl 2-[N-(pent-4-yn-1-yl)-2,2,2-trifluoroacetamido]acetate 205 
 
To a solution of tert-butyl 2-(trifluoroacetamido)acetate 210 (1.60 g, 7.06 mmol) in 
DMF (10.6 mL) was added Cs2CO3 (3.45 g, 10.6 mmol), and TBAI (652 mg, 1.77 
mmol) and the solution stirred for 5 minutes. To the suspension 5-chloropentyne (1.12 
mL, 10.6 mmol) was added and the solution was heated to 95 °C and left to stir for 12 
h, making sure the solids were well agitated. The solvent was removed in vacuo and 
the residue was re-dissolved in DCM (10 mL) and filtered through a silica pad which 
was rinsed with additional DCM (5 x 50 mL). The solvent was removed in vacuo to 
yield a dark yellow viscous oil (1.99 g, 96%). 
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Rf (4:1 Hex:EtOAc) 0.46; IR (neat, cm-1) 1744 (C=O ester), 1692 (C=O amide); 1H 
NMR (500 MHz, CDCl3) δ 4.10 (1H, q, 
5JCF = 1.6 Hz, CH2CO2
tBu), 4.02* (s, 1H, 
CH2CO2
tBu), 3.62–3.57 (2H, m, CH2CH2NR2), 2.28 (2H, ddt, J = 6.7, 2.7 Hz, 
HC≡CH2), 2.03* (0.5H, t, J = 2.7 Hz, HC≡CH2), 2.01 (0.5H, t, J = 2.7 Hz, HC≡CH2), 
1.86 (p, J = 7.0 Hz, 2H, CH2CH2CH2), 1.49 (4.5H, s, C(CH3)3), 1.49* (4.5H, s, 
C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 166.96 (C), 166.47* (C), 157.45* (q, 
2JCF 
= 36.5 Hz, C), 157.31 (q, 2JCF = 36.0 Hz, C), 116.35* (q, 
1JCF = 287.2 Hz, C), 116.20 
(q, 1JCF = 288.2 Hz, C), 83.18 (C), 82.77 (C), 82.71* (C), 82.07* (C), 69.79* (CH2), 
69.47 (CH2), 50.15 (q, 
4JCF = 3.2 Hz, CH2), 49.50* (CH2), 48.59 (CH2), 47.98* (q, 
4JCF 
= 3.1 Hz, CH2), 27.96* (3CH3), 27.89 (3CH3), 27.04* (CH2), 25.42 (CH2), 15.92 
(CH2), 15.74* (CH2); 19F NMR (471 MHz, CDCl3) δ -69.16, -69.62*; (*: trans 
rotamer); m/z (ESI+, MeCN) 625 ([2M+K]+, 20%), 609 ([2M+Na]+, 44), 604 
([2M+NH4]
+, 21), 332 ([M+K]+, 38), 316 ([M+Na]+, 48), 311 ([M+NH4]
+, 100), 238 
(21), 102 (5); HRMS (ESI+, MeCN) C13H18NO3F3Na ([M+Na]
+) requires 316.1131, 
found 316.1141 (δ 1.0 ppm). 
 
tert-butyl 2-[(pent-4-yn-1-yl)amino]acetate 206 
 
To tert-butyl 2-[N-(pent-4-yn-1-yl)-2,2,2-trifluoroacetamido]acetate 205 (297 mg, 
1.01 mmol) in MeOH (1 mL) was added aqueous K2CO3 (1 mL; 2.5 M) at 40 °C for 4 
h. The solvent was removed in vacuo and the residue re-dissolved in deionised H2O 
(10 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organic layers were washed with deionised water (2 x 10 mL) and brine (2 x 10 mL). 
The solution was dried (Na2SO4), filtered and the solvent removed in vacuo to give a 
dark yellow oil (179 mg, 90%). 
 
Rf (4:1 Hex:EtOAc) 0.09; IR (neat, cm-1) 3296 (N-H), 1730 (C=O ester); 1H NMR 
(500 MHz, CDCl3 δ 3.33 (2H, s, RNHCH2CO2
tBu), 2.74 (2H, t, J = 7.0 Hz, 
CH2CH2NHR), 2.30 (2H, dt, J = 7.0, 2.6 Hz, HC≡CH2), 1.97 (1H, t, J = 2.6 Hz, 
HC≡C), 1.85 (1H, s, NH), 1.74 (2H, qn, J = 7.0 Hz, CH2CH2CH2), 1.49 (9H, s, 
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C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 171.67 (C), 83.98 (C), 81.24 (C), 68.57 
(CH), 51.69 (CH2), 48.28 (CH2), 28.72 (CH2), 28.13 (3CH3), 16.24 (CH2); m/z (ESI+, 
MeCN) 365 (9%), 309 (10), 242 ([M+2Na-H]+, 100), 198 ([M+H]+, 17), 142 (85); 
HRMS (ESI+, MeCN) C11H20NO2 ([M+H]






To tert-butyl 2-[N-(pent-4-yn-1-yl)-2,2,2-trifluoroacetamido]acetate 205 (147 mg, 
501 μmol) in MeOH (501 μL) was added K2CO3 (501 μL; 2.5 M aq) and the solution 
was stirred at 40 °C for 4 h. The solvent was removed in vacuo and the residue re-
dissolved in MeCN (1.5 mL). To this FmocCl (156 mg, 601 μmol) was added and the 
solution stirred at rt for 2 h. The solvent was removed in vacuo and the residue 
dissolved in deionised H2O (10 mL). The aqueous solution was acidified with HCl (0.5 
M aq) and extracted with EtOAc (3 x 5 mL). The combined organic layers were 
washed with HCl (2 x 5 mL; 0.5 M aq), deionised H2O (2 x 5 mL) and brine (2 x 5 
mL). The combined organics were dried (Na2SO4), filtered and the solvent removed in 
vacuo to give a translucent orange oil. This was purified by flash column 
chromatography (9:1 Hex:EtOAc) to give an transparent oil (177 mg, 84%). 
 
Rf (4:1 Hex:EtOAc) 0.22; IR (neat, cm-1) 1742 (C=O ester), 1701 (C=O carbamate); 
1H NMR (500 MHz, CDCl3) δ 7.79 (2H, d, J = 7.5 Hz, FmocArH), 7.62 (2H, t, J = 
7.5 Hz, , FmocArH), 7.42 (2H, t, J = 7.4 Hz, FmocArH), 7.36 – 7.31 (2H, m, 
FmocArH), 4.55 (1H, d, J = 6.0 Hz, FmocCH2O), 4.42* (1H, d, J = 7.0 Hz, 
FmocCH2O), 4.29 (0.5H, t, J = 6.0 Hz, FmocH), 4.24* (0.5H, t, J = 7.0 Hz, FmocH), 
3.92* (1H, s, CH2CO2
tBu), 3.90 (1H, s, CH2CO2
tBu), 3.48 (1H, t, J = 7.1 Hz, 
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CH2CH2NR2), 3.27 (1H, t, J = 7.3 Hz, CH2CH2NR2), 2.28 (1H, dt, J = 7.0, 2.7 Hz, 
HC≡CH2), 2.06 (1H, dt, J = 7.0, 2.7 Hz, HC≡CH2), 1.99 (0.5H, t, J = 2.6 Hz, HC≡CH2), 
1.96 (0.5H, t, J = 2.6 Hz, HC≡CH2), 1.83 (1H, qn, J = 7.1 Hz, CH2CH2CH2), 1.57 (1H, 
d, J = 7.1 Hz, CH2CH2CH2), 1.48* (4.5H, s, C(CH3)3), 1.48 (4.5H, s, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δ 168.80* (C), 168.76 (C), 156.40 (C), 156.05 (C), 
144.03 (C), 143.99* (C), 141.40 (C), 141.30* (C), 127.70* (CH), 127.68 (CH), 127.10 
(CH), 127.09* (CH), 125.11* (CH), 124.87 (CH), 119.97* (CH), 119.94 (CH), 83.56* 
(C), 83.34 (C), 81.97* (C), 81.77 (C), 68.97 (CH), 68.88* (CH), 67.78* (CH2), 67.31 
(CH2), 50.26 (CH2), 50.15* (CH2), 48.16* (CH2), 47.45 (CH2), 47.39* (CH), 47.31 
(CH), 28.09 (3CH3), 26.97 (CH2), 26.84* (CH2), 15.92* (CH2), 15.75 (CH2); (*: minor 
rotamer, 48%); m/z (ESI+, MeCN): 442 (68%, [M+Na]+), 386 (28), 179 (100); HRMS 
(ESI+, MeCN) C26H29NO4Na ([M+Na]
+) requires 442.1989, found 442.1980 (δ 0.9 
ppm). 
 
2-[(pent-4-yn-1-yl)[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetic acid 188 
 
To tert-butyl 2-[N-(pent-4-yn-1-yl)-2,2,2-trifluoroacetamido]acetate 205 (1.62 g, 5.53 
mmol) in MeOH (5.5 mL) was added aqueous K2CO3 (5.5 mL; 2.5 M) and the solution 
was stirred at 40 °C for 4 h. The solvent was removed in vacuo and the residue re-
dissolved in MeCN (16.5 mL). To this FmocCl (1.72 g, 13.8 mmol) was added and the 
solution stirred at rt for 2 h. The solvent was removed in vacuo and the residue 
dissolved in deionised H2O (20 mL). The aqueous solution was acidified with HCl (0.5 
M aq) and extracted with EtOAc (3 x 20 mL). The combined organic layers were 
washed with HCl (2 x 20 mL; 0.5 M aq), deionised H2O (2 x 20 mL) and brine (2 x 20 
mL). The combined organics were dried (Na2SO4), filtered and the solvent removed in 
vacuo to give a translucent orange oil, which was re-dissolved in DCM (5 mL). TFA 
(8.47 mL, 111 mmol) was added dropwise and the solution left to stir for 2 h at rt. The 
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solvent was removed in vacuo and the residue re-dissolved in Et2O (20 mL). The 
organic layer was extracted with NaHCO3 (5 x 15 mL) and the combined aqueous 
extracts washed with Et2O (2 x 10 mL). The aqueous solution was acidified and 
extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with 
deionised H2O (2 x 15 mL) and brine (2 x 20 mL). The solution was dried (Na2SO4), 
filtered and concentrated in vacuo to give 188 as an orange wax (1.51 g, 75%). 
 
Rf (4:1 Hex:EtOAc) 0.05; IR (neat, cm-1) 1726, 1697 (broad C=O); 1H NMR (601 
MHz, CDCl3) δ 7.79 (1.22H, d, J = 7.5 Hz, FmocArH), 7.76* (0.78H, d, J = 7.5 Hz, 
FmocArH), 7.61 (1.22H, d, J = 7.4 Hz, FmocArH), 7.55* (0.78H, d, J = 7.4 Hz, 
FmocArH), 7.42 (1.22H, t, J = 7.5 Hz, FmocArH), 7.39* (0.78H, t, J = 7.3 Hz, 
FmocArH), 7.34 (1.22H, t, J = 7.4 Hz, FmocArH), 7.31* (0.78H, t, J = 7.4 Hz, 
FmocArH), 4.59 (1.22H, d, J = 5.8 Hz, FmocCH2O), 4.51* (0.78H, d, J = 6.0 Hz, 
FmocCH2O), 4.28 (0.61H, t, J = 5.7 Hz, FmocH), 4.22* (0.39H, t, J = 5.9 Hz, FmocH), 
4.04 (0.61H, s, CH2CO2H), 3.90* (0.39H, s, CH2CO2H), 3.44* (0.39H, t, J = 7.0 Hz, 
CH2CH2NR2), 3.26 (0.61H, t, J = 7.3 Hz, CH2CH2NR2), 2.23* (0.39H, dt, J = 7.0, 2.6 
Hz, HC≡CH2), 2.04 (0.61H, dt, J = 7.0, 2.4 Hz, HC≡CH2), 1.98 – 1.95 (1H, m, 
HC≡CH2), 1.77* (0.39H, qn, J = 6.8 Hz, CH2CH2CH2), 1.54 (0.61H, qn, J = 7.0 Hz, 
CH2CH2CH2); 13C NMR (151 MHz, CDCl3) δ 174.53* (C), 174.28 (C), 156.67 (C), 
155.83* (C), 143.82 (C), 141.41 (C), 141.37* (C), 127.75 (CH), 127.69* (CH), 127.15 
(CH), 127.06* (CH), 124.80 (CH), 124.77* (CH), 119.97 (CH), 83.37* (C), 83.10 (C), 
69.22 (CH), 69.06* (CH), 67.51 (CH2), 49.47 (CH2), 48.82* (CH2), 48.05* (CH2), 
47.63 (CH2), 47.27 (CH), 26.83 (CH2), 26.69* (CH2), 15.77* (CH2), 15.65 (CH2); (*: 
minor rotamer, 39%); m/z (ESI+) 408 (6%), 386 ([M+Na]+, 100), 282 (4), 179 (52); 
HRMS (ESI+) C22H21NO4Na ([M+Na]
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 Variable Temperature 1H NMR Spectra for tert-butyl 2-[N-(3-
chloropropyl)-2,2,2-trifluoroacetamido]acetate 200 
 
Figure 127- Abstracts of variable temperature 1H experiments (4.40 – 3.60 ppm, d7-
DMF) showing α-carbon CH2 rotameric signals (4.35 and 4.20 ppm) and overlapping 
CH2Cl and TfacNRCH2CH2R’ rotameric signals (3.78 – 3.66 ppm) upon heating from 
303 K to 373 K (Spectra 1 and 8, respectively) in 10 K increments. 
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Figure 128- Abstracts of variable temperature 1H experiments (2.30 – 1.40 ppm, d7-
DMF) showing coalescence of TfacNRCH2CH2CH2Cl rotameric signals (2.25 – 2.10 
ppm) and CO2CCH3 rotameric signals (1.50 – 1.45 ppm) upon heating from 303 K to 
373 K (Spectra 1 and 8, respectively) in 10 K increments. Intensity of signals at 2.25 
– 2.10 have been increased for clarity. 
 
5.2 Peptide Synthesis 
 
5.2.1 Resin Activation 
 
Polymer bound Fmoc Rink Amide AM (250 mg, 0.69 mmol g-1 loading) was swollen 
in DCM (2 mL) for 2 min and then drained and washed with DCM (2 x 1 mL). 
Piperidine (2 mL; 20% in DMF) was added to the resin and the mixture stirred at room 
temperature for 5 min. The solvent was drained and the resin washed with DMF (5 x 
2 mL) and DCM (5 x 2 mL). The piperidine addition and wash steps were repeated. 
The deprotection of the Fmoc protecting group was confirmed by a positive free amine 
test (vide infra). 
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5.2.2 Coupling Protocol 
 
Resin (173 μmol) with a free amine terminal amino acid was swollen and stirred in 
DCM (2 mL) for 2 min. Fmoc-AA-OH (518 µmol) and ethyl 2-cyano-2-
(hydroxyimino) acetate (Oxyma, 60 mg, 518 µmol) was dissolved in DMF (1.5 mL). 
To this DIC was added (80 µL, 518 µmol) and the solution was shaken for 2 min. The 
DCM was drained, the DMF solution was added to the resin and the mixture was 
stirred at room temperature for 37 min. After this time the solution was drained and 
the resin washed with DMF (5 x 2 mL), DCM (5 x 2 mL), MeOH (5 x 2 mL) and DCM 
(5 x 2 mL). The coupling was confirmed by a negative free amine test (vide infra). 
 
5.2.3 Fmoc Deprotection 
 
Resin (173 μmol) with an Fmoc-protected terminal amine was swollen and stirred in 
DCM (2 mL) for 2 min. Piperidine (2 mL; 20% in DMF) was added to the resin and 
the mixture stirred at room temperature for 5 min. The solvent was drained and the 
resin washed with DMF (5 x 2 mL) and DCM (5 x 2 mL). The piperidine addition and 
wash steps were repeated. The deprotection was confirmed by a positive free amine 
test (vide infra). 
 
5.2.4 Test for Free Amines 
 
To a few beads of resin were added 3 drops of each solution (Solution 1: 2% 
acetaldehyde in DMF [v/v, 100 µL in 5 mL], Solution 2: 2% chloranil in DMF [w/v 
100 µg in 5 mL]). The mixture was left at room temperature for 5 min and the beads 
inspected. 
Positive Test – Green/Blue beads (1°/2°) Negative test – No colour change 
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5.2.5 Capping 
 
The Fmoc deprotection (vide supra) was performed 3 times and a positive free amine 
test confirmed the deprotection step. To the resin was added neat Ac2O (326 μL 3.45 
mmol) and DIPEA (601 μL, 3.45 mmol) in DMF (1 mL) and the mixture was stirred 
at room temperature for 37 min. After this time the solution was then drained and the 
resin washed with DMF (5 x 2 mL), DCM (5 x 2 mL), MeOH (5 x 2 mL) and DCM 
(5 x 2 mL). The coupling was confirmed by a negative free amine test (vide supra). 
 
5.2.6 On–Resin CuAAC Reaction 
 
 On-Resin CuAAC Room Temperature 
 
To the resin (~86.5 μmol) was added a mixture of DCM and TFE (1.5 mL, 4:1). To 
this, a fresh solution of Cu(MeCN)4BF4 (63 mg, 173 μmol), and TBTA (106 mg, 173 
μmol) in DCM:TFE (2 mL; 4:1) was made and 173 μL was added and the mixture 
stirred for 48 h. After this time the solution was then drained and the resin washed with 
DMF (5 x 2 mL), DCM (5 x 2 mL), MeOH (5 x 2 mL) and DCM (5 x 2 mL). 
 
 On-Resin CuAAC Microwave 
 
To a curved bottom microwave vial resin (~86.5 μmol), Cu(MeCN)4BF4 (63 mg, 173 
μmol) and TBTA (106 mg, 173 μmol) and a stirrer bar were added. This was dissolved 
in DMSO (2 mL, degassed with N2 for 5-10 minutes). The vial was then heated in a 
microwave reactor (80 ℃, 0.5 h). After this time the solution was drained and the resin 
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5.2.7 Cleavage and Side Chain Deprotection 
 
To the resin was added a solution of TFA:TIS:DCM (90:5:5, 1.5 mL) and the mixture 
was left for 3 min. The syringe was then sealed with tape and the solution stirred for 3 
h. After this time the solution was collected in a vial and the syringe flushed with TFA 
(2 x 1.5 mL). The TFA was then removed using a N2 flow. To this vial was added Et2O 
(12 mL) and a white solid precipitated. The vial was then spun in a centrifuge (4500 
rpm, 2 minutes) and the supernatant liquid poured off. This procedure was repeated 
twice and the resulting solid dried overnight. 
 
Table 33- Yields and Ions Found of Peptide/Peptomer Library 
 
  
Peptide Notation Rt (minute)
a Mass (Da) Theor. Mass (Da) Ion Yield (%)
174 Native 10 1350.6289 1350.6341 [M+Na]
+
56





179c 1,4-S ,S -c 8 1451.7036 1451.6954 [M+H]
+
41
180u 1,4-S ,R -u 18 1473.6828 1473.6773 [M+Na]
+
33
180c 1,4-S ,R -c 7 1451.7029 1451.6954 [M+H]+ 47
181u 1,4-R ,S -u 16 1451.6953 1451.6954 [M+H]
+
22
181c 1,4-R ,S -c 7 1451.6921 1451.6954 [M+H]
+
31
182u 1,4-R ,R -u 16 1473.6769 1473.6773 [M+Na]
+
10
182c 1,4-R ,R -c 7 1451.7002 1451.6954 [M+H]
+
26
183u 4,1-S ,S -u 16 1473.6770 1473.6773 [M+Na]
+
34
183c 4,1-S ,S -c 9 1451.7127 1451.6954 [M+H]
+
41
184u 4,1-S ,R -u 16 1451.7028 1451.6954 [M+H]
+
27
184c 4,1-S ,R -c 8 1451.7075 1451.6954 [M+H]
+
36
185u 4,1-R ,S -u 16 1451.7014 1451.6954 [M+H]
+
28
185c 4,1-R ,S -c 6 1451.7048 1451.6954 [M+H]
+
24
186u 4,1-R ,R -u 16 1473.6824 1473.6773 [M+Na]
+
19
186c 4,1-R ,R -c 7 1451.6974 1451.6954 [M+H]
+
25
189 N -Native 5 1350.6389 1350.6341 [M+Na]
+
51
190u 1,4-N ,N -u 14 1471.7047 1471.6981 [M+H]
+
42
190c 1,4-N ,N -c 5 1449.7229 1449.7161 [M+H]
+
45
191u 4,1-N ,N -u 11 1471.7052 1471.6981 [M+Na]
+
41
191c 4,1-N ,N -c 5 1449.7165 1449.7161 [M+H]
+
46
a Isocratic gradient 62:38 (Water + 0.1% TFA:MeCN + 0.1% TFA);
b Isocratic gradient 65:35 (Water + 0.1% TFA:MeCN + 0.1% TFA)
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5.3 Circular Dichroism 
 
Each purified peptide/peptomer was dissolved in TFE (4 mg mL-1). Aliquots of these 
solutions were diluted with deionised water to produce a 25% TFE aqueous solution 
(1 mg mL-1).  These solutions were pipetted into a cuvette (0.1 cm pathlength, 400 
μL). The spectra were recorded at 25℃ with a 1 nm data pitch and 10 nm minute-1 
scanning speed. Each spectra is the accumulation of 3 scans and smoothed using the 
Savitzky-Golay method.301 
 
Figure 129- CD Spectra of Native 174 (Black) and Uncyclised Peptides 
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Figure 130- CD Spectra of Native 174 (Black) and Cyclised Peptides 
 
 
Figure 131- CD Spectra of Native 174 (Black) and Peptomers 189, 190u/c (red) and 
191u/c (blue) 
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5.4      Ligand Synthesis 
 
5.4.1 Diazide Synthesis 
 
Safety in the Handling of Sodium Azide and other Azides:226 
Sodium azide is toxic and can be absorbed through the skin. It decomposes explosively 
upon heating to above 275 °C. Sodium azide reacts vigorously with CS2, bromine, 
nitric acid, dimethyl sulfate, and a series of heavy metals, including copper and lead. 
In reaction with water or Brønsted acids the highly toxic and explosive hydrogen azide 
is released. It has been reported that sodium azide and polymer-bound azide reagents 
form explosive di- and triazidomethane with CH2Cl2 and CHCl3, respectively. Heavy-
metal azides that are highly explosive under pressure or shock are formed when 
solutions of NaN3 or HN3 vapors come into contact with heavy metals or their salts. 
Heavy-metal azides can accumulate under certain circumstances, for example, in metal 
pipelines and on the metal components of diverse equipment (rotary evaporators, 
freeze drying equipment, cooling traps, water baths, waste pipes), and thus lead to 
violent explosions. Some organic and other covalent azides are classified as toxic and 
highly explosive, and appropriate safety measures must be taken at all times.  
 
All diazides were synthesised under identical conditions from the corresponding 
dibromides: 
 
To the dibromide (10.1 mmol) was added NaN3 solution (50.5 mL; 1 M in DMSO) at 
rt. This was stirred behind a blast shield for 18 h. The solution was then diluted with 
water (50 mL) and extracted with Et2O (3 x 30 mL). The combined organic layers were 
washed with deionised water (3 x 20 mL) and brine (2 x 20 mL). The organic solution 
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Yield 1.63 g (96%); Rf (DCM) 0.72; 1H NMR (500 MHz, CDCl3) δ 3.36 – 3.25 (4H, 
t, J = 6.9 Hz, N3CH2), 1.70 – 1.58 (4H, m, N3CH2CH2), 1.48 – 1.39 (4H, m, 
N3CH2CH2CH2); 13C NMR (126 MHz, CDCl3) δ 51.32 (2CH2), 28.74 (2CH2), 26.31 
(2CH2). The 





Yield 1.80 g (99%); Rf (DCM) 0.69; 1H NMR (500 MHz, CDCl3) δ 3.33 – 3.26 (4H, 
t, J = 6.9 Hz, N3CH2), 1.67 – 1.59 (4H, m, N3CH2CH2), 1.46 – 1.34 (6H, m, 3 x CH2); 
13C NMR (126 MHz, CDCl3) δ 51.41 (2CH2), 28.75 (2CH2), 28.70 (CH2), 26.59 
(2CH2). The 





Yield 1.92 g (98%); Rf (DCM) 0.63; 1H NMR (500 MHz, CDCl3) δ 3.33 – 3.25 (4H, 
t, J = 6.9 Hz, N3CH2), 1.67 – 1.59 (4H, qn, J = 6.9 Hz, N3CH2CH2), 1.44 – 1.33 (8H, 
m, N3CH2CH2CH2CH2); 13C NMR (126 MHz, CDCl3) δ 51.45 (2CH2), 29.00 (2CH2), 
28.81 (2CH2), 26.62 (2CH2). The 
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Yield 1.96 g (99%); Rf (DCM) 0.68; 1H NMR (500 MHz, CDCl3) δ 7.44 – 7.38 (4H, 
m, ArH), 4.46 (4H, s, N3CH2); 13C NMR (126 MHz, CDCl3) δ 133.88 (2C), 130.18 
(2CH), 129.05 (2CH), 52.28 (2CH2). The 
1H and 13C data was in good agreement with 





Yield 1.92 g (97%); Rf (DCM) 0.67; 1H NMR (500 MHz, CDCl3) δ 7.47 – 7.42 (1H, 
m, ArH), 7.35 – 7.30 (3H, m, ArH), 4.40 (4H, s, N3CH2); 13C NMR (126 MHz, CDCl3) 
δ 136.20 (2C), 129.39 (2CH), 128.05 (2CH), 127.83 (2CH), 54.56 (2CH2). The 
1H and 





Yield 1.96 g (99%); Rf (DCM) 0.68; 1H NMR (500 MHz, CDCl3) δ 7.37 (4H, s, ArH), 
4.39 (4H, s, N3CH2); 13C NMR (126 MHz, CDCl3) δ 135.56 (2C), 128.67 (4CH), 54.42 
(2CH2). The 
1H and 13C data were in good agreement with the literature.302,305 
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5.4.2 Ditriazolyl Alkyne Synthesis 
 
4-(azidomethyl)methyl benzoate B13 
 
 
To 4-(bromomethyl)methyl benzoate (10.18 g, 44.5 mmol) was added NaN3 solution 
(111 mL; 1 M in DMSO) at rt. This was stirred behind a blast shield for 18 h. The 
solution was then diluted with brine (250 mL) and extracted with Et2O (3 x 150 mL). 
The combined organic layers were washed with deionised water (3 x 75 mL) and brine 
(2 x 75 mL). The organic solution was dried (MgSO4), filtered, and the solvent 
removed in vacuo to give a colourless oil (8.34 g, 98%). The 1H data was in good 
agreement with the literature.307,308  
 
Rf (DCM) 0.75; 1H NMR (400 MHz, CDCl3) δ 8.10 – 8.06 (2H, m, ArH), 7.48 – 7.36 
(2H, m, ArH), 4.44 (2H, s, N3CH2), 3.95 (3H, s, CO2CH3). 
 
Methyl 4-{[4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl]methyl}benzoate B16 
 
 
Diethylpropargyl acetal (4.72 g, 36.8 mmol) and 4-(azidomethyl)methyl benzoate 
(7.74 g, 40.5 mmol) were dissolved in a 1:1 mixture of t-BuOH/H2O (28 mL). To this 
solution, sodium bicarbonate (464 mg, 5.52 mmol), copper(II) sulfate pentahydrate 
(459 mg, 1.84 mmol) and sodium ascorbate (1.46 g, 7.36 mmol) were added, and the 
mixture was stirred at room temperature. After ~18 h, EtOAc (100 mL) was added, 
and the organic phase was washed with saturated sodium bicarbonate (2 x 50 mL) and 
brine (2 x 50 mL). The organic layer was dried (MgSO4), filtered, and concentrated in 
vacuo to give a tan crystalline solid (11.63 g, 99%). 
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1H NMR (400 MHz, CDCl3) δ 8.09 – 8.03 (2H, m, ArH), 7.55 (1H, s, TriazoleH), 7.34 
(2H, d, J = 8.5 Hz, ArH), 5.73 (1H, s, (EtO)2CH), 5.60 (2H, s, ArCH2), 3.94 (3H, s, 
CO2CH3), 3.67 (2H, dq, J = 9.4, 7.1 Hz, CH3CHAHBO), 3.59 (2H, dq, J = 9.4, 7.0 Hz, 
CH3CHAHBO), 1.24 (6H, t, J = 7.1 Hz, 6H, CH3CH2O). 
 
Methyl 4-[(4-formyl-1H-1,2,3-triazol-1-yl)methyl]benzoate B15 
 
 
To a solution of methyl 4-{[4-(diethoxymethyl)-1H-1,2,3-triazol-1-
yl]methyl}benzoate (11.75 g, 36.7 mmol) in CHCl3 (74 mL), TFA (56 mL, 736 mmol) 
was added. The reaction mixture was stirred vigorously for 5 h at room temperature. 
Water (75 mL) was added and the aqueous phase washed with CHCl3 (3 x 110 mL). 
The organic phase was washed with saturated NaHCO3 (2 x 150 mL) and brine (150 
mL). The organic layer was dried (MgSO4), filtered, and the solvent were removed in 
vacuo affording a beige solid (8.87 g, 95%). 
1H NMR (400 MHz, CDCl3) δ 10.17 (1H, s, CHO), 8.12 – 8.07 (2H, m, ArH), 8.05 







Methyl 4-[(4-formyl-1H-1,2,3-triazol-1-yl)methyl]benzoate (8.87 g, 34.9 mmol) and 
propargylamine (1.06 mL, 16.6 mmol) were stirred in CHCl3 (150 mL). NaBH(OAc)3 
(10.56 g, 49.8 mmol) was added in portions. After addition was complete, the reaction 
was stirred at room temperature for 6 h. Water (95 mL) and H2SO4 (4.7 mL) were 
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added and stirred for ~15 min. The solution was then basified with saturated K2CO3 
and water (75 mL) was added. The organic phase was separated and the aqueous phase 
was extracted with CHCl3 (2 x 100 mL). The combined organic extracts were dried 
(Na2SO4), filtered, and the solvent was removed in vacuo to give colourless solid (5.03 
g, 59%). 
 
Rf (95:5 DCM:MeOH) 0.26; 1H NMR (500 MHz, CDCl3) δ 8.09 – 8.00 (4H, m, ArH), 
7.56 (2H, s, TriazoleH), 7.33 (4H, d, J = 8.3 Hz, ArH), 5.59 (4H, s, ArCH2), 3.95 (6H, 
s, CO2CH3), 3.87 (4H, s, RNCH2Triazole), 3.36 (2H, d, J = 2.4 Hz, HC≡CCH2), 2.27 
(1H, t, J = 2.4 Hz, HC≡C); 13C NMR (126 MHz, CDCl3) δ 166.41 (2C), 145.08 (2C), 
139.54 (2C), 130.58 (2C), 130.38 (4CH), 127.80 (4CH), 123.19 (2CH), 78.37 (C), 









diylmethanediyl)] dibenzoate (160 mg, 312 µmol) and 1,8-diazidooctane (30 mg, 156 
µmol) were dissolved in MeCN (6 mL). To this solution copper(I) iodide (3 mg, 15.6 
µmol) and NEt3 (26 µL, 187 µmol) were added, and the mixture was stirred at room 
temperature for 6 hours. The solvent was removed in vacuo and the crude material 
redissolved in EtOAc (5 mL). The organic phase was washed with water (2 x 3 mL) 
and brine (2 x 3 mL). The organic layer was dried (Na2SO4), filtered, and concentrated 
in vacuo to give a colourless solid (216 mg, 56%). 
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1H NMR (500 MHz, CDCl3) δ 8.06 – 8.02 (8H, m, ArH), 7.77 (4H, s, 
(TriazoleHCH2)2NR), 7.74 (2H, s, TriazoleHCH2NR2), 7.32 (8H, d, J = 8.3 Hz, ArH), 
5.59 (8H s, ArCH2Triazole), 4.33 (4H, t, J = 7.2 Hz, TriazoleCH2CH2), 3.93 (12H, s, 
CO2CH3), 3.74 (8H, s, (TriazoleCH2)2NR), 3.73 (4H, s, TriazoleCH2NR2), 1.89 (4H, 
qn, J = 7.5 Hz, TriazoleCH2CH2), 1.35–1.27 (8H, m, TriazoleCH2CH2CH2CH2); 13C 
NMR (126 MHz, CDCl3) δ 166.42 (4C), 144.46 (4C), 143.55 (2C), 139.64 (4C), 
130.50 (4C), 130.35 (8CH), 127.76 (8CH), 124.09 (4CH), 123.69 (2CH), 53.62 
(4CH2), 52.26 (4CH3), 50.22 (2CH2), 47.01 (2CH2), 46.96 (4CH2), 30.16 (2CH2), 
28.68 (2CH2), 26.30 (2CH2). 
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